0001493152-19-004187.txt : 20190329 0001493152-19-004187.hdr.sgml : 20190329 20190329090607 ACCESSION NUMBER: 0001493152-19-004187 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 58 CONFORMED PERIOD OF REPORT: 20181031 FILED AS OF DATE: 20190329 DATE AS OF CHANGE: 20190329 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Advanced Biomedical Technologies Inc. CENTRAL INDEX KEY: 0001385799 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 980516589 STATE OF INCORPORATION: NV FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-53051 FILM NUMBER: 19714152 BUSINESS ADDRESS: STREET 1: 350 FIFTH AVE., 59TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10118 BUSINESS PHONE: (718) 766-7898 MAIL ADDRESS: STREET 1: 350 FIFTH AVE., 59TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10118 FORMER COMPANY: FORMER CONFORMED NAME: Geostar Mineral CORP DATE OF NAME CHANGE: 20070110 10-K/A 1 form10-ka.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-K/A

(Amendment No. 1)

[X]	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the fiscal year ended October 31, 2018

	OR

[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 000-53051

Advanced Biomedical Technologies Inc.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of incorporation or organization)

Empire State Building

350 Fifth Ave, 59^th Floor

New York, NY 10118

(Address of principal executive offices, including zip code.)

(718) 766-7898

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.00001 par value

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [ ] No [X]

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes [ ] No [X]

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES [X] NO [ ]

Indicate by check mark whether registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES [X] NO [ ]

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “small reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	[ ]	Accelerated filer	[ ]

Non-accelerated filer	[ ]	Smaller reporting company	[X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes [ ] No [X]

There was no active public trading market as of the last business day of the Company’s year-end.

The aggregate market value of common stock held by non-affiliates of the registrant, computed by reference to the price at which the common equity was last sold being $0.55 on April 30, 2018 which is the last trading day of the second quarter, was approximately $11,983,373 as of April 28, 2018 (the last business day of the registrant’s most recently completed second quarter), assuming solely for the purpose of this calculation that all directors, officers and more than 10% stockholders of the registrant are affiliates. The determination of affiliate status for this purpose is not necessarily conclusive for any other purpose.

As of March 29, 2019, there are 69,624,850 shares of common stock outstanding.

TABLE OF CONTENTS

		Page
Special Note Regarding Forward Looking Statements		4
PART I
Item 1.	Business	5
Item 1A.	Risk Factors	11
Item 1B.	Unresolved Staff Comments	11
Item 2.	Properties	11
Item 3.	Legal Proceedings	11
Item 4.	Mine Safety Disclosures	11

PART II
Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	12
Item 6.	Selected Financial Data	12
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13
Item 7A.	Quantitative and Qualitative Disclosures about Market Risk	20
Item 8.	Financial Statements and Supplementary Data	21
Item 9.	Changes In and Disagreements With Accountants on Accounting and Financial Disclosure	22
Item 9A.	Controls and Procedures	22
Item 9B.	Other Information	22

PART III
Item 10.	Directors, Executive Officers and Corporate Governance	23
Item 11.	Executive Compensation	25
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	26
Item 13.	Certain Relationships and Related Transactions, and Director Independence	27
Item 14.	Principal Accounting Fees and Services	28
Item 15.	Exhibits, Financial Statement Schedules	29

EXPLANATORY NOTE

Advanced Biomedical Technologies Inc. (the “Company”) is filing this Amendment No. 1 (the “Amendment No. 1”) to its Annual Report on Form 10-K for the fiscal year ended October 31, 2018, filed on February 13, 2019 (the “Original 10-K”), as the audit of the Company’s annual financial statements contained therein has now been completed. The Company is now filing this Amendment No. 1 to include the Report of Independent Registered Public Accounting Firm,

For convenience and ease of reference, the Company is filing the annual report in its entirety with applicable changes. Unless otherwise stated, all information contained in this Form 10K/A is as of February 13, 2019, the filing date of the original Annual Report. Except as stated herein, this Form 10K/A does not reflect events or transactions occurring after such filing date and does not contain any modifications or updates to the disclosure in the Annual Report that may have been affected by events or transactions occurring subsequent to such filing date. No information in the Annual Report other than as set forth above is amended hereby.

SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS

Investors are cautioned that certain statements contained in this document, as well as some statements in periodic press releases and some oral statements of Advanced Biomedical Technologies Inc. (“ABMT”) officials during presentations about ABMT, are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”). Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, which include words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” or similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future ABMT actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-looking statements are based on current expectations and projections about future events and are subject to risks, uncertainties, and assumptions about ABMT, economic and market factors and the industries in which ABMT does business, among other things. These statements are not guaranties of future performance and we have no specific intention to update these statements.

Actual events and results may differ materially from those expressed or forecasted in forward-looking statements due to a number of factors. Although forward-looking statements in this Annual Report on Form 10-K reflect the good faith judgment of our management, forward-looking statements are inherently subject to known and unknown risks, business, economic and other risks and uncertainties that may cause actual results to be materially different from those discussed in the forward-looking statements, and Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report on Form 10-K.

ITEM 1. BUSINESS

Organizational History

Advanced Biomedical Technologies, Inc. has one direct wholly owned subsidiary, Masterise Holdings Ltd., a limited liability company organized under the laws of British Virgin Islands (“Masterise”). Masterise, owns seventy percent (70%) of the issued and outstanding equity or voting interests in Shenzhen Changhua, a company formed under the laws of the People’s Republic of China. (ABMT, Masterise, and Shenzhen Changhua are collectively referred to throughout this document as “We, “Us,” “Our” (and similar pronouns), “ABMT” and the “Company”).

We were incorporated in the State of Nevada on September 12, 2006. We maintain our statutory registered agent’s office at The Corporation Trust Company of Nevada, 311 S Division Street, Carson City, Nevada 89703, and our business office is located at 350 Fifth Avenue, 59th Floor, New York, NY 10118. We have not been subject to any bankruptcy, receivership, or similar proceeding, or any material reclassification or consolidation.

Our primary business is carried out by Masterise through Shenzhen Changhua, as set forth in the following diagram:

Shenzhen Changhua does not have any subsidiary.

Organizational History of Masterise and Shenzhen Changhua

Masterise is a wholly owned subsidiary of Advanced Biomedical Technologies, Inc.

Masterise is a limited liability company which was organized under the laws of British Virgin Islands (“BVI”) on May 31, 2007, and owns 70% of the capital stock of Shenzhen Changhua.

Shenzhen Changhua is a limited liability company which was organized under the laws of PRC on September 25, 2002.

Since their founding, Shenzhen Changhua has been involved in the development of polymer screws, rods and binding wires for fixation on human fractured bones. The Company is currently involved in researching, manufacturing and conducting clinical trials on its products and intends to raise additional capital to produce and market its products commercially. The Company holds one Class III permit and one Class II permit from the China Food and Drug Administration (“CFDA”), formally the State Food and Drug Administration (“SFDA”) of the PRC. The Company holds two patents issued by the State Intellectual Property Office of the P.R.C. (“SIPO”) and further patent applications are currently under review by the SIPO.

Primary Products

Our primary products include Polymer Osteosynthesis Devices made of a proprietary material compositing of polyamide 6 (PA6), hydroxyapatite (HA) and poly(methyl methacrylate-co-N-vinylpyrrolidone) (P(MMA-co-NVP)). These advanced materials are used in surgical screws, binding wires, rods and related medical devices for the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, and related treatments, and reconstructive dental procedures. Our polymer orthopaedic internal fixation screws received approval from the China Food and Drug Administration (“CFDA”) in April 2018; and our PA Binding Wires are under clinical trials; and our PA Mini-Screws are under animal test.

Product Characteristics:

The Company’s new and unique material has ideal mechanical properties with similar strength, toughness, tensile strength and flexibility etc. to the human bone. Its elasticity, toughness and high fatigue resistance can effectively stabilize fractures without causing stress shielding. Its strong biocompatibility includes: no inflammation, no pyrogen, no cytotoxicity, no subchronic systemic toxicity etc. Additionally, the biomaterials promotes the synthesis of matrix mature protein (ALP, collagen I, osteopontin, osteocalcin) gene expressions, via local transcription factors of osterix, Runx2 mRNA for a long time. Facilitating the continuous synthesis of extracellular matrix proteins required for cell mineralization, and bone tissue regeneration from an effective bio-interface integration.

The bone screw products produced by the materials have been proved to be safe and reliable after clinical trials and long-term follow-ups spanning 10 years. Unlike metallic screws, they can be implanted for a long time without the need for a secondary removal surgery. Our biomedical composite material exhibit three key technological innovations:

	1.	A notably reduced need for a secondary surgery to remove implant due to post-operative complications, therefore avoiding unnecessary risk and expense on all patient care;
	2.	Enhancing the performance of the materials by manufacturing them to be easily fitted to each patient, forming an exact fit;
	3.	Improving the biological activity of materials. Clinical trial results have shown that PA implants promote a progressive shift of load to the new bone creating micro-motion and thereby avoiding bone atrophy due to ‘stress shielding’;
	4.	Reducing the chance of post-operative infection;
	5.	Stimulate bone tissues to facilitate effective biological integration, benefitting the regeneration of bone;
	6.	Ease of post-operative care i.e. no distortion during x-ray imaging;
	7.	Simple and cost-effective to manufacture.

The Company has developed six proprietary polymer fixation implant product lines, including screws, pins, tacks, rods and binding wires, which provide an alternative to metal implants and overcome the limitations of first generation re-absorbable fixation devices. The Company’s product range will ultimately cover the full gamut of components for implantation, including human orthopedic and dental applications, as well as veterinary applications.

Industry Development

The fracture fixation industry has developed through three generations of materials science:

The first generation internal-fracture fixation material:

The first generation internal-fracture-fixer components are usually made of stainless steel, titanium and alloy. Due to their high intensity, low costs and easy machining character, these components have achieved huge success in fracture treatment and remain the most widely used internal-fracture-fixer material. However, their prominent flaws are the huge difference between metal’s elasticity co-efficient, easily causing second-time bone fracture. The metallic ion can also cause tissue inflammation, and the need of a secondary surgery to have them taken out. These flaws stimulated the development of the degradable macromolecule material.

The second generation fracture fixation material:

The second generation bone-fracture-fixed components are made of degradable macromolecule material, such as PLLA, PGA and PDS, etc. The disadvantage of these components is rapid self-degeneration in early stages after the initial implant. For example, the strength of SR-PLLA decreases to 10-20Mpa after 4 weeks of implantation. Therefore, the second generation bone-fracture-fixed components can be only used to treat substantial spongiosa bone fractures.

The third generation fracture fixation material:

The third generation fracture fixation material, biodegradable fracture fixation components are currently under research by developed countries. There are many technical challenges to research in the third generation fracture fixation material field; for example, the materials must have a high degree of bio-compatibility and mechanical compatibility. They also must be of high biological activity, self-absorbable, and degeneration controllable.

Product Development

After careful deliberation, we selected the polymer screw as our first product to market. In order to replace the widely-used metal components, the new materials must meet multiple bio-consistency and mechanical-consistency requirements. Furthermore, they must also exhibit specific properties with respect to bio-activities, degradability, and controllable degradation speed. Although many macromolecule materials are degradable inside human body, relatively few provide the physical characters required for fracture fixation.

Development began with selection of macromolecule materials that exhibited the desired physical characters, leading, ultimately, to our selection of polyamide. In order to achieve the desired mechanical performance and degrading speed, various chemical and physical techniques were employed to modify the bio-degradable polyamide so as to synthesize the required new bio-degradable material. This phase of our research also entailed the selection of monomer class, polymerization conditions, the mensuration of polymer molecular weight, hydrophile capability, crystal capability, the mensuration and controlled degrading speed of the polymer, the mensuration and control of the mechanical performance of the polymer, and numerous other critical considerations.

Our next challenge was to identify a suitable bio-active inorganic material, and to optimize the compound and associated production conditions. It was critical that we could predict and control the bio-activities of the implanted fixture material, and to this end we used high grade and mature phosphate type bio-active materials, taking into account the preparation characteristics of the compound material, and the surface character requirements of the finished products. We also improved current technical parameters by modifying the surface character, thereby achieving critical control over the desired grain size and surface activities.

The third technological hurdle involved the actual preparation and utilization of the engineered compound in conjunction with a bio-active material. Hydronium bombardment of the surface, with spread and cover techniques, was employed during this critical step in the process. This had the effect of creating a well-knit bio-active membrane on the degradable polymer’s surface, and embedding a bio-active core inside the degradable polymer stick, so as to form the bio-active degradable compound material.

The final step entailed strengthening and shaping the processed compound by using directional extrusion and molding. Degradable acantha inoculators, fixation screws, orthopedics stuffing, enlace strings, and anti-conglutination membrane can all be manufactured, as needed, using this same technique.

Our company has studied and researched Polyamide, changing its chemical and physical properties to meet the above requirements. As a result of our research we have:

1.	Increased mechanical strength to 170Mpa.

2.	Increased biological activities to accelerate bone cell substitution.

3.	Extended the degeneration period during the implant. While the PA is degenerating layer by layer, the bone cells grow and take its place.

Product Analysis

Our products are manufactured in a 100,000 level GMP factory with stringent quality management system, workshop alongside a 10,000-level bacteria purification zone. The R&D, production and quality management capabilities satisfies the requirements of implantable medical device production management specifications, ISO9001 and ISO13485. Over the years, Shenzhen Changhua has developed a series of orthopedic internal fixation products such as bone screws, rib nails, tying lines and bone plates using a newly synthsized material, PPH (PA6-P(MMA-co-NVP)-HA)

Overview of PA Devices and Market in the US, China and Worldwide

According to Transparency Market Research, the global orthopedic device market will reach US$41.2 billion by the end of 2019, owing to multiple factors that are enabling it to progress at a CAGR of 15% from 2019 to 2023.

The key drivers of the global orthopedic devices market are the 2 factors below:

	1.	Rapidly aging population
	2.	High demand for painless treatments

Growth in geriatric population is primarily pushing demand for orthopedic solutions globally. Effects of aging, such as diminishing bone density and weakening bones due to excessive loss of bone mass, make their presence felt from 35 years of age and become more prominent after 55 years. By 2050, 1 billion or more people would be above 60 years old.

In addition, the demand more pain-free treatments and increasing number of sport related injuries and road accidents are expected to fuel the need for orthopedic devices. However, stringent regulatory approval procedures as well as the high cost of surgical procedures and these devices are the main reasons restraining market growth, and making it a high-barrier of entry.

China’s Market for PA Devices

With a population of over 1.3 billion, China is the world’s most densely populated country and makes up of one-fifth of the world’s population. China’s population is nearly five times more than United States even though both roughly cover the same geographic area. There are 32 Provinces, Autonomous Regions, and Municipalities of Mainland China.

China’s orthopedic implant device industry is in a state of rapid market growth. With the acceleration of population aging, the improvement of medical policies, and an increase in people’s treatment awareness, China’s orthopedic implant medical device sector continues to boom, with a huge potential orthopaedic market base and developmental space. According to Frost & Sullivan, the compound growth rate of the orthopedic industry from 2008 to 2012 was 18.2%. In 2017, the market size reached 3.23 billion USD and by 2020, the market for implantable orthopedic consumables in China will reach 4 billion US dollars.

Competitive Analysis

To the best of our knowledge, our Company is the only patent holder of PA technologies in China, as well as the only company received CFDA approval in China. At this time there are no similar products in this market. Moreover, due to the nature of the regulatory environment, and the requirements and logistics of mounting a clinical trial, it would take any new competitor a minimum of three years to catch up to our lead in this area alone. Factoring in our established relationships with key customers, distributors, and regulators, as well as our ready-to-run production facilities, and our actual advantage is considerable longer than the 3 year regulatory advantage. This represents an invaluable window in which to firmly entrench our company as the preferred purveyor of self-reinforced, absorbable biodegradable PA components in the Chinese health care environment.

To reiterate, our company and product line offer several critical competitive advantages, specifically:

	●	There are no similar patent registrations in China.
	●	Our initial product, the PA Screw approved by the CFDA in 2018, has completed 100% of the required clinical trials, with a 100% success rate.
	●	We are the only company qualified and permitted to conduct clinical trials of other PA products by China’s CFDA.
	●	We have a timing advantage over other companies in China, which would have to go through the preclinical testing before they could even apply for a permit to conduct actual clinical trials.
	●	Under existing regulation structure, it will take at least 3 years for any competitor’s clinical trials to be completed, and total of 7 or more years to reach the point where we are now.

Specific Competition

Competition in the medical implant device industry is intense both in China and in global markets. In orthopedics, ABMT’s principal competitors are the numerous companies that sell metal implants. ABMT competes with the manufacturers and marketers of metal implants by emphasizing the ease of implantation of the Company’s polymer implants, the cost effectiveness of such products, and the elimination of risks associated with the necessity of performing removal surgeries frequently required with less modern products.

Our Polymer (PA) Bone Screw is the first of its kind among all polymer-based implantations and has no competitors due to the sophisticated manufacturing technologies and technique needed for its production.

According to the record from CFDA and our estimates, it will take at least 5 years for another medical device provider with similar technology to appear in the market. This is because much time will need to be spent on developing material compatibility, safety and undergoing clinical trials in reaching proper standards.

In addition, the current market is mainly saturated with metallic compound bone screws, and the medical industry has been using it predominantly since the 1900s. Not only is our invented material biologically stable and easily accepted by the human body, it is also very versatile and therefore has a great market potential.

Our primary competition will be the generation-one and generation-two counterparts, which, despite their functional inferiority, enjoy the benefit of familiarity and an established manufacturing and marketing base. This competition comes from a number of entrenched players worldwide, including DePuySynth, Zimmer Biomet Holdings Inc., Medtronic Plc, Smith and Nephew Plc, Stryker Corp. and others. Although many of these competitors have substantially greater resources upon which to draw, we are confident that the technological superiority of the more forward-looking product will ultimately equalize the playing field by orthopaedic innovation.

Product advantage and Market Opportunity:

-	There are no similar patent registrations in China.
-	We are the only company approved by the CFDA and permitted to take clinical trials.
-	We have a timing advantage over other companies in China which would have to go through the preclinical testing for the CFDA permit on Clinical Trials.
-	Under existing regulation by CFDA, it will take at least 3-5 years to complete clinical trials for a new product similar to the Company’s PA Screw, which has finished all required clinical trials.

Product Comparisons

Among many other advantages, a main advantage of ABMT’s proprietary PA technology is the elimination of the need for secondary surgery to remove an implantation device. Implant removal belongs to the most common elective orthopaedic procedures in industrial countries. In children, implant removal may be necessary to remove implants early to avoid disturbances to the growing skeleton, to prevent their bony immuring making later removal technically difficult or impossible, and to allow for planned reconstructive surgery after skeletal maturation (e.g., in case of hip dysplasia). In adults, pain, soft tissue irritation, the resumption of strenuous activities or contact sports after fracture healing, and the patient’s demand are typical indications for implant removal in clinical practice. However, implant removal requires a second surgical procedure in scarred tissue, and poses a risk for nerve damage and re-fractures. (cite: Hanson et al.BMC Musculoskeletal Disorders 2008)

	Metallic Compounds	Poly-lactic Acid	ABMT’s Material (Polyamide)
Market Size & Growth	~97% CAGR = 7% (From Oxford Academics)	~3% CAGR = 15% (From Oxford Academics on polymer based medical devices)	N/A CAGR = 15% (From Oxford Academics on polymer based medical devices)
Bio-compatibility level	Bending Strength and tensile strength exceeds that of the human bone.	Bending strength and tensile strength are close to that of the human bone	Bending strength and tensile strength are close to that of the human bone
Problems/ Issues	Metallic ions cause extreme inflammation; Reduction in mechanical hold and sturdiness	Acidic compounds in bones result in aseptic inflammation and severe water accumulation	No apparent issues and with mechanical sturdiness; no inflammation resulted.
Long-term Effects	Impair and damage nearby tissues If placed too long	High degradation speed; resulting in empty slots in bones; could cause a 2nd bone fracture	High bio-stability and long-lasting support
Surgical cost	Requires removal surgery (40% of the time); Increasing cost (Additional $500 USD), physical and mental pain	Does not require a 2nd surgery, acidic compounds excreted out from the body	Does not require 2nd surger. No toxic compounds released into blood circulation
Remarks	Composition not easily affected by external factors during production	Characteristics and properties easily altered during manufacturing, purification and storage processes	Composition and characteristics not easily affected by external factors during production

¹Metallic Compounds have been traced in serum and hair of 16 of 46 patients after receiving titanium implants. (cite: Kasai Y, Iida R, Uchida A: Metal concentrations in the serum and hair of patients with titanium alloy spinal implants.)

²Implant removal belongs to the most common elective orthopaedic procedures in the industrial countries. In a frequently cited Finnish study, implant removal contributed to almost 30% of all planned orthopaedic operations, and 15% of all operations. (cite: Bostman O, Pihlajamaki H: Routine implant removal after fracture surgery: a potentially reducible consumer of hospital resources in trauma units.)

Towards the end of the last century, spinal and orthopedic implants evolved towards progressively stronger and stiffer devices, as it was presumed that increased construct rigidity would optimize the biological milieu and provide more rapid and robust healing and arthrodesis. For the past 20 years, titanium has been the most widely used, and the most expensive material for fixing fractures (in both elective and emergency surgery). More than 1,000 tons (2.2 million pounds) of titanium devices of every description and function are implanted in patients worldwide each year. Although metal exhibits the desired strength and rigidity to allow the healing process to begin, there are a number of issues associated with using permanent titanium systems. Our PA materials deliver many of the benefits of their metal counterparts, without the disadvantages:

	METAL	ABMT’s PA devices
Cranial Growth	● Growth restriction ● Intracranial implant migration	● Stimulation of growth leading to better bone healing

Accumulation of Metal in tissues	Yes	No

Adverse Effect	● Many necessitate removal operation either for mechanical strength of the overall structure ● majority of implant failures occur at the bone-screw interface with screw pullout being the most common mechanistic cause of construct failure ● should the bone fail to heal, these micromotions will persist and cause the metallic screw to oscillate within the far softer surrounding bone interface	None

Stiffness for optimal healing	● Too stiff ● Stress shielding can result in bone atrophy and degradation	● Optimal stiffness/flexibility characteristics to achieve surgical fixation, while conforming to the softer, more pliable bone of the patient

Other Effects	● Implant palpability ● Temperature sensitivity ● Occasionally visibility ● Could cause trauma in the event of mechanical failure ● Imaging and radiotherapy interference ● Potential for cross contamination	● No long-term palpability ● No temperature sensitivity ● Predictable degradation ● Reduced patient trauma ● No imaging and radiotherapy interference ● No second surgery required

Cost of product	Cost to hospital: $400-$2200	Cost to hospital: $800

Intellectual Property

The Company has been granted one patent for its material by the State Intellectual Property Office of the P.R.China (“SIPO”), patent no. ZL971190739. This patent also protects the use and manufacturing process of the material.

In January 2017, SIPO has issued the Company a new patent titled “Bone Fracture Plate Made of High Polymer Materials”, patent no. ZL 2014 1 0647464.1, which strengthens the Company’s position in manufacturing process and related controls using our unique polyamide materials.

The company is establishing broad and new intellectual property protection schemes around our unique PA product lines, not only on its combination compounds, but also to lead as an outstanding material in the future of clinical activity.

Abstract

The present invention discloses a macromolecular implant for human body and its preparation process, and relates to the products made up by using said macromolecular implant and their application. Said invented product is made up by using resin fiber through hot-pressing treatment according to the formula provided by said invention, and its strength is high, tenacity is good and its shape can be processed according to the requirement in the period of bone union after implantation, and said implant can be made into the fixation block, eurymeric block, fastening piece and suture for reduction of fracture, and can be started to be degraded from twenty-fourth week after implantation, and can be absorbed by human body after 1.5-2 years, and its cost is low.

Employees

As of October 31, 2018, we had 15 employees, with 6 employees in R&D, Clinical and Regulatory, 4 employees in Manufacturing, 4 employees in General and Administration, and 1 employee in Accounting.

We believe that our future success will depend in part on our continued ability to attract, hire and retain qualified personnel. None of our employees are represented by a labor union, and our employee relations have been good.

The company’s facilities are located at Block A, Longcheng Tefa Industrial park, Longgang, Shenzhen, China.

Insurance

While we are carrying out the Clinical Trials, we do not have any Product Liability Insurance coverage for the use of our proposed products. We intend to obtain Product Liability Insurance coverage for commercial sale of our products in due course.

Government Regulations

Our primary target market is the medical community of the People’s Republic of China (PRC). Medical devices manufactured by the Company in China are subject to regulation by the China Food and Drug Administration (“CFDA”), formally the State Food and Drug Administration (“SFDA”) of the PRC. The manufacturing facilities are also required to meet China’s Good Manufacturing Practices (“GMP”) standards.

The Company’s production facilities are fully compliant with GMP requirements. The Company’s PA Screw was approved by the CFDA in April 2018. Furthermore, due to the uniqueness of our PA Screw, it has been independently categorized so the marketing prices are set by the Company rather than healthcare platforms.

ITEM 1A. RISK FACTORS

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 1B. UNRESOLVED STAFF COMMENTS

There are no unresolved comments from the SEC.

ITEM 2. PROPERTIES

None.

ITEM 3. LEGAL PROCEEDINGS

We are not involved in any pending or imminent litigations or current legal proceedings.

ITEM 4. MINE SAFETY DISCLOSURE

Not applicable.

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Only a limited market exists for our securities. There is no assurance that a regular trading market will develop, or if developed, that it will be sustained. Therefore, a shareholder in all likelihood will be unable to resell his securities in our company. Furthermore, it is unlikely that a lending institution will accept our securities as pledged collateral for loans unless a regular trading market develops.

Our company’s securities are traded on the world’s largest electronic interdealer quotation system “OTCQB” operated by the OTC Markets Group under the symbol “ABMT”.

Fiscal Quarter	High Bid		Low Bid
2018
Fourth Quarter 08-01-18 to 10-31-18	$	0.55	$	0.21
Third Quarter 05-01-18 to 07-31-18	$	0.74	$	0.25
Second Quarter 02-01-18 to 04-30-18	$	2.00	$	0.13
First Quarter 11-01-17 to 01-31-18	$	0.18	$	0.12

Fiscal Quarter	High Bid		Low Bid
2017
Fourth Quarter 08-01-17 to 10-31-17	$	0.21	$	0.12
Third Quarter 05-01-17 to 07-31-17	$	0.21	$	0.10
Second Quarter 02-01-17 to 04-30-17	$	0.20	$	0.10
First Quarter 11-01-16 to 01-31-17	$	0.20	$	0.10

Shareholders

At October 31, 2018, we had 51 shareholders of record of our common stock, including shares held by brokerage clearing houses, depositories or otherwise in unregistered form. We have no outstanding options or warrants, or other securities convertible into, common equity.

Dividend Policy

We have not declared any cash dividends. We do not intend to pay dividends in the foreseeable future, but rather to reinvest earnings, if any, in our business operations.

Section 15(g) of the Securities Exchange Act of 1934

Our shares are covered by section 15(g) of the Securities Exchange Act of 1934, as amended that imposes additional sales practice requirements on broker/dealers who sell such securities to persons other than established customers and accredited investors (generally institutions with assets in excess of $5,000,000 or individuals with net worth in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 jointly with their spouses). For transactions covered by the Rule, the broker/dealer must make a special suitability determination for the purchase and have received the purchaser’s written agreement to the transaction prior to the sale. Consequently, the Rule may affect the ability of broker/dealers to sell our securities and also may affect your ability to sell your shares in the secondary market.

Section 15(g) also imposes additional sales practice requirements on broker/dealers who sell penny securities. These rules require a one-page summary of certain essential items. The items include the risk of investing in penny stocks in both public offerings and secondary marketing; terms important to in understanding of the function of the penny stock market, such as “bid” and “offer” quotes, a dealers “spread” and broker/dealer compensation; the broker/dealer compensation, the broker/dealers duties to its customers, including the disclosures required by any other penny stock disclosure rules; the customers rights and remedies in causes of fraud in penny stock transactions; and, the FINRA’s toll free telephone number and the central number of the North American Administrators Association, for information on the disciplinary history of broker/dealers and their associated persons.

Securities authorized for issuance under equity compensation plans

We have no equity compensation plans and accordingly we have no shares authorized for issuance under an equity compensation plan.

ITEM 6. SELECTED FINANCIAL DATA

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This section of the report includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like: believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements, which apply only as of the date of this annual report. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions.

Overview

The following discussion is an overview of the important factors that management focuses on in evaluating our businesses, financial condition and operating performance and should be read in conjunction with the financial statements included in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those anticipated in these forward looking statements as a result of any number of factors, including those set forth in this Annual Report on Form 10-K, and elsewhere in our other public filings. Factors that may cause actual results, our performance or achievements, or industry results to differ materially from those contemplated by such forward-looking statements include without limitation:

1.	The company’s lack of funds in new R&D, especially in clinical testing;
2.	The company’s lack of funds in new equipment and the utilization of the production process after CFDA approval;
3.	The company may need to seek funding through such vehicles as convertible notes and warrants, private placements, and/or convertible debentures;
4.	The company needs funding for marketing and network build-up;
5.	The company plans to seek approval for clinical testing and marketing on a worldwide basis, including US FDA approval for testing and marketing in the United States of America, and there is no guaranty that we will obtain any such approval;
6.	While the company currently holds two patents originating in China, the patents does not protect our intellectual property in the United States, and the company is unsure of the validity of the patent in other countries. However, specific trade secrets are involved in the manufacturing of our product to help protect our technologies, and reverse engineering is unlikely for our types of products and technologies. New patents are expected to be filed as result of our continuous research works for new and refined materials. Additionally, all machinery used to manufacture our products is protected by Chinese patents.

The Company is subject to a number of risks similar to other companies in the medical device industry. These risks include rapid technological change, uncertainty of market acceptance of our products, uncertainty of regulatory approval, competition from substitute products from larger companies, the need to obtain additional financing, compliance with government regulations, protection of proprietary technology, product liability, and the dependence on key individuals.

All written and oral forward-looking statements made in connection with this Form 10-K that are attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given the uncertainties that surround such statements, you are cautioned not to place undue reliance on such forward-looking statements.

Our Business

We are engaged in the business of designing, developing, manufacturing and marketing of biomaterial internal fixation devices. We hold one medical device permit from the China Food and Drug Administration (“CFDA”) for our product - polymer orthopaedic internal fixation screws and two patents issued by the State Intellectual Property Office of the P.R.C. (“SIPO”). Our polyamide materials, their uses and manufacturing processes are protected by Patent No. ZL971190739. A new patent, No. ZL201410647464.1 titled “Bone Fracture Plate Made of High Polymer Materials” was granted to us in January 2018. Our polyamide materials are used in producing screws, binding wires, rods and related products. These products are used in a variety of applications including orthopedic trauma, sports related medical treatment, or cartilage injuries, and reconstructive dental procedures. At this time, our company is the sole patent holder and market permit holder of PA technologies in China, as well as the only company currently engaged in clinical trials, manufacturing and marketing for PA orthopaedic internal fixation devices in the PRC. Our products are made of a very unique material called PA6-P(MMA-CO-NVP)-HA (“PA”). Our PA products, such as screws, binding wires, rods, suture anchors and rib-pins consist of enhanced fibers and high molecular polymers which are designed to facilitate quick healing of complex fractures in many areas of the human skeletal system.

Our products offer a number of significant advantages over existing metal implants and the first generation of degradable implants (i.e. PLLA) for patients, surgeons and other customers including:

	1.	A notably reduced need for a secondary surgery to remove implant due to post-operative complications, therefore avoiding unnecessary risk and expense on all patient care;
	2.	Enhancing the performance of the materials by manufacturing them to be easily fitted to each patient, forming an exact fit;
	3.	Improving the biological activity of materials. Clinical trial results have shown that PA implants promote a progressive shift of load to the new bone creating micro-motion and thereby avoiding bone atrophy due to ‘stress shielding’;
	4.	Reducing the chance of post-operative infection;
	5.	Stimulate bone tissues to facilitate effective biological integration, benefitting the regeneration of bone;
	6.	Ease of post-operative care i.e. no distortion during x-ray imaging;
	7.	Simple and cost-effective to manufacture.

Our products are designed to replace the traditional internal fixation device made of stainless steel and titanium and overcome the limitations of previous generations of products such as PLA and PLLA. Our laboratory statistics show that our PA products have a higher mechanical strength, last longer in degradation ratio and are more evenly absorbed form outer layer inwards as compared with similar materials such as PLA and PLLA. Thus PA allows increased restoration time for bone healing and re-growth. The Company’s polymer orthopaedic internal fixation screws received approval from the China Food and Drug Administration (“CFDA”) in April 2018.

CFDA Application Process and Approval for Polymer Screws

The Company first submitted its application for PA Screws to the CFDA in 2008. The application has been withheld by the CFDA pending additional clinical trial cases. This is due to the amended CFDA regulations, which unlike previous regulations require the applicant to specify the position on the body where the clinical trial is carried out. Our amended CFDA application has specified the ankle fracture as the body part of our clinical trial. This is because bones around this part carry most of the body weight.

Due to the uniqueness of our material, there were no established CFDA Product Standards that we could follow during our application process for our PA Screws. To establish our own Product Standards, the Company had been carrying out extra tests. The Company submitted its Product Standards and supplementary reports to the CFDA in 2014. In December 2016, the Company received a notice from the CFDA requesting supplementary report as part of the review process. The Company completed the supplementary report and submitted it to the CFDA in June 2017.

In April 2018, the Company’s application for its PA Screws was approved by the CFDA in China (Medical Device Certification Number: 20183460133).

Clinical Trials on Other Products

The Company has completed a total of 83 successful clinical human trial cases, including 71 cases on ankle fractures and 57 successful PA Binding Wire trial cases. We have been conducting human trials at the 6 state level hospitals recognized by CFDA for clinical trials in different cities throughout China; including Nanchang, Changsha, Luoyang, Nanning and Tianjin. The cities and provinces where our clinical trial hospitals are based will be the initial target regions on our marketing plan. These regions are both densely populated and have experienced high or above medium economic growth. The clinical trials for the Company’s PA Screws have been completed with 100 percent success rate. Having gained CFDA approval for PA Screws, the Company is planning to start clinical trials on series of orthopaedic products the Company has developed using the same unique biomaterial.

Government Regulation

Medical implant devices/products manufactured or marketed by the Company in China are subject to extensive regulations by the CFDA. Pursuant to the related laws and acts, as amended, and the regulations promulgated there under (the “CFDA Regulations”), the CFDA regulates the clinical testing, manufacture, labeling, distribution and promotion of medical devices. The CFDA also has the authority to request repair, replacement, or refund of the cost of any device manufactured or distributed by the Company.

Under the CFDA Regulations, medical devices are classified into three classes (class I, II or III), the basis of the controls deemed necessary by the CFDA to reasonably assure their safety and efficacy. Under the CFDA’s regulations, class I devices are subject to general controls (for example, labeling and adherence to Good Manufacturing Practices (“GMP”) requirements) and class II devices are subject to general and special controls. Generally, class III devices are those which must receive premarket approval by the CFDA to ensure their safety and efficacy (for example, life-sustaining, life-supporting and certain implantable devices, or new devices which have not been found substantially equivalent to legally marketed class I or class II devices). The Company is classified as a manufacturer of class III medical devices. Current CFDA enforcement policy prohibits the marketing of approved medical devices for unapproved uses.

Before a new device can be introduced into the market in China, the manufacturer generally must obtain CFDA marketing clearance through clinical trials. Since the Company is classified as a manufacturer of Class III medical devices, the Company must carry out all clinical trials in pre-selected CFDA approved hospitals.

Manufacturers of medical devices for marketing in China are required to adhere to GMP requirements. Enforcement of GMP requirements has increased significantly in the last several years and the CFDA has publicly stated that compliance will be more strictly scrutinized. From time to time the CFDA has made changes to the GMP and other requirements that increase the cost of compliance. Changes in existing laws or requirements or adoption of new laws or requirements could have a material adverse effect on the Company’s business, financial condition and results of operations. There can be no assurance that the Company will not incur significant costs to comply with applicable laws and requirements in the future or that applicable laws and requirements will not have a material adverse effect upon the Company’s business, financial condition and results of operations.

Regulations regarding the development, manufacturing and sale of the Company’s products are subject to change. The Company cannot predict the impact, if any, that such changes might have on its business, financial condition and results of operations.

Results of Operations

The “Results of Operations” discussed in this section merely reflect the information and results of Masterise and Shenzhen Changhua for the years ended October 31, 2018 and 2017.

Revenues

The Company is in its development stage and does not have any revenue. The management team is continuously looking for fundraising possibilities for product improvement, machinery upgrades, facility expansions, continuous research and development, and sales and marketing preparation.

Our facility is located in Shenzhen, China, which is built to meet the GMP standards. Our facility covers about 865 square meters, which includes the combined facilities of offices, laboratories, and workshops. There is one production line for the PA Screw and another production line for the PA Binding Wire. The annual production capabilities of each production line are 100,000 pieces for PA Screw, and 240,000 packs for the PA Binding Wires. Both production lines, at their maximum production capacities are capable of generating approximately $30,000,000 in annual revenue.

Estimate current production lines in full capacity

	Output Quantity (Max.)	Price at ex-factory (US$)		Total Turnover (US$)
PA Screw	100,000 (piece)	180		18,000,000
PA Binding Wire	240,000 (pack)		50		12,000,000
			Total:		30,000,000

The Company will market its products through a hybrid sales force comprised of a managed network of independent regional distributors/sales agents (80%) and direct sales representatives (20%) in China.

There are two ways the company will generate revenue, 1) through our nationwide and regional distributors and 2) through our direct sales channels.

Funding Needs

The Company estimates that it will need to raise minimum $900,000 over the next 12 months to bring its current products to market, and begin earning revenues. This amount may increase if we decide to start clinical trials on new products. Once we start to market our PA Screw, our revenue will cover our expenditures. Otherwise, we will continue to rely on external investments and shareholder’s loans to meet our cash needs. While the Company has no outside sources of funding, the Company’s shareholders have committed to advance the Company funds as needed. There is a Letter of Continuing Financial Support signed between the Company and one of its major shareholders, Titan Technology Development Ltd.

China’s Marketing Analysis and Sales Strategy

We have established long term relationships with many hospitals and national distributors in China. Ms. Hui Wang, the Company’s CEO, has over 25 years’ sales experience in medical distribution. She will be in charge of our sales programs. Professor LIU, Shangli, our chief medical advisor for Greater China, is one of the highest ranked orthopedic doctors in China as well as being highly renowned in the rest of the world. He will assist the Company in nationwide product promotion and joint projects with associated academic institutions and medical schools.

During product development and clinical trial stages we developed close relationships with many major national hospitals. We expect these relationships to boost our revenue generation following CFDA final approval. In order to better serve our customers, including hospitals, distributors, patients and the general public, the Company will set up Regional Service Offices to provide technical support, product information, and customer aid service.

China’s market for PA devices depends on 3 major conditions:

- Patients

- Advanced technology level

- Performance and price of the materials

The demand for internal fixation medical devices has rapidly increased during the last decade. According to China Health Care Year Book 2013, the total revenue of Chinese orthopaedic hospitals in 2013 was US$1.28 billion with over 11.5 million patients. From 2009 to 2013, the market size of China’s orthopaedic devices has grown from US$1.1 billion to US$1.92 billion, and it is estimated to reach US$4 billion in 2020. China has overtaken Japan as the second largest market in the world. The Chinese market size for trauma treatment implant devices such as our PA Screw and PA Wire was US$1.88 billion in 2013 and US$2.12 billion in 2014 with a growth rate of 12.7%, it is estimated to grow to US$3.02 billion in 2017 and reach US$3.17 billion in 2018 with a growth rate of 11.6%. (Source: Shenwan Hongyuan Securities research report).

China has gradually entered the Old Age Society. It is expected that there will be 245 million people over 60 years of age by 2020, and, according to the survey of 50 years old, the incidence of osteoporosis is as high as 60%, accompanied by osteoporosis, fracture, bone necrosis, disability and other diseases, resulting in continued high demand of orthopaedic implant medical devices. (Source: The UN; Shenwan Hongyuan Securities research report).

Other factors such as new and improved medical technology will continue to rapidly grow throughout hospitals in China, and material optimization and product pricing is expected to directly stimulate double digits market growth rate in the near future in China.

The Company has advantages and more opportunities over others competitors due to:

- No other similar patent registrations in China.

- We are the only company received market approval and permitted to perform PA clinical trials by the CFDA to the best of our knowledge.

- We have a timing advantage over other companies in China, which would have to go through the preclinical testing for the CFDA permit on clinical trials.

- Under new regulations by the CFDA, it will take at least 5-10 years for clinical trials of new materials.

- Our patented material will enables us to rapidly diversify our product line according to market trend and demand.

Number of Hospitals at the end of November 2018 Statistic and Census report by the National Health Commission of the People’s Republic of China.

Statistic and Census report by National Health Commission of the People’s Republic of China

(November 2018)

	November 2018		November 2017		Increase / (Decrease)
Total No. of Hospitals		32,476		30,294		2,182
Public Hospital		12,072		12,181		(109	)
Private Hospital		20,404		18,113		2,291
Hospital Rating
AAA		2,498		2,311		187
AA		8,806		8,285		521
A		10,477		9,632		845

In general, technological advancements and the marketing potential within Asia are the biggest factors in driving significant growth within the global orthopedic devices market. Another major factor that positively influences this market is the growing number of aging baby boomers with active lifestyles. This sector represents a large portion of the total population.

Distribution Model

Dealer/Distributor System:

We collaborate with dealers to sell and distribute our products to various hospitals and reach the consumers, i.e. bone fracture victims. The company will assist dealers to promote products to famous orthopaedic hospitals

By utilizing a distributor, ABMT will further benefit from promotional activities by having a second party help with common objectives, and at the same time, increase our sales audience through their contacts.

Currently, we have established contacts with various national and district distributors, every distributor covers a minimum of 50 hospitals so our total coverage is 6,000 hospitals. We will provide ongoing after-sales service, technical supports and conventional meetings, etc., to help our distributors better promote our products.

Direct Hospital Sales (DHS):

Our Direct Hospital Sales (DHS) regions will include Guangdong, Jiangsu, Zhejiang, Xinjiang, Shanghai and Beijing at the beginning. We have already established close relationships with the 7 state-level hospitals where our clinical tests have been conducted at. These hospitals are located in one of the fastest growing areas of China, healthcare coverage for 20% of the Chinese population. These 7 State level hospitals are:

	1.	The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine.
	2.	The Second Affiliated Hospital of Zhongshan University.
	3.	The First Affiliated Hospital of Guangxi Traditional Chinese Medicine University.
	4.	The First Affiliated Hospital of Guangxi Medical University.
	5.	The People’s Hospital of Guangxi Zhuang Autonomous Region.
	6.	The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine.
	7.	Luoyang Orthopaedic-Traumatological Hospital.

Apart from assisting in our sales. These 7 hospitals will also be assisting ABMT in future clinical applications and trials.

In addition, we will receive up-to-date information directly from physicians to develop new products better suited for current patient needs and hence, speed up product commercialization.

Research and Development

Research and development costs related to both present and future products are expensed as incurred. Total expenditure on research and development charged to general and administrative expenses for the years ended October 31, 2018 and 2017 was $56,512 and $48,053.

We expect research and development expenses to grow as we continue to invest in basic research, clinical trials, product development and in our intellectual property.

Finance Costs

As of October 31, 2018 and 2017, the Company owed $718,808 and $582,795 respectively to a stockholder – Titan Technology Development Limited, which is unsecured and repayable on demand. Interest is charged at 7% per annum on the amount owed.

As of October 31, 2018 and 2017, the Company owed $1,715,840 and $1,710,759 to Chi Fung Yu, $2,344,849 and $1,800,541 to Tie Jun Chen, $36,040 and $35,782 to Que Feng, $228,842 and $220,098 to Shenzhen Hygeian Medical Device Company, Limited., which are unsecured and repayable on demand. Interest is charged at 7% per annum on the amount owed.

Total interest expenses on advances from a stockholder accrued for the year ended October 31, 2018 and October 31, 2017 are $42,884 and $37,379 for Titan Technology Development Limited.

Total interest expenses on advances from following related parties accrued for the year ended October 31, 2018 and October 31, 2017 are $98,431 and $93,951 for Chi Fung Yu; $128,680 and $97,045 for Tie Jun Chen; $2,133 and $2,059 for Que Feng; $14,628 and $11,710 for Shenzhen Hygeian Medical Device Company.

As of October 31, 2018 and October 31, 2017, the Company owed the following amounts respectively to three directors for advances made - $252,377 and $298,818 to Wang Hui; $20,930 and $22,602 to Chi Ming Yu; $567 and $0 to Kai Gui. These advances were made on an unsecured basis, repayable on demand and interest free.

Imputed interest charged at 5% per annum on the amounts owed to the directors for the year ended October 31, 2018 and 2017 respectively is $13,815 and $15,623 for Wang Hui; $0 and $0 for Chi Ming Yu and Kai Gui.

Income Tax

ABMT was incorporated in the United States and has incurred net operating loss for income tax purposes for 2018 and 2017. ABMT has net operating loss carry forwards for income taxes amounting to approximately $2,082,118 and $1,915,159 as of October 31, 2018 and 2017 respectively which may be available to reduce future years’ taxable income. These carry forwards, will expire, if not utilized, commencing in 2029. Management believes that the realization of the benefits from these losses appears uncertain due to the Company’s limited operating history and continuing losses. Accordingly, a full, deferred tax asset valuation allowance has been provided and no deferred tax asset valuation allowance has been provided and no deferred tax asset benefit has been recorded. The valuation allowance at October 31, 2018 and 2017 was $707,920 and $651,154 respectively. The net change in the valuation allowance for 2018 was an increase of $56,766.

Masterise was incorporated in the BVI and under current law of the BVI, is not subject to tax on income.

Shenzhen Changhua was incorporated in the PRC and is subject to PRC income tax which is computed according to the relevant laws and regulations in the PRC. The income tax rate has been 25%. No income tax expense has been provided by Shenzhen Changhua as it is waiting for CFDA approval and it has incurred losses.

Net Loss

As reflected in the accompanying audited consolidated financial statements, the Company has an accumulated deficit of $8,632,618 at October 31, 2018 that includes a net loss of $953,320 for the year ended October 31, 2018. We therefore do not have any revenue from inception to October 31, 2018 but have to incur operating expenses for the upkeep of the Company and the clinical trials.

Liquidity and Capital Resources

We had a working capital deficit of $5,721,907 at October 31, 2018 compared to a working capital deficit of $5,055,542 as of October 31, 2017. Our working capital deficit increased as a result of the fact that we are in clinical trial phase, the company has put all resources to complete the clinical trials. We do not have a CFDA permit to produce, market or sell in China. We had no revenues during the year and that our sole source of financing came in the form of a loan from our related parties and stockholders.

Cash Flows

Net Cash Used in Operating Activities

Net cash used in operating activities was $832,421 in the year ended October 31, 2018. This amount was attributable primarily to the net loss after adjustment for non-cash items, such as depreciation and imputed interest on advances from directors.

Net Cash Used in Investing Activities

We recorded $64,405 net cash used in investing activities in the year ended October 31, 2018. This amount reflected purchases of property and equipment, primarily for research and development to our facilities.

Net Cash Provided by Financing Activities

Net cash provided by financing activities in the year ended October 31, 2018 was $889,901, which represented advances from related parties.

Operating Capital and Capital Expenditure Requirements

Our ability to continue as a going concern and support the commercialization of current products is dependent upon our ability to obtain additional financing in the near term. We anticipate that such funding will be in the form of equity financing from sales of our common stock. However, there is no assurance that we will be able to raise sufficient funding from the sale of our common stock to fund our business plan should we decide to proceed. We anticipate continuing to rely on advances from our related parties and stockholders in order to continue to fund our business operations

We believe that our existing cash, cash equivalents at October 31, 2018, will be insufficient to meet our cash needs. The management is actively pursuing additional funding and strategic partners, which will enable the Company to implement our business plan, business strategy, to continue research and development, manufacturing and marketing our products, clinical trials or further development that may arise.

Going Concern

These factors raise substantial doubt about our ability to continue as a going concern. In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon continued operations of the Company, which in turn is dependent up the Company’s ability to raise additional capital, obtain financing and succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Management has taken steps to revise its operating and financial requirements, which it believes are sufficient to provide the Company with the ability to continue as a going concern. The Company is now pursuing additional funding and potential merger or acquisition candidates, which would enhance stockholders’ investment. Management believes that the above actions will allow the Company to continue operations through the next fiscal year.

As of October 31, 2018, loans from the Company’s stockholder, two directors, three related parties and a non-related third party totaling $5,312,246 were provided to us for use as working capital. Management believes that such financing will allow us to continue operations through the next fiscal year. The Company is also actively pursuing a number of private placements funding which would ensure continued operations.

OFF-BALANCE SHEET ARRANGEMENTS

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our investors.

CRITICAL ACCOUNTING POLICIES

The preparation of our financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, including but not limited to those related to income taxes and impairment of long-lived assets. We base our estimates on historical experience and on various other assumptions and factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Based on our ongoing review, we plan to adjust to our judgments and estimates where facts and circumstances dictate. Actual results could differ from our estimates.

We believe the following critical accounting policies are important to the portrayal of our financial condition and results and require our management’s most difficult, subjective or complex judgments, often because of the need to make estimates about the effect of matters that are inherently uncertain.

1.	Property and equipment

Property and equipment are stated at cost, less accumulated depreciation. Expenditures for additions, major renewals and betterments are capitalized and expenditures for maintenance and repairs are charged to expense as incurred.

Depreciation is provided on a straight-line basis, less estimated residual value over the assets estimated useful lives. The estimated useful lives of the assets are 5 years.

2.	Long-lived assets

In accordance with FASB Codification Topic 360 (ASC Topic 360), “Accounting for the impairment or disposal of Long-Lived Assets”, long-lived assets and certain identifiable intangible assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets, the recoverability test is performed using undiscounted net cash flows related to the long-lived assets. The Company reviews long-lived assets to determine that carrying values are not impaired.

Long-lived assets, such as property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the book value of the asset may not be recoverable. Impairment of the carrying value of long-lived assets would be indicated if the best estimate of future undiscounted cash flows expected to be generated by the asset grouping is less than its carrying value. If an impairment is indicated, any loss is measured as the difference between estimated fair value and carrying value and is recognized in operating income. For the year ended October 31, 2018 and 2017, the company has not recognized any impairment charges.

3.	Fair value of financial instruments

FASB Codification Topic 825(ASC Topic 825), “Disclosure About Fair Value of Financial Instruments,” requires certain disclosures regarding the fair value of financial instruments. The carrying amounts of other receivables and prepaid expenses, other payables and accrued expenses, due to a stockholder, directors and related parties approximate their fair values because of the short-term nature of the instruments. The management of the Company is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial statements.

4.	Government grant

Government grants are recognized when there is reasonable assurance that the Company complies with any conditions attached to them and the grants will be received.

5.	Income taxes

The Company accounts for income taxes under the FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period included the enactment date.

6.	Research and Development

Research and development costs related to both present and future products are expensed as incurred.

7.	Foreign currency translation

The financial statements of the Company’s subsidiary denominated in currencies other than US $ are translated into US $ using the closing rate method. The balance sheet items are translated into US $ using the exchange rates at the respective balance sheet dates. The capital and various reserves are translated at historical exchange rates prevailing at the time of the transactions while income and expenses items are translated at the average exchange rate for the year. All exchange differences are recorded within equity.

Recent Accounting Pronouncements

Business Combination: Clarifying the Definition of a Business

In January 2017, the FASB issued ASU No. 2017-1 “Topic 805, Business Combinations: Clarifying the Definition of a Business”. The amendments in this update provide a screen to determine when a set is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. The amendments in this update affect all reporting entities that must determine whether they have acquired or sold a business. Public business entities should apply the amendments in this update to annual periods beginning after December 15, 2017, including interim periods within those periods. All other entities should apply the amendments to annual periods beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2019. The Company does not expect the adoption of ASU 2017-1 to have a material impact on its consolidated financial statements.

Simplifying the Test for Goodwill Impairment

In January 2017, the FASB issued ASU No. 2017-4 “Topic 350: Intangibles-Goodwill and Other: Simplifying the Test for Goodwill Impairment.” The amendments in this update eliminate step two of the goodwill impairment test and specifies that goodwill impairment should be measured by comparing the fair value of a reporting unit with its carrying amount. Additionally, the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets should be disclosed. The amendments in this update are effective for annual or interim goodwill impairment tests performed in fiscal years beginning after December 15, 2019; early adoption is permitted. The Company does not expect the adoption of ASU 2017-4 to have a material impact on its consolidated financial statements.

Share-based Compensation

In May 2017, the FASB issued guidance on changes to terms and conditions of share-based payment awards. The amendment provides guidance about which changes to terms or conditions of a share-based payment award require an entity to apply modification accounting. The guidance is effective for the fiscal year beginning on January 1, 2018, including interim periods within that year.

In June 2018, the scope of Topic 718 has been expanded to include sharebased payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2018 and after December 15, 2019 for all other entities. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606.

The Company does not anticipate that adoption of these guidances will have a material impact on its consolidated financial statements.

Revenue Recognition

In May 2014, the FASB issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. Under the new standard, a good or service is transferred to the customer when (or as) the customer obtains control of the good or service, which differs from the risk and rewards approach under current guidance. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. In March, April and May 2016, the FASB issued three additional updates regarding identifying performance obligations and licensing, certain principal versus agent considerations and various narrow scope improvements based on practical questions raised by users. In September 2017, the FASB issued additional amendments providing clarification and implementation guidance. The guidance may be adopted through either retrospective application to all periods presented in the financial statements (full retrospective approach) or through a cumulative effect adjustment to retained earnings at the effective date (modified retrospective approach). The guidance is effective for the fiscal periods beginning on January 1, 2018.

Leases

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. The new standard, as amended by ASU 2018-01 and ASU 2018-11, is effective for annual periods beginning after December 15, 2018 on a modified retrospective basis. The Company will adopt ASU 2016-02 in its first quarter of the year ending October 31 2020. The Company expects its leases designated as operating leases in Note 6, “Commitments and Contingencies,” will be reported on the consolidated balance sheets upon adoption. However, the ultimate impact of adopting ASU 2016-02 will depend on the lease terms as of the adoption date.

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoptions of any such pronouncements may be expected to cause a material impact on the financial condition or the results of operations.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

ADVANCED BIOMEDICAL TECHNOLOGIES, INC.
AND SUBSIDIARIES

CONSOLIDATED FINANCIAL STATEMENTS
AS OF OCTOBER 31, 2018

ADVANCED BIOMEDICAL TECHNOLOGIES, INC.
AND SUBSIDIARIES

CONTENTS

	Pages

Reports of Independent Registered Public Accounting Firm	F-2

Consolidated Balance Sheets	F-3

Consolidated Statements of Operations and Comprehensive Loss	F-4

Consolidated Statements of Stockholders’ Deficit	F-5

Consolidated Statements of Cash Flows	F-6

Notes to Consolidated Financial Statements	F-7 – F-13

F-1

Report of Independent Registered Public Accounting Firm

To the shareholders and the board of directors of Advanced Biomedical Technologies, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Advanced Biomedical Technologies, Inc. and subsidiaries (the “Company”) as of October 31, 2018 and 2017, and the related consolidated statements of comprehensive loss, changes in equity and cash flows for each of two years in the period ended October 31, 2018, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at October 31, 2018 and 2017, and the results of its operations and its cash flows for each of the two years in the period ended October 31, 2018, in conformity with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 9 to the financial statements, the Company has suffered from losses from operation and significant accumulated deficits. The Company comes to have insufficient cash flows generated from operation and provided for development. In addition, the Company continues to experience negative cash flows from operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ Centurion ZD CPA & Co.

Centurion ZD CPA & Co. (as successor to Centurion ZD CPA Limited)

We have served as the Company’s auditor since 2016.

Hong Kong, China

25 March 2019

F-2

ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	October 31,			October 31,
	2018			2017

ASSETS

CURRENT ASSETS
Cash and cash equivalents	$	6,860		$	7,463
Other receivables and prepaid expenses		32,649			17,469

Total Current Assets		39,509			24,932

Property and equipment, cost		521,120			483,482
Less: Accumulated depreciation		(418,225	)		(422,967	)
PROPERTY AND EQUIPMENT, NET		102,895			60,515
LONG-TERM PREPAID EXPENSES, NET		-			-
DEPOSIT FOR PURCHASE OF PROPERTY AND EQUIPMENT		-			-
TOTAL ASSETS	$	142,404		$	85,447

LIABILITIES AND STOCKHOLDERS’ DEFICIT

CURRENT LIABILITIES
Other payables and accrued expenses	$	443,163		$	409,079
Due to directors		273,874			321,420
Due to a stockholder		718,808			582,795
Due to related parties		4,325,571			3,767,180

Total Current Liabilities		5,761,416			5,080,474

COMMITMENTS AND CONTINGENCIES		-			-

STOCKHOLDERS’ DEFICIT
Common stock, $0.00001 par value, 100,000,000 shares authorized, 69,624,850 issued and outstanding as of October 31, 2018 and October 31, 2017		696			694
Additional paid-in capital		2,740,183			2,673,620
Accumulated deficit		(8,632,618	)		(7,679,298	)
Accumulated other comprehensive income/(loss)		272,727			9,957

Total Deficit		(5,619,012	)		(4,995,027	)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	142,404		$	85,447

The accompanying notes are an integral part of these consolidated financial statements

F-3

ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

	Year ended
	October 31,			October 31,
	2018			2017
OPERATING EXPENSES
General and administrative expenses	$	561,210		$	341,956
Depreciation		16,295			13,604
Research and development		56,512			48,053
Total Operating Expenses		634,017			403,613

LOSS FROM OPERATIONS		(634,017	)		(403,613	)

OTHER (EXPENSES) INCOME
Interest income		36			36
Interest paid to a stockholder and related parties		(286,756	)		(242,144	)
Interest paid to a third party		-
Imputed interest		(13,815	)		(15,623	)
Other, net		(18,768	)		(30,256	)
Total Other (Expenses) Income, net		(319,303	)		(287,987	)

LOSS BEFORE TAXES		(953,320	)		(691,600	)
Income tax expense		-			-
NET LOSS		(953,320	)		(691,600	)
Net loss attributable to non-controlling interests		-			-
NET LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS		(953,320	)		(691,600	)

OTHER COMPREHENSIVE INCOME
Foreign currency translation income		262,770			(94,255	)

Total other comprehensive gain/(loss)		262,770			(94,255	)
COMPREHENSIVE GAIN/(LOSS) ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS	$	(690,550	)	$	(785,855	)

Net loss per share-basic and diluted
- basic and diluted	$	(0.01	)	$	(0.01	)

Weighted average number of shares outstanding during the year
- basic and diluted		69,381,015			68,277,590

The accompanying notes are an integral part of these consolidated financial statements

F-4

ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

	Common stock				Additional					Accumulated other
	Number				paid-in		Accumulated			comprehensive
	of shares		Amount		capital		deficit			loss			Total
Balance at October 31, 2015		56,874,850	$	569	$	1,949,132	$	(6,262,961	)	$	(148,227	)	$	(4,461,487	)

Stock issued for debt conversion at 0.05 per shares		10,000,000		100		499,900		-			-			500,000

Stock issued for services ($1 per share)		250,000		2		52,498		-			-			52,500

Imputed interest on advances from directors						18,990		-			-			18,990

Net loss for the year		-		-		-		(724,737	)		-			(724,737	)

Foreign currency translation gain		-		-		-		-			252,439			252,439

Balance at Oct 31, 2016		67,124,850	$	671	$	2,520,520	$	(6,987,698	)	$	104,212		$	(4,362,295	)

Stock issued for debt conversion at 0.05 per share		2,000,000		20.00		99,980		-			-			100,000

Stock issued for services ($0.15 per share)		250,000		3.00		37,497		-			-			37,500

Imputed interest on advances from directors		-		-		15,623		-			-			15,623

Net loss for the year		-		-		-		(691,600	)		-			(691,600	)

Foreign currency translation gain		-		-		-		-			(94,255	)		(94,255	)

Balance at October 31, 2017		69,374,850	$	694	$	2,673,620	$	(7,679,298	)	$	9,957		$	(4,995,027	)

Stock issued for services ($0.211 per share)		250,000		2.00		52,748		-			-			52,750

Imputed interest on advances from directors		-		-		13,815.00		-			-			13,815

Net loss for the year		-		-		-		(953,320	)		-			(953,320	)

Foreign currency translation loss		-		-		-		-			262,770			262,770

Balance at October 31, 2018		69,624,850	$	696	$	2,740,183	$	(8,632,618	)	$	272,727		$	(5,619,012	)

The accompanying notes are an integral part of these consolidated financial statements

F-5

ADVANCED BIOMEDICAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Year ended
	October 31,
	2018			2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss attributable to ABMT common stockholders	$	(953,320	)	$	(691,600	)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation		16,295			13,604
Loss on disposal of property and equipment		-			37,500
Stock issued for services		52,750			-
Imputed interest		13,815			15,623
Changes in operating assets and liabilities
Decrease (increase) in:
Other receivables and prepaid expenses		(16,861	)		3,291
Increase in:
Other payables and accrued expenses		54,900			63,870
Net cash used in operating activities		(832,421	)		(557,712	)

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment		(64,405	)		(453	)
(Increase) decrease in deposit for purchase of property and equipment		-			1,213
Net cash used in investing activities		(64,405	)		760

CASH FLOWS FROM FINANCING ACTIVITIES
Due to a stockholder		136,441			89,444
Due to directors		(34,932	)		(48,351	)
Due to related parties		794,771			516,658
Net cash provided by financing activities		896,280			557,751

EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS		(57	)		105

NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS		(603	)		904

CASH AND CASH EQUIVALENTS AT THE BEGINNING OF YEAR		7,463			6,559

CASH AND CASH EQUIVALENTS AT THE END OF YEAR	$	6,860		$	7,463

Supplemental of cash flow information
Interest income	$	36		$	36
Income tax	$	-		$	-

Other non cash items
Interest expenses	$	286,756		$	242,144

The accompanying notes are an integral part of these consolidated financial statements

F-6

ADVANCED BIOMEDICAL TECHNOLOGIES, INC.
AND SUBSIDIARIES

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION

(A)

Organization

Advanced Biomedical Technologies, Inc. (fka “Geostar Mineral Corporation” or “Geostar”) (“ABMT”) was incorporated in Nevada on September 12, 2006.

Shenzhen Changhua Biomedical Engineering Co., Ltd. (“Shenzhen Changhua”) was incorporated in the People’s Republic of China (“PRC”) on September 25, 2002 as a limited liability company with a registered capital of $724,017. Shenzhen Changhua is owned by two stockholders in the proportion of 70% and 30% respectively. Shenzhen Changhua has been involved in the development of polymer screws, rods and binding wires for fixation on human fractured bones. The Company is currently involved in researching, manufacturing and conducting clinical trials on its products and intends to raise additional capital to produce and market its products commercially. The Company holds one Class III permit and one Class II permit from the China Food and Drug Administration (“CFDA”), formally the State Food and Drug Administration (“SFDA”) of the PRC. The Company holds two patents issued by the State Intellectual Property Office of the P.R.C. (“SIPO”). The Company has no revenue since its inception and, in accordance with Accounting Standards Codification (“ASC”) Topic 915, “Development Stage Entities”, is considered a Development Stage Company.

Masterise Holdings Limited (“Masterise”) was incorporated in the British Virgin Islands on 31 May, 2007 as an investment holding company. Masterise is owned as to 63% by the spouse of Shenzhen Changhua’s 70% majority stockholder and 37% by a third party corporation.

On January 29, 2008, Masterise entered into a Share Purchase Agreement (“the Agreement”) with a stockholder of Shenzhen Changhua whereupon Masterise acquired 70% of Shenzhen Changhua for US$64,100 in cash. The acquisition was completed on February 25, 2008. As both Masterise and Shenzhen Changhua are under common control and management, the acquisition was accounted for as a reorganization of entities under common control. Accordingly, the operations of Shenzhen Changhua were included in the consolidated financial statements as if the transactions had occurred retroactively.

On December 31, 2008, ABMT consummated a Share Exchange Agreement (“the Exchange Agreement”) with the stockholders of Masterise pursuant to which Geostar issued 50,000 shares of Common Stock to the stockholders of Masterise for 100% equity interest in Masterise.

Concurrently, on December 31, 2008, a major stockholder of ABMT also consummated an Affiliate Stock Purchase Agreement (the “Affiliate Agreement”) with thirteen individuals including all the stockholders of Masterise, pursuant to which the major stockholder sold a total of 5,001,000 shares of ABMT’s common stock for a total aggregate consideration of $5,000, including 4,438,250 shares to the stockholders of Masterise.

On consummation of the Exchange Agreement and the Affiliate Agreement, the 70% majority stockholder of Masterise became an 80.7% stockholder of ABMT.

On March 13, 2009, the name of the Company was changed from Geostar Mineral Corporation to Advanced Biomedical Technologies, Inc.

The merger of ABMT and Masterise was treated for accounting purposes as a capital transaction and recapitalization by Masterise (“the accounting acquirer”) and a re-organization by ABMT (“the accounting acquiree”). The financial statements have been prepared as if the re-organization had occurred retroactively.

Accordingly, these financial statements include the following:

	(1)	The balance sheet consisting of the net assets of the acquirer at historical cost and the net assets of the acquiree at historical cost.

	(2)	The statement of operations including the operations of the acquirer for the periods presented and the operations of the acquiree from the date of the transaction.

ABMT, Masterise and Shenzhen Changhua are hereinafter referred to as (“the Company”).

F-7

(B)

Principles of consolidation

The accompanying consolidated financial statements include the financial statements of ABMT and its wholly owned subsidiaries, Masterise and its 70% owned subsidiary, Shenzhen Changhua. The noncontrolling interests represent the noncontrolling stockholders’ 30% proportionate share of the results of Shenzhen Changhua.

All significant inter-company balances and transactions have been eliminated in consolidation.

(C)

Use of estimates

The preparation of the financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

(D)

Cash and cash equivalents

For purpose of the statements of cash flows, cash and cash equivalents include cash on hand and demand deposits with a bank with a maturity of less than three months. As of October 31, 2018 and 2017, all the cash and cash equivalents were denominated in United States Dollars (“US$”), Hong Kong Dollars (“HK$”) and Renminbi (“RMB”) and were placed with banks in the United States of America, Hong Kong and PRC. Balances at financial institutions or state-owned banks within the PRC are not freely convertible into foreign currencies and the remittance of these funds out of the PRC is subject to exchange control restrictions imposed by the PRC government.

(E)

Property and equipment

Depreciation is provided on a straight-line basis, less estimated residual value over the assets estimated useful lives. The estimated useful lives of the assets are 5 years.

(F)

Long-lived assets

The Company accounts for long-lived assets under the FASB Codification Topic 360 (ASC 360) “Accounting for Impairment or Disposal of Long-Lived Assets”. In accordance with ASC Topic 360, long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets, when undiscounted future cash flows will not be sufficient to recover an asset’s carrying amount, the asset is written down to its fair value. The long-lived assets of the Company, which are subject to evaluation, consist primarily of property and equipment. For the years ended October 31, 2018 and 2017, the Company has not recognized any allowances for impairment.

(G)

Fair value of financial instruments

FASB Codification Topic 825 (ASC Topic 825), “Disclosure About Fair Value of Financial Instruments,” requires certain disclosures regarding the fair value of financial instruments. The carrying amounts of other receivables and prepaid expenses other payables and accrued liabilities and due to directors, a stockholder and related parties approximate their fair values because of the short-term nature of the instruments. The management of the Company is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial statements.

(H)

Income taxes

We assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where there is greater than 50% likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that may potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is a 50% or less likelihood that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements.

(I)

Research and development

F-8

(J)

Foreign currency translation

The reporting currency of the Company is the US dollar. ABMT, Masterise and Shenzhen Changhua maintain their accounting records in their functional currencies of US$, HK$ and RMB respectively.

Foreign currency transactions during the year are translated to the functional currency at the approximate rates of exchange on the dates of transactions. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the approximate rates of exchange at that date. Non-monetary assets and liabilities are translated at the rates of exchange prevailing at the time the asset or liability was acquired. Exchange gains or losses are recorded in the statement of operations.

The financial statements of Masterise and Shenzhen Changhua (whose functional currency is HK$ and RMB respectively) are translated into US$ using the closing rate method. The balance sheet items are translated into US$ using the exchange rates at the respective balance sheet dates. The capital and various reserves are translated at historical exchange rates prevailing at the time of the transactions while income and expenses items are translated at the average exchange rate for the year. All exchange differences are recorded within equity.

The exchange rates used to translate amounts in HK$ and RMB into US$ for the purposes of preparing the financial statements were as follows:

October 31, 2018

October 31, 2017

Balance sheet items, except for share capital, additional paid-in capital and accumulated deficits, as of year end

US$1=HK$7.8393=RMB6.9737

US$1= HK$7.8015=RMB6.6328

Amounts included in the statements of operations and cash flows for the year

US$1=HK$7.8351=RMB6.5629

US$1= HK$7.7842=RMB6.8013

The translation gain and loss recorded for the years ended October 31, 2018 and 2017 were $262,770 and $94,255 respectively.

No presentation is made that RMB amounts have been, or would be, converted into US$ at the above rates. Although the Chinese government regulations now allow convertibility of RMB for current account transactions, significant restrictions still remain. Hence, such translations should not be construed as representations that RMB could be converted into US$ at that rate or any other rate.

The value of RMB against US$ and other currencies may fluctuate and is affected by, among other things, changes in China’s political and economic conditions. Any significant revaluation of RMB may materially affect the Company’s financial condition in terms of US$ reporting.

(K)

Other comprehensive loss

The foreign currency translation gain or loss resulting from translation of the financial statements expressed in RMB and HK$ to US$ is reported as other comprehensive gain or loss in the statements of operations and stockholders’ deficit. Other comprehensive gain and loss for the years ended October 31, 2018 and 2017 were $262,770 and $94,255 respectively.

(L)

Loss per share

Basic loss per share are computed by dividing income available to stockholders by the weighted average number of shares outstanding during the year. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the potential shares had been issued and if the additional shares were diluted. There are no potentially dilutive securities as at October 31, 2018 and October 31, 2017.

(M)

Segments

The Company operates in only one segment, thereafter segment disclosure is not presented.

(N)

Recent Accounting Pronouncements

Business Combination: Clarifying the Definition of a Business

F-9

Simplifying the Test for Goodwill Impairment

Share-based Compensation

The Company does not anticipate that adoption of these guidances will have a material impact on its consolidated financial statements.

Revenue Recognition

Leases

F-10

2. PROPERTY AND EQUIPMENT

The following is a summary of property and equipment at October 31, 2018 and 2017:

	October 31,
	2018		2017

Plant and machinery	$	296,517	$	280,871
Motor vehicles		39,534		41,566
Office equipment		34,572		34,902
Computer software		5,017		5,017
Office improvements		145,480		121,126

		521,120		483,482
Less: accumulated depreciation		418,225		422,967

Property and equipment, net	$	102,895	$	60,515

Depreciation expense for the year ended October 31, 2018 and 2017 was $16,295 and $13,604 respectively.

3. OTHER PAYABLES AND ACCRUED EXPENSES

Other payables and accrued expenses at October 31, 2018 and 2017 consisted of the followings:

	October 31,
	2018		2017

Other payables	$	215,095	$	223,437
Accrued expenses		228,068		185,642
	$	443,163	$	409,079

4. RELATED PARTY TRANSACTIONS

As of October 31, 2018 and 2017, the Company owed $718,808 and $582,795 respectively to Titan Technology Development Limited, a stockholder.

As of October 31, 2018 and 2017, advances from related parties were as follows:

	October 31,
	2018		2017

Yu Chi Fung	$	1,715,840	$	1,710,759
Que Feng		36,040		35,782
Chen Tie Jun		2,344,849		1,800,541
Shenzhen Hygeian Medical Device Co., Ltd.		228,842		220,098
Amount due to related parties	$	4,325,571	$	3,767,180

F-11

Advances from a stockholder and related parties are unsecured, repayable on demand and bearing interest at 7% per annum. Interest expenses on advances from a stockholder and the related parties accrued for the years ended October 31, 2018 and 2017 were as follows:

	October 31,
	2018		2017

Titan Technology Development Limited, a stockholder	$	42,884	$	37,379
Related parties:
Que Feng		2,133		2,059
Yu Chi Fang		98,431		93,951
Chen Tie Jun		128,680		97,045
Shenzhen Hygeian Medical Device Co., Ltd.		14,628		11,710
Interest expenses to a stockholder and related parties	$	286,756	$	242,144

As of October 31, 2018 and 2017, advances from directors were as follows:

	October 31,
	2018		2017

Wang Wei	$	252,377	$	298,818
Gui Kai		567		-
Yu Chi Ming		20,930		22,602
Amount due to directors	$	273,874	$	321,420

Advances from directors were unsecured, repayable on demand and interest free. Imputed interests on the amounts owed to Wang Wei, a director, were $13,815 and $15,623 for the years ended October 31, 2018, and 2017 respectively.

5. STOCKHOLDERS’ DEFICIENCY

Common stock

On December 8, 2011, the Company issued 100,000 shares of restricted common stock at $0.2 to Dr. John Lynch, the Company’s chief officer of dental technologies, for services for a term of twelve months. The shares were valued at the closing price on the date of grant yielding an aggregate fair value of $20,000, fully recognised in prior years as consultancy fees included in general and administrative expenses.

On 28 October 2013, the Company issued 150,000 shares of restricted common stock as directors’ services compensation for past services to each of Mr. Chi Ming Yu and Kai Gui, directors of the Company. The shares were valued at the closing price of $0.71 per share on the date of grant, yielding an aggregate fair value of $213,000.

On 13 November 2015, $106,506 of the interest payable to a Company’s stockholder and $393,494 of the interest payable to two related parties, totaled $500,000, were converted into 10,000,000 shares of common stock at a conversion price of $0.05 per share and which were issued to the said stockholder.

On 31 March 2016, the Company issued 100,000 and 150,000 shares of restricted common stock as directors’ compensation for past services to Mr. Chi Ming Yu and Mr. Kai Gui, directors of the Company respectively. The shares were valued at the closing price of $0.21 per share on the date of grant, yielding an aggregate fair value of $52,500.

On 28 April 2017, the Company issued 100,000 and 150,000 shares of restricted common stock as directors’ compensation for past services to Mr. Chi Ming Yu and Mr. Kai Gui, directors of the Company respectively. The shares were valued at the closing price of $0.15 per share on the date of grant, yielding an aggregate fair value of $37,500.

On 23 October 2018, the Company issued 100,000 and 150,000 shares of restricted common stock as directors’ compensation for past services to Mr. Chi Ming Yu and Mr. Kai Gui, directors of the Company respectively. The shares were valued at the closing price of $0.211 per share on the date of grant, yielding an aggregate fair value of $52,750.

6. COMMITMENTS AND CONTINGENCIES

(A)

Employee benefits

The full time employees of the Company are entitled to employee benefits including medical care, welfare subsidies, unemployment insurance and pension benefits through a Chinese government mandated multi-employer defined contribution plan. The Company is required to accrue for these benefits based on certain percentages of the employees’ salaries and make contributions to the plans out of the amounts accrued for medical and pension benefits. The total provisions and contributions made for such employee benefits was $58,469 and $37,440 for the years ended October 31, 2018 and 2017 respectively. The Chinese government is responsible for the medical benefits and the pension liability to be paid to these employees.

F-12

(B)

Lease commitments

As of October 31, 2018, the Company had outstanding commitments with respect to operating leases, which are due as follows:

2018	$	41,298
2019		34,415
2020		14,340
Total	$	90,053

The Company leased from a third party office space at monthly rent prevailing at October 31, 2018 of $1,867 (2017: $1,963). This operating lease expired on July 20, 2015. The Company continues to lease this premises at same monthly rent pending a formal renewal of the lease.

(C)

Capital commitments

The Company has no outstanding commitments contracted for, net of deposit paid, in respect of acquisitions of plant and machineries as of October 31, 2018 (2017: Nil).

7. INCOME TAX

Masterise was incorporated in the BVI and under current law of the BVI, is not subject to tax on income.

Shenzhen Changhua was incorporated in the PRC and is subject to PRC income tax which is computed according to the relevant laws and regulations in the PRC. The income tax rate has been 25%. No income tax expense has been provided by Shenzhen Changhua as it has incurred losses. The losses cannot be carried forward as Shenzhen Changhua has not yet commenced operation.

8. CONCENTRATIONS AND RISKS

As at October 31, 2018 and 2017, 94% and 6% of the Company’s assets were located in the P.R.C. and the United States respectively.

9. GOING CONCERN

As reflected in the accompanying consolidated financial statements, the Company has an accumulated deficit of $8,632,618 as of October 31, 2018 that includes a net loss of $953,320 for the year ended October 31, 2018. The Company’s total current liabilities exceed its total current assets by $5,721,907 and the Company used cash in operations of $832,421. These factors raise substantial doubt about its ability to continue as a going concern. In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to raise additional capital, obtain financing and succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

To continue as a going concern, the Company is actively pursuing additional funding and strategic partners to enable it to implement its business plan. Management believes that these actions, if successful, will allow the Company to continue its operations through the next fiscal year.

10. SUBSEQUENT EVENT

The Company has evaluated the existence of significant events subsequent to the balance sheet date through the date the financial statements were issued and has determined that there were no subsequent events or transactions which would require recognition or disclosure in the financial statements.

F-13

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

There were no disagreements related to accounting principles or practices, financial statement disclosure, internal controls or auditing scope or procedure during the two fiscal years and interim periods, including the interim period up through the date the relationship ended.

ITEM 9A. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

We have established disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934. Our disclosure controls and procedures are designed to ensure that material information relating to us, including our consolidated subsidiaries, is made known to our principal executive officer and principal financial officer by others within our organization. Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of October 31, 2018 to ensure that the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of October 31, 2018.

Management’s Annual Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of October 31, 2018, based on the criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations (COSO) of the Treadway Commission (1992). Based on this evaluation, our management concluded that our internal control over financial reporting was effective as of October 31, 2018. The Company’s internal control over financial reporting as of October 31, 2018 has not been audited by the Company’s independent accountants.

Changes in Internal Control Over Financial Reporting

During the year ended October 31, 2018, there were no significant changes in our internal control over financial reporting that materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.

ITEM 9B. OTHER INFORMATION

None.

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Officers and Directors

Our directors serve until his successor is elected and qualified. Each of our officers is elected by the board of directors to a term of one (1) year and serves until his or her successor is duly elected and qualified, or until he or she is removed from office. The board of directors has no nominating, auditing or compensation committees.

The name, age and position of our officers and directors are set forth below:

Name and Address	Age		Position(s)
Chi Ming Yu		45	President, Director
Hui Wang		49	Chief Executive Officer, Director
Kai Gui		49	Director, Secretary, Chief Financial Officer, Chief Operating Officer

The person named above has held his offices/positions since inception of our company and is expected to hold his offices/positions until the next annual meeting of our stockholders.

Background of our Officers and Directors

Chi Ming Yu, Director and President, is Director of Operations at Titan Holdings, Inc. where his main responsibilities are in Administration, Company Finance and Investment, Marketing Research and Customer Relationship. From 2000 to 2003, Mr. Yu worked as a sales manager at Fu Feng LLC. From 2003 to present, Mr. Yu worked as Vice President at Titan Technology Development Ltd. Mr. Yu studied Computer Science at Rutgers University, New Jersey. Mr. Yu has extensive knowledge of the Company’s product line, and is fluent in several languages, including English and Chinese. The Board concluded that Mr. Yu should serve as a Director due to his background in the Company’s product line together with his communication skills

Hui Wang, Director and Chief Executive Officer, started her career at Hainan Xinte Pharmaceutical Ltd in China in 1990. She worked her way up from cashier to sales representative and then to sales manager. She then worked as District Manager of Southern China with Hainan Tianfeng Pharmaceutical Ltd, from 1995 to 2000 and as General Manager with Hainan Yichen Pharmaceutical Ltd. from 2001 to 2004. She is now the General Manager of Shenzhen Changhua. Ms. Wang has skills and experience in R&A, marketing and business development in Chinese medical industry. The Board concluded that Hui Wang should serve as a Director due to her skills and experience in pharmaceutical sales and business development.

Kai Gui, Director, Secretary and Chief Financial Officer, worked as an Analyst Programmer in the British media industry, and as IT Manager, Circulation Manager, and Foreign Publishing Director at S.J.P. Ltd in London from 1994 to 2008. Beginning in 2000 Mr. Gui participated in several business projects involving Chinese publicly listed companies. He was the Director of China Feed Industry Association Information Centre’s European Office. He is Vice President of Titan Technology Development Ltd. After graduating from the University of Westminster in London, Mr. Gui took a Post-graduate course in Financial Management at Middlesex University in London. The Board concluded that Kai Gui should serve as a Director due to his business experience and financial management skills.

Involvement in Certain Legal Proceedings

To the best of our knowledge, none of our directors or executive officers, during the past ten years, has been involved in any legal proceeding of the type required to be disclosed under applicable SEC rules, including:

	1.	Any petition under the Federal bankruptcy laws or any state insolvency law being filed by or against, or a receiver, fiscal agent or similar officer being appointed by a court for the business or property of such person, or any partnership in which he was a general partner at or within two years before the time of such filing, or any corporation or business association of which he was an executive officer at or within two years before the time of such filing;

	2.	Conviction in a criminal proceeding, or being a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses);

Being the subject of any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from, or otherwise limiting, the following activities:

	i.	Acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant, any other person regulated by the Commodity Futures Trading Commission, or an associated person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person, director or employee of any investment company, bank, savings and loan association or insurance company, or engaging in or continuing any conduct or practice in connection with such activity;

	ii.	Engaging in any type of business practice; or

	iii.	Engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of Federal or State securities laws or Federal commodities laws;

	4.	Being the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any Federal or State authority barring, suspending or otherwise limiting for more than 60 days the right of such person to engage in any activity described in paragraph (3)(i) of this section, or to be associated with persons engaged in any such activity;

	5.	Being found by a court of competent jurisdiction in a civil action or by the Securities and Exchange Commission to have violated any Federal or State securities law, and the judgment in such civil action or finding by the Commission has not been subsequently reversed, suspended, or vacated;

	6.	Being found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any Federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not been subsequently reversed, suspended or vacated;

	7.	Being the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of:

	i.	Any Federal or State securities or commodities law or regulation; or

	ii.	Any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or

	iii.	Any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or

Being the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

Audit Committee and Charter

We have a separately-designated audit committee of the board. Our board of directors performs audit committee functions. None of our directors are deemed independent. All directors also hold positions as our officers. Our audit committee is responsible for: (1) selection and oversight of our independent accountant; (2) establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal controls and auditing matters; (3) establishing procedures for the confidential, anonymous submission by our employees of concerns regarding accounting and auditing matters; (4) engaging outside advisors; and, (5) funding for the outside auditory and any outside advisors engagement by the audit committee. A copy of our audit committee charter is filed as an exhibit to this report.

Audit Committee Financial Expert

None of our directors or officers has the qualifications or experience to be considered a financial expert. We believe the cost related to retaining a financial expert at this time is prohibitive. Further, because of our limited operations, we believe the services of a financial expert are not warranted.

Code of Ethics

We have adopted a corporate code of ethics. We believe our code of ethics is reasonably designed to deter wrongdoing and promote honest and ethical conduct; provide full, fair, accurate, timely and understandable disclosure in public reports; comply with applicable laws; ensure prompt internal reporting of code violations; and provide accountability for adherence to the code. A copy of the code of ethics is filed as an exhibit to this report.

Disclosure Committee and Charter

We have a disclosure committee and disclosure committee charter. Our disclosure committee is comprised of all of our officers and directors. The purpose of the committee is to provide assistance to the Chief Executive Officer and the Chief Financial Officer in fulfilling their responsibilities regarding the identification and disclosure of material information about us and the accuracy, completeness and timeliness of our financial reports. A copy of the disclosure committee charter is filed as an exhibit to this report.

ITEM 11. EXECUTIVE COMPENSATION

The following table sets forth information with respect to compensation paid by the registrant to its officers during the last completed fiscal year ended October 31, 2018.

Executive Officer Compensation Table

Fees

Earned

Nonqualified

Non-Equity

Deferred

Paid in

Stock

Option

Incentive Plan

Compensation

All Other

Cash

Awards

Compensation

Earnings

Compensation

Total

Name

(US$)

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

Hui Wang

36,770

Chi Ming Yu

Kai Gui

The following table sets forth information with respect to compensation paid by the registrant to its directors during the last completed fiscal year ended October 31, 2018.

Director Compensation

Fees

Earned

Nonqualified

Non-Equity

Deferred

Paid in

Stock

Option

Incentive Plan

Compensation

All Other

Cash

Awards

Compensation

Earnings

Compensation

Total

Name

(US$)

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

Hui Wang

Chi Ming Yu

21,100

Kai Gui

31,650

All compensation received by our officers and directors has been disclosed.

There are no stock option, retirement, pension, or profit sharing plans for the benefit of our officers and directors.

Long-Term Incentive Plan Awards

We do not have any long-term incentive plans that provide compensation intended to serve as incentive for performance.

Indemnification

Under our Bylaws, we may indemnify an officer or director who is made a party to any proceeding, including a lawsuit, because of his position, if he acted in good faith and in a manner he reasonably believed to be in our best interest. We may advance expenses incurred in defending a proceeding. To the extent that the officer or director is successful on the merits in a proceeding as to which he is to be indemnified, we must indemnify him against all expenses incurred, including attorney’s fees. With respect to a derivative action, indemnity may be made only for expenses actually and reasonably incurred in defending the proceeding, and if the officer or director is judged liable, only by a court order. The indemnification is intended to be to the fullest extent permitted by the laws of the State of Nevada.

Regarding indemnification for liabilities arising under the Securities Act of 1933, which may be permitted to directors or officers under Nevada law, we are informed that, in the opinion of the Securities and Exchange Commission, indemnification is against public policy, as expressed in the Act and is, therefore, unenforceable.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The registrant has no compensation plans (including individual compensation arrangements) under which equity securities of the registrant are authorized for issuance.

The following table sets forth, as of the date of this Annual Report on Form 10-K, the total number of shares owned beneficially by each of our directors, officers and key employees, individually and as a group, and the present owners of 5% or more of our total outstanding shares. The stockholders listed below have direct ownership of his/her shares and possess voting and dispositive power with respect to the shares.

(1) Title of Class	(2) Name and address of beneficial owner	(3) Amount and nature of beneficial ownership		(4) Percent of class
Common Stock	Hui Wang, CEO & Director		22,153,540		31.818	%
Common Stock	Chi Ming Yu, President & Director		450,000		0.646	%
Common Stock	Kai Gui, Secretary & Director		750,000		1.077	%
Common Stock	Titan Technology Development, LTD., Room 1903 Hing Yip, Commercial Centre, 272 Des Voeux Road Central, Hong Kong, 718332		24,183,359		34.734	%
All Officers & Directors			23,353,540		33.541	%

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE

Total interest expenses on advances from a stockholder accrued for the year ended October 31, 2018 and October 31, 2017 are $42,884 and $37,379 for Titan Technology Development Limited.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

(1) Audit Fees

The aggregate fees billed for each of the last two fiscal years for professional services rendered by the principal accountant for our audit of annual financial statements and review of financial statements included in our Form 10-Qs or services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements for those fiscal years was:

2018		$	37,000			Centurion ZD CPA Limited
2017		$	37,000			Centurion ZD CPA Limited

(2) Audit-Related Fees

There is no fee billed in each of the last two fiscal years for assurance and related services by the principal accountants that are reasonably related to the performance of the audit or review of our financial statements and are not reported in the preceding paragraph.

(3) Tax Fees

There is no fee billed in each of the last two fiscal years for professional services rendered by the principal accountant for tax compliance, tax advice, and tax planning.

(4) All Other Fees

There is no fee billed in each of the last two fiscal years for the products and services provided by the principal accountant, other than the services reported in paragraphs (1), (2), and (3).

(5) Our audit committee’s pre-approval policies and procedures described in paragraph (c)(7)(i) of Rule 2-01 of Regulation S-X were that the audit committee pre-approves all accounting related activities prior to the performance of any services by any accountant or auditor.

(6) There is no hour expended on the principal accountant’s engagement to audit our financial statements for the most recent fiscal year that were attributed to work performed by persons other than the principal accountant’s full time and permanent employees was.

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

		Incorporated by reference
Exhibit	Document Description	Form	Date	Number	Filed herewith

3.1	Articles of Incorporation	SB-2	01-16-07	3.1
3.2	Bylaws	SB-2	01-16-07	3.2
4.1	Specimen Stock Certificate	SB-2	01-16-07	4.1
10.1	Titan – ABMT Loan Agreement				X
14.1	Code of Ethics				X
31.1	Certification of Chief Executive Officer pursuant to 15d-15(e), promulgated under the Securities and Exchange Act of 1934, as amended.				X
31.2	Certification of Chief Financial Officer pursuant to 15d-15(e), promulgated under the Securities and Exchange Act of 1934, as amended.				X
32.1	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Executive Officer)				X
32.2	Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Chief Financial Officer)				X
99.1	Audit Committee Charter				X
99.2	Disclosure Committee Charter				X

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

ADVANCED BIOMEDICAL TECHNOLOGIES, INC.

Signature	Title	Date

*/s/ Chi Ming Yu*	President and Director	March 29, 2019
Chi Ming Yu	(Principal Executive Officer)

*/s/ Kai Gui*	Director, Secretary and Chief Financial Officer	March 29, 2019
Kai Gui	(Principal Financial Officer)

*/s/ Hui Wang*	Director and Chief Executive Officer	March 29, 2019
Hui Wang	(Controller)

GRAPHIC 2 image_001.jpg begin 644 image_001.jpg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end GRAPHIC 3 image_002.jpg begin 644 image_002.jpg M_]C_X 02D9)1@ ! @$ V@#: #_X1!A17AI9@ 34T *@ @ !P$2 , M ! $ $: 4 ! 8@$; 4 ! :@$H , ! ( $Q M ( < <@$R ( 4 CH=I 0 ! I - (4JZ G M$ A2KH "<0061O8F4@4&AO=&]S:&]P($-3-"!7:6YD;W=S #(P,3DZ,#(Z M,3(@,C Z,3@Z,38 Z ! , !__\ * " 0 ! $N: # 0 M ! "F & 0, P $ !@ 1H !0 $ $> 1L !0 M $ $F 2@ P $ @ @$ ! $ $N @( ! $ \K M $@ ! 2 '_V/_@ !!*1DE& $" !( $@ /_M Q!9&]B M95]#30 "_^X #D%D;V)E &2 ?_; (0 # @(" D(# D)#!$+"@L1%0\, M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P, M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P, M# P,# P,# P,# P,# P,# P,# P,_\ $0@ 6 "@ P$B (1 0,1 ?_= 0 M"O_$ 3\ $% 0$! 0$! , 0($!08'" D*"P$ 04! 0$! 0$ M 0 " P0%!@<("0H+$ !! $# @0"!0<&" 4###,! (1 P0A$C$% M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F M]C='5V=WAY>GM\?7Y_<1 (" 0($! ,$!08'!P8%-0$ A$#(3$2!$%187$B M$P4R@9$4H;%"(\%2T? S)&+A7U5F9VAI:FML;6YO8G-T=7 M9W>'EZ>WQ__: P# 0 "$0,1 #\ ]#S>F9]^0^VCJ-F,Q[0WTVM#HTVNV[CM M_E_0]7?_ (7^;],8Z9UD"/VL_<72Y_HL^B&[65-9]#Z9=99;_.+2=36]VYPD MGS*;[/3^[^)24YG[*ZVX-]3K#]T0[92P3.KX_M-;L?\ SC/^N*3^E]8-3@WJ MUGJ@AU3S56 V&V,V.8T?I&O]1CG^IO\ YK]&M'[/3^[^)2^ST_N_B4E-!_3. MK;K#3U6RL/<7,::JWAH=^;[QN=[O['_!J)Z9UH.J%?57"MO\]-3"YQW66/G]W\2E]GI_=_$I*X>BVMP8QK)L:=WVK27MLC_P:M_9Z M?W?Q*7V>G]W\2DIS:>C=1I-A_:EMPLK>QHM;.TN:UK+&^F^IVZM[/]?YQ%Q^ MEY=):YV=;/ST_YM7?L]/[OXE+[/3^[^)24YM' M1NHU.K<>J6O-- M 02XOY=X_P"OZ/T[Z%]GI_=_$I?9Z?W?Q*2DJ2%]GI_=_$I?9Z?W?Q*2DJ2% M]GI_=_$I?9Z?W?Q*2DJ2%]FI_=_$HJ2G_]#U55?MCVX]M]N-;4*G.!8367%K M?\,W9:YOIN_K>K_P:CT[*NR/M/JQ^AO?4P#F&1J[^LEF9%%O3\EU=C'M%=C" MYK@0'!I]FGYR2FXDDDDI22222E))))*4DJ'6,BZJAE=)#3>YU;G&9#=ECYKV M.9ML]GTT+I.7DOOLHM<'M#?5#O=NESW;F^][_P!'_HV_X--XX\0A^D5GN1XQ M"_4742223EZQ<&@N<8 U)/ "I5=9P;H676YUS"\AE+@Q@ [.;3S;[D?-II9T_):UC6M])Y@- M$AFT?]%JK]#W@9X> #]LMXC@AAUV_G(F5CW5]-RFNR;+"6/<'N%<@;/YOVUA MNS<-WT=Z2F\DG47/8P O<&@F!)B2>R2ETE0R.KT,<64'U7 EP:]S?7-&>.7'&B.(> DULL)0YR,9CA/#M_@R=A).AV M7TU$"Q[6%T!H<0)ES:VQ/[UEE=?]=ZN-AAF_T+(_XI__ %)6!5]+'_XVC_SY M4JF7U/.>+KG/;O L &W0!HMJ;[=_N]EC_I*XT0^@#@6T?^?*E0^]8L\P,9)] MJ7#.QP^J_P#T%AY_#/'+ 95ZR2*_P'I$E"O(IM>YC'2]@!>W@@$N:V9_J/4G M.#1+N-!X\F%?9ER0.3'Q6!E_\H96O^$;_P">J4+KF:^[*973=NQ?2:]H:&EI M<774O=NBO _P"&Q\[@G'EHY37#*0 _>_3_ .]=WI%E8P*6%X#SNAI(G5UD>W^P]7ER M]&]N,;&V/:\"R"UY$;7W;(_J;G;5TN.YSL>ISC+G,:2?$D*^(D1CX@*Q3$H@ M#]$!_]+TCI>';BLO-X:+LBY]KC6XN;#C[(WM9L]OYB679D.Z;D.?3L?LL&S> M#[=I]^Z%=5'*S<2[IN395HZQ\_HV8[?T>STU:_ MQF-<[ P@T%Q]9W )_,*YSZK?HVY8L]D^E&[28];Q67\4RYHX\D<9(TA7#\WS MQ_2#N\ERG*GD!S$H@Y^,Q]4OT;X?YOY/^:]1@%SFW;G.<1; +B28%=4-]RZ# MHW_)[/Z]O_GVQ_2\W,B/.YKF_U7+R_IO6NK9?4,?'RQ[R0X-.YNZ?I>[ MW+TGJMK\CZKYEI'OMP;7%K0>74N=#1])>5]'8]G5,5[FEK18)<080^(F? 1& M]83NO)Z7X+##+E>F=/R*WY=Q:VVMS6&NNRW5K MF.=N^SLMV?2_/5?X+ \.($'>?3^\X'Q,G[^)1U] _*3U/3LQV5418TLNJVMM MT :7%H?-W96VUX:W]'6[V,#MK/=^ZN MY^J_4,/J-.5DX3W64BUK-SF/K.YM=9<-E[:W_GKS[ZX56.^LW4"UCB-[=0#_ M *.M:'.\485&P1+ZNQ_Q<&.?-2]Z,2/9D:R I[W%SWXK7 M/<3)+G5[G.<>ZRGZW@$]JE MO<[&482%$&A^;+\#B/ON 9 #'C-\?R_(X_U:R,C(JRGY%K[GM=6T.LI?7GZQX69F86-A468U%U]=5KJ;7$LWV;7N>VUK'>T_NKU_'$8]0\ M&-_(NGR8Y0AB)KU1L4;Z1<;!$@&_!__3]53!K6\ "==/$I))*74;"\,<6-#G M@$M:3 )[-W>[:G224Y^/F]6LRA5?T_T:)(-_JM=H-VNP#=V8M%,DDI=)4[NG M^L<@_:+V?:6,9M:^&LV%QWT-C]&^W?\ IO\ 2(N-C?9_5_2V7&VPV$VD';(: MW97 ;MK]F[8DDUT-H'Y74QD6LKPPZIOT+2\#=HW\S^LY7*]Y8TV !\#>&F0# M^=M<0U5LC %]!I-]S)X.&S_BF^I[:TU/3C7?9<;,BN\9%U9J :&,=#3&\$V-(/J;_4_/\ M^MI873OLE1K^T7W2]K]UK]Q&UK6>F#_H_8BIEFY&92:QBXWVC<3O]P9M CN[ MXI8-^9W;^F?O_ '?<=/I^WZ2N)*87OLKHL?4SU+&M)8P?G. ]K>WTE4QLOJMF M0VO(P1349W6BUKH@._-AKOI#:KR22ETDR22G_]3TS(RKJ;-K,:R]D [JRWG7 MV[;'5^"9V9:UQ Q+W ?G#TX/]6;5\OI)*?I]^9D,?M^R6O;,;F%G']M]:;[; MDC;NPK3N /M+#$B7-=N>SW,=[5\PI)*?IYV;D[068=LDP6N+ 1'YWM>]G_34 MG964T C%<_W0X-<&W:TG< 6%\ ;@6L M#O?_ )Z7V_(W$?8;X'<&O_TJOF)))3]/NS" :S'_ ((U?,*22GZFIL=;6'NK=4=06/C<(/\ (<]G M_21%\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?_9_^T5#E!H;W1O $ #A"24T$&@ #0P 8 M I@ 2Y !P!! #D 4@ R $8 10 P 0 M ! 2Y "F ! M ! ! ;G5L; ( &8F]U M;F1S3V)J8P $ !28W0Q ! !4;W @;&]N9P M3&5F=&QO;F< $)T;VUL;VYG "F !29VAT;&]N9P !+D M &7!E $YO;F4 )=&]P3W5T)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F M=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$ @(! @0$ P0%!@<'!@4U 0 "$0,A M,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:V MQM;F]B7I[?'_]H # ,! (1 Q$ /P#T/-Z9GWY#[:.HV8S'M#?3 M:T.C3:[;N.W^7]#U=_\ A?YOTQCIG60(_:S]Q=+G^BSZ(;M94UGT/IEUEEO\ MXM)U-;W;G"2?,IOL]/[OXE)3F?LKK;@WU.L/W1#ME+!,ZOC^TUNQ_P#.,_ZX MI/Z7U@U.#>K6>J"'5/-58#8;8S8YC1^D:_U&.?ZF_P#FOT:T?L]/[OXE+[/3 M^[^)24T'],ZMNL-/5;*P]Q&AWYOO&YWN_L?\&HGIG6@ZH5]5<*V_ST MU,+G'=98]S7/W[=^^NK9_-U55_HUH_9Z?W?Q*7V>G]W\2DISCT[KA]1S>JEK MB^PUM]&LM#2[] SZ._V5_3_UWF;T_/,>KU![AZ+:W!C&LFQIW?:M)>VQS?:^ MO=Z/_!JW]GI_=_$I?9Z?W?Q*2G-IZ-U&DV']J6W"RM[&BUL[2YK6LL;Z;ZG; MJWL_U_G$7'Z7ETEKG9UMSF$G]),&=X]S6/9^99_VY6Q[/3_FU=^ST_N_B4OL M]/[OXE)3FT=&ZC4ZMQZI:\US([Z#_ '_ZUVUK]D]5T4^DW=9LV>_P"@Q:7V>G]W\2E]GI_=_$I*:O3^GY6+:]]^ M;9E-G]W\2E]GI_=_$I*2I(7V>G]W\2E]G MI_=_$I*2I(7V>G]W\2E]GI_=_$I*2I(7V:G]W\2BI*?_T/555^V/;CVWVXUM M0JT5V,+FN! <&GV:?G)*;B2222E))))*4DDDDI22H=8R+JJ&5TD--[G5 MN<9D-V6/FO8YFVSV?30NDY>2^^RBUP>T-]4.]VZ7/=N;[WO_ $?^C;_@TWCC MQ"'Z16>Y'C$+]1=1))).7K%P:"YQ@#4D\ *E5UG!MR1CM>-9#+-S-CC[ QK' M!^YSK/4_1^W_ =B/G?T+(_XI_\ U)6!7,X__&T?^?*E'DR!GAX /VRWB."&'7;^ MX5R!L_F_;6&[-PW?1WI*;R2=1<]C "]P:"8$F))[)*725#(ZO0QQ90?5< "7 M!KW-]P%E9#ZV/:]KFN_,5O'R*LFD74DECI )!:9:2QWM?M=])J D":!%]D"4 M2:!!(Z6D23JGG]2KQ,9]S-MSV%H],. /NL&/K]+;L>?W4I2$8F4C48@R)\ N M )( W.@0=;^AC?\ &G_SU:@='_IUG_$C_JW*@[J=^5;53<"1O+VN);H&U&HL MAE=>[U'EUV[^PM#I'].L_P")'_5N53'FQYD24*\BFU[F,=+V %[>" M 2YK9G^H]2[U8F -&LJ:T0QK&^UJH9N;QSR M3Y<"7N8_5*QZ*\#_ (;'SN"<>6CE-<,I #][]/\ [UW>D65C I87@/.Z&DB= M761[?[#U>7+T;VXQL;8]KP+(+7D1M?=LC^IN=M72X[G.QZG.,NUFSV_F)9=F0[IN M0Y].Q^RP;-X/MVGW[H5U4:Y#PPM@;MPW5WM=_FKG\7ZS9/7++7AMF*V@-&QMQ(=ZCK'S^C M9CM_1[/35K_&8USL#"#07'UG< G\PKG/JM^C;EBSV3Z4;M)CUO%9?Q3+FCCR M1QDC2%0',2B#GXS'U2_1OA_F_D_YKU& 7.;=N!=2&W2]HFV1)C\RI2JZWC8X+3U&FDTO?\ MHG.(C;998WU&^HW=OW>_]^M3?#A.48$V9>W$RXM[]+SB MZY;93T7J%U+C7;7C7/K>W0MJVOR/JOF6D>^W!M<6M!Y=2YT-'TEY7T=CV=4Q7N:6M%@E MQ!A#XB9\!$;UA.Z\GI?@L,,N5YR62,#.(O&9B/'$\$_DXGM*/Z73_;_Z@K3Q M_6?Y*GF=9Z9T_(K?EW%K; M:W-8:Z[+=6N8YV[[.RW9]+\]5_@L#PX@0=Y]/[S@?$R?OXE'7T#\I/4].S'9 M51%C2RZK:VW0!I<6A\UP^WV>[\Y>;?6SJW5:/K%G4TYN174Q[=E;;7AK?T=; MO8P.VL]W[J[GZK]0P^HTY63A/=92+6LW.8^L[FUUEPV7MK?^>O/OKA58[ZS= M0+6.(WMU /\ HZUH<[Q1A4;!$OJ['_%P8Y\U+WHQ(]F1K(!P\7'C_?=K'>Y_ M1ZGO<7/?BM<]Q,DN=7N?3XA:G4<_%QL*S)>XV,IV6.95#WD-?6YPK9+=SEC_"XR]W)8.N6/_2DYWQW M7)R_#TX]O/&Z6&QC.H8Q:(_2.!@GCTKC_!9/^,G)R<>KIYQ[K*=SK=WIO-1F,L 3VJ6]SL91A(40:'YLOP.(^^X!D ,>,WQ_+\CC_5K(R,BK*?D6ON>U MU;0ZQSGD"+#M!>7+HNG_ $+?^./_ %-:YGZK_HZ

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ex10-1.htm

Exhibit 10.1

Loan Agreement

TTD/ABMT/L1810-01

Lender: TITAN TECHNOLOGY DEVELOPMENT LIMITED

Address: 1903 HING YIP COMMERCIAL CENTRE, 272 DES VOEUX ROAD CENTRAL, HONG KONG.

(Hong Kong Company Registration No.: 718332)

Borrower: ADVANCED BIOMEDICAL TECHNOLOGIES, INC.

Address: 350 FIFTH AVE., 59TH FLOOR, NEW YORK, NY 10118

USA (Incorporated in the State of Nevada, USA)

Borrower is the controlling shareholder of Shenzhen Changhua Biomedical Engineering Co. Ltd., approved by Shenzhen Bureau of Trade and Industry’s permit, February 25, 2008 (2008) No. 0539 and Guangdong Shenzhen Joint Venture Permit (2008) No. 0008. Shenzhen Changhua Biomedical Engineering Co., Ltd. is a company engaged in research and development and production of biodegradable medical materials. Lender is a major shareholder of Borrower.

1) Loan:

Lender agrees to advance to Borrower’s subsidiary Shenzhen Changhua Biomedical Engineering Co., Ltd. (Changhua) the total amount of USD700,000 - (Seven Hundred Thousand US dollars).

Borrower accepts that Lender may send the total amount in several advances using different financial institutions, associated companies or individuals that is appointed by Lender.

2) Use of Proceed: For Changhua’s R&D, Clinical Trial, GMP Facilities Upgrading and Operation Expenses.

3) Interest Rate: Annual interest rate is seven percent (7%).

4) Loan Repayment period: 12 months

5) Repayment:

Debt maturity: after 12 months, Borrower will repay Lender the total amount of loan plus interest.

Outstanding loan: after 6 months, Lender may demand the return of part of the loan plus interest occurred.

6) Repayment Methods and Repayment Source

Repayment Methods: cash or securities;

Repayment Source: banks and securities firms.

7) Warranty:

Borrower and its subsidiary guarantee that the loan will be used for the purposes stipulated in this agreement and the fund may not be used for other purposes or illegal activities;

Borrower will return the loan within the terms stipulated in this agreement;

Borrower and its subsidiary agree to accept the supervision of Lender on the use of proceed provided under this agreement.

8) Miscellaneous

This Agreement may not be amended or modified except by a writing executed by each of the parties. Neither party shall assign (including the engagement of subcontractors) any of its rights or obligations under this Agreement without the prior written consent of the other party. The provisions of this Agreement, including without limitation the obligation to make loan and interest repayments, shall be binding on Borrower, its Parent Company, its successors and assigns. All terms of this Agreement, which by their nature extend beyond its termination, shall remain in effect until fulfilled, and shall apply to the respective successors and assigns of the parties;

This Agreement, including all controversies arising from or relating to performance under this Agreement, shall be governed by and construed in accordance with the laws of Hong Kong, China. Venue for any action or dispute arising from or relating to this Agreement shall conclusively lie in the Courts located in Hong Kong, China. Each party hereby waives any objection that it may have based upon lack of personal jurisdiction, improper venue or forum non conveniens.

Lender: TITAN TECHNOLOGY DEVELOPMENT LIMITED

Signature: /s/ Chi Fung YU

Name and Title: Chi Fung YU, Chairman

Borrower: ADVANCED BIOMEDICAL TECHNOLOGIES, INC.

Signature: /s/ Hui Wang

Name and Title: Hui Wang, Director and Chief Executive Officer

Date: October 31, 2019

EX-14.1 5 ex14-1.htm

Exhibit 14.1

ADVANCED BIOMEDICAL TECHNOLOGIES INC
CODE OF ETHICS

TOPICS

1. Statement of Policy

2. Implementation and Enforcement

3. Relations with Competitors and Other Third Parties

4. Insider Trading, Securities Compliance and Public Statements

5. Financial Reporting

6. Human Resources

7. Environmental, Health and Safety

8. Conflicts of Interest

9. International Trade

10. Government Relations

11. Contractors, Consultants, and Temporary Workers

12. Conclusion

1. STATEMENT OF POLICY

The Company has adopted eight Corporate Values (Focus, Respect, Excellence, Accountability, Teamwork, Integrity, Very Open Communications and Enjoying Our Work) to provide a framework for all employees in conducting ourselves in our jobs. These policies are not intended to substitute for those Values, but will serve as guidelines in helping you to conduct the Company’s business in accordance with our Values. Compliance requires meeting the spirit, as well as the literal meaning, of the law, the policies and the Values. It is expected that you will use common sense, good judgment, high ethical standards and integrity in all your business dealings.

If you encounter a situation you are not able to resolve by reference to these policies, ask for help. Contact Chi Ming Yu, President and Director, who has been identified as responsible for overseeing compliance with these policies.

Violations of the law or the Company’s policies will subject employees to disciplinary action, up to and including termination of employment. In addition, individuals involved may subject themselves and the Company to severe penalties including fines and possible imprisonment. Compliance with the law and high ethical standards in the conduct of Company business should be a top priority for each employee, officer and director.

2. IMPLEMENTATION AND ENFORCEMENT

Chi Ming Yu, our President and Director, has been appointed as Compliance Officer of the Company, responsible for overseeing compliance with, and enforcement of, all Company policies.

Employees are expected to be familiar with these policies as they apply to their duties. They should consult with their managers if they need assistance in understanding or interpreting these policies. Each employee is required to follow these policies and to comply with their terms. A refusal by any employee to agree to be bound by these policies shall be grounds for discipline up to and including dismissal.

1

Any employee who, in good faith, has reason to believe a Company operation or activity is in violation of the law or of these policies must call the matter to the attention of Chi Ming Yu, our President and Director. All reports will be reviewed and investigated and as necessary under the circumstances, and the reporting employee should provide sufficient information to enable a complete investigation to be undertaken.

Any employee who makes an allegation in good faith reasonably believing that a person has violated these policies or the law, will be protected against retaliation.

3. RELATIONS WITH COMPETITORS AND OTHER THIRD PARTIES

The Company’s policy is to comply fully with competition and antitrust laws throughout the world. These laws generally prohibit companies from using illegal means to maintain, obtain or attempt to obtain a monopoly in a market. They also prohibit companies from engaging in unfair trade practices. “Unfair trade practices” include fixing prices, dividing markets, agreeing with competitors not to compete, or agreeing to boycott certain customers. It is advised that you consult with Chi Ming Yu before attending a meeting with a party who may be viewed as a competitor.

4. INSIDER TRADING, SECURITIES COMPLIANCE AND PUBLIC STATEMENTS

Securities laws prohibit anyone who is in possession of material, non-public information (“Insider Information”) about a company from purchasing or selling stock of that company, or communicating the information to others. Information is considered “material” if a reasonable investor would consider it to be important in making a decision to buy or sell that stock. Some examples include financial results and projections, new products, acquisitions, major new contracts or alliances prior to the time that they are publicly announced. Employees who become aware of such Inside Information about the Company must refrain from trading in the shares of the Company until the Inside Information is publicly announced.

Employees must also refrain from disclosing that information to persons who do not have a Company need to know, whether they are inside the Company or outside, such as spouses, relatives or friends.

The Company makes regular formal disclosures of its financial performance and results of operations to the investment community. We also regularly issue press releases. Other than those public statements, which go through official Company channels, employees are prohibited from communicating outside the Company about the Company’s business, financial performance or future prospects. Such communications include questions from securities analysts, reporters or other news media, but also include seemingly innocent discussions with family, friends, neighbors or acquaintances.

5. FINANCIAL REPORTING

The Company is required to maintain a variety of records for purposes of reporting to the government. The Company requires all employees to maintain full compliance with applicable laws and regulations requiring that its books of account and records be accurately maintained. Specifics of these requirements are available from Chi Ming Yu.

6. HUMAN RESOURCES

The Company is committed to providing a work environment that is free from unlawful harassment and discrimination, and respects the dignity of its employees. The Company has policies covering various aspects of its relationship with its employees, as well as employees’ relationships with each other. For more detailed information, you should consult Chi Ming Yu. Each employee is expected to be familiar with these policies and to abide by them.

2

7. ENVIRONMENTAL, HEALTH AND SAFETY

The Company is committed to protecting the health and safety of our employees, as well as the environment in general. The Company expects employees to obey all laws and regulations designed to protect the environment, and the health and safety of our employees, and to obtain and fully observe all permits necessary to do business.

At the very least, all employees should be familiar with and comply with safety regulations applicable to their work areas. The Company will make, to the extent possible, reasonable accommodations for the known physical or mental limitations of our employees. Employees who require an accommodation should contact Chi Ming Yu. The Company will then engage in an interactive process to determine what reasonable accommodations may exist.

8. CONFLICTS OF INTEREST

Each employee is expected to avoid any activity, investment or association that interferes with the independent exercise of his or her judgment in the Company’s best interests (“Conflicts of Interest”). Conflicts of Interest can arise in many situations. They occur most often in cases where the employee or the employee’s family obtains some personal benefit at the expense of the Company’s best interests.

No employee, or any member of employee’s immediate family, shall accept money, gifts of other than nominal value, unusual entertainment, loans, or any other preferential treatment from any customer or supplier of the Company where any obligation may be incurred or implied on the giver or the receiver or where the intent is to prejudice the recipient in favor of the provider. Likewise, no employee shall give money, gifts of other than nominal value, unusual entertainment or preferential treatment to any customer or supplier of the Company, or any employee or family members thereof, where any obligation might be incurred or implied, or where the intent is to prejudice the recipient in favor of the Company. No such persons shall solicit or accept kickbacks, whether in the form of money, goods, services or otherwise, as a means of influencing or rewarding any decision or action taken by a foreign or domestic vendor, customer, business partner, government employee or other person whose position may affect the Company’s business.

No employee shall use Company property, services, equipment or business for personal gain or benefit.

Employees may not: (1) act on behalf of, or own a substantial interest in, any company or firm that does business, or competes, with the Company; (2) conduct business on behalf of the Company with any company or firm in which the employee or a family member has a substantial interest or affiliation. Exceptions require advance written approval from the Legal Department.

Employees should not create the appearance that they are personally benefiting in any outside endeavor as a result of their employment by the Company, or that the Company is benefiting by reason of their outside interests. Any employee who is not sure whether a proposed action would present a conflict of interest or appear unethical should consult with Chi Ming Yu.

9. INTERNATIONAL TRADE

The Company must comply with a variety of laws around the world regarding its activities. In some cases, the law prohibits the disclosure of information, whether the disclosure occurs within the U.S. or elsewhere, and whether or not the disclosure is in writing.

Payments or gifts to non-U.S. government officials are prohibited by law and by Company policy. The Foreign Corrupt Practices Act precludes payments to non-U.S. government officials for the purpose of obtaining or retaining business, even if the payment is customary in that country. This law applies anywhere in the world to U.S. citizens, nationals, residents, businesses or employees of U.S. businesses. Because Advanced Biomedical Technologies Inc. is a U.S. company, this law applies to the Company and all of its subsidiaries. Any questions on this policy should be directed to Chi Ming Yu.

3

10. GOVERNMENT RELATIONS

The Company is prohibited by law from making any contributions or expenditures in connection with any U.S. national election. This includes virtually any activity that furnishes something of value to an election campaign for a federal office. Use of the Company’s name in supporting any political position or ballot measure, or in seeking the assistance of any elected representative, requires the specific approval of the Chairman and Chief Executive Officer of the Company. Political contributions or expenditures are not to be made out of Company funds in any foreign country, even if permitted by local law, without the consent of the Company’s Chairman and Chief Executive Officer.

U.S. law also prohibits giving, offering, or promising anything of value to any public official in the U.S. or any foreign country to influence any official act, or to cause an official to commit or omit any act in violation of his or her lawful duty. Company employees are expected to comply with these laws.

11. VENDORS, CONTRACTORS, CONSULTANTS AND TEMPORARY WORKERS

Vendors, contractors, consultants or temporary workers who are acting on the Company’s behalf, or on Company property, are expected to follow the law, Company policies and honor Company Values. Violations will subject the person or firm to sanctions up to and including loss of the contract, contracting or consulting agreement, or discharge from temporary assignment.

12. CONCLUSION

This Code of Ethics is not intended to cover every possible situation in which you may find yourself. It is meant to give you the boundaries within which the Company expects you to conduct yourself while representing Advanced Biomedical Technologies Inc. You may find yourself in a situation where there is no clear guidance given by this Code of Ethics. If that occurs, return to the foundations stated earlier: common sense, good judgment, high ethical standards and integrity. And refer to the Company’s Values. In addition, there are many resources upon which you may rely: your management chain, Human Resources, Legal or other Advanced Biomedical Technologies Inc. departments, and the CEO.

Employee

4

ADVANCED BIOMEDICAL TECHNOLOGIES INC.

VALUES

FOCUS We exist only because we are involved in medical device research and manufacturing.

RESPECT We value all people, treating them with dignity at all times.

EXCELLENCE We strive for “Best in Class” in everything we do.

ACCOUNTABILITY We do what we say we will do and expect the same from others.

TEAMWORK We believe that cooperative action produces superior results.

INTEGRITY We are honest with ourselves, each other, our customers, our partners and our shareholders.

VERY OPEN COMMUNICATION We share information, ask for feedback, acknowledge good work, and encourage diverse ideas.

ENJOYING OUR WORK We work hard, are rewarded for it, and maintain a good sense of perspective, humor and enthusiasm.

5

Reportable Violations - Anonymous Reporting Program

Accounting Error

Accounting Omissions

Accounting Misrepresentations

Auditing Matters

Compliance/Regulation Violations

Corporate Scandal

Domestic Violence

Discrimination

Embezzlement

Environmental Damage

Ethics Violation

Fraud

Harassment

Industrial Accidents

Misconduct

Mistreatment

Poor Customer Service

Poor Housekeeping

Sabotage

Securities Violation

Sexual Harassment

Substance Abuse

Theft

Threat of Violence

Unfair Labor Practice

Unsafe Working Conditions

Vandalism

Waste

Waste of Time and Resources

Workplace Violence

6

EX-31.1 6 ex31-1.htm

Exhibit 31.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Hui Wang, certify that:

1. I have reviewed this annual report on Form 10-K of Advanced Biomedical Technologies Inc.; (the “registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13(a)-15(e) and 15(d)-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 29, 2019

By: /s/ Hui Wang

Name: Hui Wang,

Title:
Director and Chief Executive Officer

(Principal Executive Officer)

EX-31.2 7 ex31-2.htm

Exhibit 31.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Kai Gui, certify that:

1. I have reviewed this annual report on Form 10-K of Advanced Biomedical Technologies Inc.; (the “registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13(a)-15(e) and 15(d)-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 29, 2019

By: /s/ Kai Gui

Name: Kai Gui,

Title: Director, Secretary and Chief Financial Officer

EX-32.1 8 ex32-1.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. Section 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Advanced Biomedical Technologies Inc. (the “Company”) on Form 10-K for the year ended October 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “report”), I, Hui Wang, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and

(2) The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated this 29th day of March, 2019.

/s/ Hui Wang

Hui Wang

Director and Chief Executive Officer

EX-32.2 9 ex32-2.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. Section 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Advanced Biomedical Technologies Inc. (the “Company”) on Form 10-K for the year ended October 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “report”), I, Kai Gui, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated this 29th day of March, 2019.

/s/ Kai Gui

Kai Gui

Director, Secretary, and Chief Financial Officer

EX-99.1 10 ex99-1.htm

Exhibit 99.1

ADVANCED BIOMEDICAL TECHNOLOGIES INC.

CHARTER - AUDIT COMMITTEE

Committee Role

The committee’s role is to act on behalf of the board of directors and oversee all material aspects of the company’s reporting, control, and audit functions, except those specifically related to the responsibilities of another standing committee of the board. The audit committee’s role includes a particular focus on the qualitative aspects of financial reporting to shareholders and on company processes for the management of business/financial risk and for compliance with significant applicable legal, ethical, and regulatory requirements.

In addition, the committee responsible for: (1) selection and oversight of our independent accountant; (2) establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal controls and auditing matters; (3) establishing procedures for the confidential, anonymous submission by our employees of concerns regarding accounting and auditing matters; (4) establishing internal financial controls; (5) engaging outside advisors; and, (6) funding for the outside auditor and any outside advisors engagement by the audit committee.

The role also includes coordination with other board committees and maintenance of strong, positive working relationships with management, external and internal auditors, counsel, and other committee advisors.

Committee Membership

The committee shall consist of the entire board directors. The committee shall have access to its own counsel and other advisors at the committee’s sole discretion.

Committee Operating Principles

The committee shall fulfill its responsibilities within the context of the following overriding principles:

(1) Communications - The chairperson and others on the committee shall, to the extent appropriate, have contact throughout the year with senior management, other committee chairpersons, and other key committee advisors, external and internal auditors, etc., as applicable, to strengthen the committee’s knowledge of relevant current and prospective business issues.

(2) Committee Education/Orientation - The committee, with management, shall develop and participate in a process for review of important financial and operating topics that present potential significant risk to the company. Additionally, individual committee members are encouraged to participate in relevant and appropriate self-study education to assure understanding of the business and environment in which the company operates.

(3) Annual Plan - The committee, with input from management and other key committee advisors shall develop an annual plan responsive to the “primary committee responsibilities” detailed herein. The annual plan shall be reviewed and approved by the full board.

(4) Meeting Agenda - Committee meeting agendas shall be the responsibility of the committee chairperson, with input from committee members. It is expected that the chairperson would also ask for management and key committee advisors, and perhaps others, to participate in this process.

(5) Committee Expectations and Information Needs - The committee shall communicate committee expectations and the nature, timing, and extent of committee information needs to management, internal audit, and external parties, including external auditors. Written materials. Including key performance indicators and measures related to key business and financial risks shall be received from management, auditors, and others at least one week in advance of meeting dates. Meeting conduct will assume board members have reviewed written materials in sufficient depth to participate in committee/board dialogue.

(6) External Resources -The committee shall be authorized to access internal and external resources, as the committee requires, carrying out its responsibilities.

(7) Committee Meeting Attendees - The committee shall request members of management, counsel, internal audit, and external auditors, as applicable, to participate in committee meetings, as necessary, to carry out the committee responsibilities. Periodically and at least annually, the committee shall meet in private session with only the committee members. It shall be understood that either internal or external auditors, or counsel, may, at any time, request a meeting with the audit committee or committee chairperson with or without management attendance. In any case, the committee shall meet in executive session separately with internal and external auditors, at least annually.

(8) Reporting to the Board of Directors - The committee, through the committee chairperson, shall report periodically, as deemed necessary, but at least semi-annually, to the full board. In addition, summarized minutes from committee meetings, separately identifying monitoring activities from approvals, shall be available to each board member at least one week prior to the subsequent board of directors meeting.

(9) Committee Self Assessment - The committee shall review, discuss, and assess its own performance as well as the committee role and responsibilities, seeking input from senior management, the full board, and others. Changes in role and/or responsibilities, if any, shall be recommended to the full board for approval.

Meeting Frequency

The committee shall meet at least three times quarterly. Additional meetings shall be scheduled as considered necessary by the committee or chairperson.

Reporting to Shareholders

The committee shall make available to shareholders a summary report on the scope of its activities. This may be identical to the report that appears in the company’s annual report.

Committee’s Relationship with External and Internal Auditors

(1) The external auditors, in their capacity as independent public accountants, shall be responsible to the board of directors and the audit committee as representatives of the shareholders.

(2) As the external auditors review financial reports, they will be reporting to the audit committee. They shall report all relevant issues to the committee responsive to agreed-on committee expectations. In executing its oversight role, the board or committee should review the work of external auditors.

(3) The internal audit function shall be responsible to the board of directors through the committee.

(4) If either the internal or the external auditors identify significant issues relative to the overall board responsibility that have been communicated to management but, in their judgment, have not been adequately addressed, they should communicate these issues to the committee chairperson.

(5) Changes in the directors of internal audit or corporate compliance shall be subject to committee approval.

Primary Committee Responsibilities

Monitor Financial Reporting and Risk Control Related Matters

The committee should review and assess:

(1) Risk Management - The company’s business risk management process, including the adequacy of the company’s overall control environment and controls in selected areas representing significant financial and business risk.

(2) Annual Reports and Other Major Regulatory Filings - All major financial reports in advance of filings or distribution.

(3) Internal Controls and Regulatory Compliance - The company’s system of internal controls for detecting accounting and reporting financial errors, fraud and defalcations, legal violations, and noncompliance with the corporate code of conduct.

(4) Internal Audit Responsibilities - The annual audit plan and the process used to develop the plan. Status of activities, significant findings, recommendations, and management’s response.

(5) Regulatory Examinations - SEC inquiries and the results of examinations by other regulatory authorities in terms of important findings, recommendations, and management’s response.

(6) External Audit Responsibilities - Auditor independence and the overall scope and focus of the annual/interim audit, including the scope and level of involvement with unaudited quarterly or other interim-period information.

(7) Financial Reporting and Controls - Key financial statement issues and risks, their impact or potential effect on reported financial information, the processes used by management to address such matters, related auditor views, and the basis for audit conclusions. Important conclusions on interim and/or year-end audit work in advance of the public release of financials.

(8) Auditor Recommendations - Important internal and external auditor recommendations on financial reporting, controls, other matters, and management’s response. The views of management and auditors on the overall quality of annual and interim financial reporting.

The committee should review, assess, and approve:

(1) The code of ethical conduct.

(2) Changes in important accounting principles and the application thereof in both interim in and annual financial reports.

(3) Significant conflicts of interest and related-party transactions.

(4) External auditor performance and changes in external audit firm (subject to ratification by the full board).

(5) Internal auditor performance and changes in internal audit leadership and/or key financial management.

(6) Procedures for whistle blowers.

(7) Pre-approve allowable services to be provided by the auditor.

(8) Retention of complaints.

EX-99.2 11 ex99-2.htm

Exhibit 99.2

ADVANCED BIOMEDICAL TECHNOLOGIES INC.

DISCLOSURE COMMITTEE

CHARTER

Disclosure Policy

All financial disclosures made by the Corporation to its security holders or the investment community should (i) be accurate, complete and timely, (ii) fairly present, in all material respects, the Corporation’s financial condition, results of operations and cash flows, and (iii) meet any other legal, regulatory or stock exchange requirements.

Committee Purpose

The Corporation’s Disclosure Committee (the “Committee”) shall assist the Corporation’s officers and directors (collectively, the “Senior Officers”) fulfilling the Corporation’s and their responsibilities regarding (i) the identification and disclosure of material information about the Corporation and (ii) the accuracy, completeness and timeliness of the Corporation’s financial reports.

Responsibilities

Subject to the supervision and oversight of Senior Officers, the Committee shall be responsible for the following tasks:

● Review and, as necessary, help revise the Corporation’s controls and other procedures (“Disclosure Controls and Procedures”) to ensure that (i) information required by the Corporation to be disclosed to the Securities and Exchange Commission (the “SEC”), and other written information that the Corporation will disclose to the public is recorded, processed, summarized and reported accurately and on a timely basis, and (ii) such information is accumulated and communicated to management, including the Senior Officers, as appropriate to allow timely decisions regarding required disclosure.

● Assist in documenting, and monitoring the integrity and evaluating the effectiveness of, the Disclosure Controls and Procedures.

● Review the Corporation’s (i) Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, proxy statement, material registration statements, and any other information filed with the SEC (collectively, the “Reports”), (ii) press releases containing financial information, earnings guidance, forward-looking statements, information about material transactions, or other information material to the Corporation’s security holders, (iii) correspondence broadly disseminated to shareholders, and (iv) other relevant communications or presentations (collectively, the “Disclosure Statements”).

● Discuss information relative to the Committee’s responsibilities and proceedings, including (i) the preparation of the Disclosure Statements and (ii) the evaluation of the effectiveness of the Disclosure Controls and Procedures.

Other Responsibilities

The Committee shall have such other responsibilities, consistent with the Committee’s purpose, as any Senior Officer may assign to it from time to time.

Disclosure Control Considerations

The Committee shall base the review and revision of the Disclosure Controls and Procedures on the following factors:

● Control Environment: The directives of the Board and Audit Committee; the integrity and ethical values of the Corporation’s officers and employees, including the “tone at the top”; the Corporation’s Code of Conduct; and the philosophy and operating style of management, including how employees are organized and how authority is delegated.

● Risk Assessment: The identification and analysis of relevant risks to achieving the goal of accurate and timely disclosure, forming a basis for determining how the risks should be managed.

● Control Activities: The procedures to ensure that necessary actions are taken to address and handle risks to achievement of objectives.

● Information and Communication: The accumulation, delivery and communication of financial information throughout (i.e., up, down and across) the organization.

● Monitoring: The assessment of the quality of the financial reporting systems over time through ongoing monitoring and separate evaluations, including through regular management supervision and reporting of deficiencies upstream.

Organization

The members of the Committee will be comprised of the Corporation’s officers and directors.

The Committee may designate two or more individuals, at least one of whom shall be knowledgeable about financial reporting and another about law, who can, acting together, review Disclosure Statements when time does not permit full Committee review.

The Senior Officers at their option may, at any time and from time to time, assume any or all of the responsibilities of the Disclosure Committee identified in this Charter, including, for example, approving Disclosure Statements when time does not permit the full Committee (or the designated individuals) to meet or act.

Chair

The Chief Financial Officer of the Corporation shall act as the Chair of the Committee (unless and until another member of the Committee shall be so appointed by any Senior Officer).

Meetings and Procedures

The Committee shall meet or act as frequently and as formally or informally as circumstances dictate to (i) ensure the accuracy, completeness and timeliness of the Disclosure Statements and (ii) evaluate the Disclosure Controls and Procedures and determine whether any changes to the Disclosure Controls and Procedures are necessary or advisable in connection with the preparation of the Reports or other Disclosure Statements, taking into account developments since the most recent evaluation, including material changes in the Corporation’s organization and business lines and any material change in economic or industry conditions.

The Committee shall adopt, whether formally or informally, such procedures as it deems necessary to facilitate the fulfillment of its responsibilities.

Full Access

The Committee shall have full access to all of Corporation’s books, records, assets, facilities and personnel, including the internal auditors, in connection with fulfilling its responsibilities.

Charter Review

The Committee shall review and assess this Charter annually, and recommend any proposed changes to the Senior Officers for approval.

Interpretation

Any questions of interpretation regarding this Charter, or the Committee’s responsibilities or procedures, shall be determined initially by the Chair and, to the extent necessary, ultimately by the Senior Officers.

EX-101.INS 12 abmt-20181031.xml XBRL INSTANCE FILE 0001385799 2017-11-01 2018-10-31 0001385799 2016-10-31 0001385799 2017-10-31 0001385799 2015-11-01 2016-10-31 0001385799 us-gaap:CommonStockMember 2015-11-01 2016-10-31 0001385799 us-gaap:CommonStockMember 2016-11-01 2017-10-31 0001385799 us-gaap:CommonStockMember 2015-10-31 0001385799 us-gaap:CommonStockMember 2016-10-31 0001385799 us-gaap:CommonStockMember 2017-10-31 0001385799 us-gaap:AdditionalPaidInCapitalMember 2015-11-01 2016-10-31 0001385799 us-gaap:AdditionalPaidInCapitalMember 2016-11-01 2017-10-31 0001385799 us-gaap:AdditionalPaidInCapitalMember 2015-10-31 0001385799 us-gaap:AdditionalPaidInCapitalMember 2016-10-31 0001385799 us-gaap:AdditionalPaidInCapitalMember 2017-10-31 0001385799 us-gaap:RetainedEarningsMember 2015-11-01 2016-10-31 0001385799 us-gaap:RetainedEarningsMember 2016-11-01 2017-10-31 0001385799 us-gaap:RetainedEarningsMember 2015-10-31 0001385799 us-gaap:RetainedEarningsMember 2016-10-31 0001385799 us-gaap:RetainedEarningsMember 2017-10-31 0001385799 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-11-01 2016-10-31 0001385799 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-11-01 2017-10-31 0001385799 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-10-31 0001385799 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-10-31 0001385799 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-10-31 0001385799 2015-10-31 0001385799 srt:ParentCompanyMember 2008-12-31 0001385799 ABMT:TitanTechnologyDevelopmentLimitedStockholderMember 2017-10-31 0001385799 ABMT:IncomeStatementAndCashFLowsMember currency:CNY 2017-10-31 0001385799 ABMT:BalanceSheetMember currency:HKD 2017-10-31 0001385799 ABMT:BalanceSheetMember currency:CNY 2017-10-31 0001385799 ABMT:BalanceSheetMember currency:USD 2017-10-31 0001385799 ABMT:IncomeStatementAndCashFLowsMember currency:USD 2017-10-31 0001385799 ABMT:IncomeStatementAndCashFLowsMember currency:HKD 2017-10-31 0001385799 us-gaap:MachineryAndEquipmentMember 2017-10-31 0001385799 us-gaap:VehiclesMember 2017-10-31 0001385799 us-gaap:OfficeEquipmentMember 2017-10-31 0001385799 us-gaap:SoftwareDevelopmentMember 2017-10-31 0001385799 us-gaap:LeaseholdImprovementsMember 2017-10-31 0001385799 us-gaap:RestrictedStockMember ABMT:Director4Member 2016-03-30 2016-03-31 0001385799 us-gaap:RestrictedStockMember ABMT:Director3Member 2016-03-30 2016-03-31 0001385799 ABMT:TwoRelatedPartiesMember 2015-11-12 2015-11-13 0001385799 ABMT:CompanyStockholderMember 2015-11-12 2015-11-13 0001385799 2015-11-12 2015-11-13 0001385799 us-gaap:RestrictedStockMember ABMT:Director3Member 2013-10-27 2013-10-28 0001385799 us-gaap:RestrictedStockMember ABMT:Director4Member 2013-10-27 2013-10-28 0001385799 us-gaap:RestrictedStockMember us-gaap:OfficerMember 2011-12-07 2011-12-08 0001385799 us-gaap:RestrictedStockMember ABMT:Director3Member 2016-03-31 0001385799 us-gaap:RestrictedStockMember ABMT:Director4Member 2016-03-31 0001385799 2015-11-13 0001385799 us-gaap:RestrictedStockMember ABMT:Director4Member 2013-10-28 0001385799 us-gaap:RestrictedStockMember ABMT:Director3Member 2013-10-28 0001385799 us-gaap:RestrictedStockMember us-gaap:OfficerMember 2011-12-08 0001385799 ABMT:YuChiFungMember 2017-10-31 0001385799 ABMT:QueFengMember 2017-10-31 0001385799 ABMT:ChenTieJunMember 2017-10-31 0001385799 ABMT:QueFengMember 2016-11-01 2017-10-31 0001385799 ABMT:YuChiFungMember 2016-11-01 2017-10-31 0001385799 ABMT:ChenTieJunMember 2016-11-01 2017-10-31 0001385799 ABMT:TitanTechnologyDevelopmentLimitedStockholderMember 2016-11-01 2017-10-31 0001385799 ABMT:WangWeiMember 2017-10-31 0001385799 ABMT:YuChiMingMember 2017-10-31 0001385799 ABMT:OfficeSpaceMember 2016-11-01 2017-10-31 0001385799 us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember country:US 2016-11-01 2017-10-31 0001385799 us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember ABMT:PeoplesRepublicOfChinaMember 2016-11-01 2017-10-31 0001385799 ABMT:ShenzhenHygeianMedicalDeviceCoLtdMember 2017-10-31 0001385799 ABMT:ShenzhenHygeianMedicalDeviceCoLtdMember 2016-11-01 2017-10-31 0001385799 us-gaap:RestrictedStockMember ABMT:Director3Member 2017-04-26 2017-04-28 0001385799 us-gaap:RestrictedStockMember ABMT:Director3Member 2017-04-28 0001385799 us-gaap:RestrictedStockMember ABMT:Director4Member 2017-04-26 2017-04-28 0001385799 us-gaap:RestrictedStockMember ABMT:Director4Member 2017-04-28 0001385799 us-gaap:RestrictedStockMember ABMT:MrChiMingYuAndKaiGuiMember 2013-10-27 2013-10-28 0001385799 us-gaap:RestrictedStockMember ABMT:MrChiMingYuAndKaiGuiMember 2016-03-30 2016-03-31 0001385799 us-gaap:RestrictedStockMember ABMT:MrChiMingYuAndKaiGuiMember 2017-04-26 2017-04-28 0001385799 2018-10-31 0001385799 us-gaap:CommonStockMember 2017-11-01 2018-10-31 0001385799 us-gaap:CommonStockMember 2018-10-31 0001385799 us-gaap:AdditionalPaidInCapitalMember 2017-11-01 2018-10-31 0001385799 us-gaap:AdditionalPaidInCapitalMember 2018-10-31 0001385799 us-gaap:RetainedEarningsMember 2017-11-01 2018-10-31 0001385799 us-gaap:RetainedEarningsMember 2018-10-31 0001385799 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-11-01 2018-10-31 0001385799 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-10-31 0001385799 2016-11-01 2017-10-31 0001385799 ABMT:ShenzhenChanghuaBiomedicalEngineeringCompanyLimitedMember 2002-09-25 0001385799 ABMT:ShenzhenChanghuaBiomedicalEngineeringCompanyLimitedMember 2002-09-24 2002-09-25 0001385799 ABMT:MasteriseHoldingsLimitedMember 2008-01-29 0001385799 ABMT:MasteriseHoldingsLimitedMember 2008-01-28 2008-01-29 0001385799 srt:ParentCompanyMember 2008-12-30 2008-12-31 0001385799 srt:ParentCompanyMember us-gaap:MajorityShareholderMember 2008-12-30 2008-12-31 0001385799 us-gaap:MajorityShareholderMember ABMT:MasteriseMember 2008-12-30 2008-12-31 0001385799 us-gaap:MajorityShareholderMember ABMT:MasteriseMember 2008-12-31 0001385799 us-gaap:MajorityShareholderMember srt:ParentCompanyMember 2008-12-31 0001385799 2019-03-29 0001385799 2018-04-28 0001385799 us-gaap:MachineryAndEquipmentMember 2018-10-31 0001385799 us-gaap:VehiclesMember 2018-10-31 0001385799 us-gaap:OfficeEquipmentMember 2018-10-31 0001385799 us-gaap:SoftwareDevelopmentMember 2018-10-31 0001385799 us-gaap:LeaseholdImprovementsMember 2018-10-31 0001385799 ABMT:TitanTechnologyDevelopmentLimitedStockholderMember 2018-10-31 0001385799 ABMT:YuChiFungMember 2018-10-31 0001385799 ABMT:QueFengMember 2018-10-31 0001385799 ABMT:ChenTieJunMember 2018-10-31 0001385799 ABMT:ShenzhenHygeianMedicalDeviceCoLtdMember 2018-10-31 0001385799 ABMT:GuiKaiMember 2017-10-31 0001385799 ABMT:WangWeiMember 2018-10-31 0001385799 ABMT:GuiKaiMember 2018-10-31 0001385799 ABMT:YuChiMingMember 2018-10-31 0001385799 ABMT:TitanTechnologyDevelopmentLimitedStockholderMember 2017-11-01 2018-10-31 0001385799 ABMT:QueFengMember 2017-11-01 2018-10-31 0001385799 ABMT:YuChiFungMember 2017-11-01 2018-10-31 0001385799 ABMT:ChenTieJunMember 2017-11-01 2018-10-31 0001385799 ABMT:ShenzhenHygeianMedicalDeviceCoLtdMember 2017-11-01 2018-10-31 0001385799 us-gaap:RestrictedStockMember ABMT:Director4Member 2018-10-22 2018-10-23 0001385799 us-gaap:RestrictedStockMember ABMT:Director4Member 2018-10-23 0001385799 us-gaap:RestrictedStockMember ABMT:Director3Member 2018-10-22 2018-10-23 0001385799 us-gaap:RestrictedStockMember ABMT:Director3Member 2018-10-23 0001385799 us-gaap:RestrictedStockMember ABMT:MrChiMingYuAndKaiGuiMember 2018-10-22 2018-10-23 0001385799 ABMT:OfficeSpaceMember 2017-11-01 2018-10-31 0001385799 country:CN 2017-11-01 2018-10-31 0001385799 us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember country:US 2017-11-01 2018-10-31 0001385799 us-gaap:AssetsTotalMember us-gaap:GeographicConcentrationRiskMember ABMT:PeoplesRepublicOfChinaMember 2017-11-01 2018-10-31 0001385799 ABMT:BalanceSheetMember currency:USD 2018-10-31 0001385799 ABMT:BalanceSheetMember currency:HKD 2018-10-31 0001385799 ABMT:BalanceSheetMember currency:CNY 2018-10-31 0001385799 ABMT:IncomeStatementAndCashFLowsMember currency:USD 2018-10-31 0001385799 ABMT:IncomeStatementAndCashFLowsMember currency:HKD 2018-10-31 0001385799 ABMT:IncomeStatementAndCashFLowsMember currency:CNY 2018-10-31 0001385799 ABMT:MasteriseHoldingsLimitedMember 2007-05-30 2007-05-31 0001385799 srt:ParentCompanyMember ABMT:MasteriseHoldingsLimitedMember 2018-12-31 0001385799 srt:ParentCompanyMember ABMT:ShenzhenChanghuaBiomedicalEngineeringCompanyLimitedMember 2018-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure ABMT:Segment Advanced Biomedical Technologies Inc. 0001385799 10-K/A 2018-10-31 true --10-31 FY 2018 69624850 0.00001 0.00001 100000000 100000000 69624850 69624850 69624850 69624850 56874850 67124850 69374850 69624850 -4362295 -4995027 569 671 694 1949132 2520520 2673620 -6262961 -6987698 -7679298 -148227 104212 9957 -4461487 -5619012 696 2740183 -8632618 272727 10000000 2000000 500000 100 20 499900 99980 100000 250000 250000 100000 150000 150000 150000 100000 150000 100000 250000 100000 150000 52750 52500 2 3 52498 37497 20000 213000 52500 37500 2 52748 37500 52750 -953320 -724737 -724737 -691600 -953320 -691600 13815 18990 18990 15623 13815 15623 262770 252439 252439 -94255 262770 -94255 0.05 0.05 0.05 1 0.15 0.21 0.21 0.71 0.71 0.20 0.15 0.15 0.211 0.211 0.211 0.70 0.63 0.30 0.37 0.70 0.70 0.807 50000 5000 5001000 4438250 724017 582795 582795 718808 718808 3767180 1710759 35782 1800541 220098 4325571 1715840 36040 2344849 228842 286756 2059 93951 97045 37379 11710 242144 42884 2133 98431 128680 14628 321420 298818 22602 273874 252377 567 20930 13815 15623 -7679298 -8632618 -953320 -691600 -832421 -557712 262770 -94255 56512 48053 262770 -94255 16295 13604 483482 280871 41566 34902 5017 121126 521120 296517 39534 34572 5017 145480 422967 418225 60515 102895 7463 6860 24932 39509 85447 142404 5080474 5761416 694 696 9957 272727 85447 142404 561210 341956 634017 403613 -634017 -403613 36 36 18768 30256 -319303 -287987 -953320 -691600 -690550 -785855 -0.01 -0.01 69381015 68277590 16861 -3291 64405 453 -1213 -64405 760 896280 557751 5721907 ABMT 0.07 0.07 34415 90053 52750 17469 32649 409079 443163 54900 63870 794771 516658 34932 48351 2673620 2740183 -136441 -89444 4. RELATED PARTY TRANSACTIONS   As of October 31, 2018 and 2017, the Company owed $718,808 and $582,795 respectively to Titan Technology Development Limited, a stockholder.   As of October 31, 2018 and 2017, advances from related parties were as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="6" style="text-align: center">October 31,</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Yu Chi Fung</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">1,715,840</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">1,710,759</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Que Feng</td> <td> </td> <td> </td> <td style="text-align: right">36,040</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">35,782</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Chen Tie Jun</td> <td> </td> <td> </td> <td style="text-align: right">2,344,849</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,800,541</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Shenzhen Hygeian Medical Device Co., Ltd.</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">228,842</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">220,098</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Amount due to related parties</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">4,325,571</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,767,180</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Advances from a stockholder and related parties are unsecured, repayable on demand and bearing interest at 7% per annum. Interest expenses on advances from a stockholder and the related parties accrued for the years ended October 31, 2018 and 2017 were as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="6" style="text-align: center">October 31,</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Titan Technology Development Limited, a stockholder</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">42,884</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">37,379</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Related parties:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Que Feng</td> <td> </td> <td> </td> <td style="text-align: right">2,133</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,059</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Yu Chi Fang</td> <td> </td> <td> </td> <td style="text-align: right">98,431</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">93,951</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Chen Tie Jun</td> <td> </td> <td> </td> <td style="text-align: right">128,680</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">97,045</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Shenzhen Hygeian Medical Device Co., Ltd.</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">14,628</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">11,710</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Interest expenses to a stockholder and related parties</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">286,756</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">242,144</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   As of October 31, 2018 and 2017, advances from directors were as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="6" style="text-align: center">October 31,</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Wang Wei</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">252,377</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">298,818</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Gui Kai</td> <td> </td> <td> </td> <td style="text-align: right">567</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Yu Chi Ming</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">20,930</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">22,602</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Amount due to directors</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">273,874</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">321,420</td> <td style="padding-bottom: 1.5pt"> </td></tr> </table>   Advances from directors were unsecured, repayable on demand and interest free. Imputed interests on the amounts owed to Wang Wei, a director, were $13,815 and $15,623 for the years ended October 31, 2018, and 2017 respectively. 6. COMMITMENTS AND CONTINGENCIES   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"> </td> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">(A)</td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">Employee benefits</td></tr> </table>   The full time employees of the Company are entitled to employee benefits including medical care, welfare subsidies, unemployment insurance and pension benefits through a Chinese government mandated multi-employer defined contribution plan. The Company is required to accrue for these benefits based on certain percentages of the employees’ salaries and make contributions to the plans out of the amounts accrued for medical and pension benefits. The total provisions and contributions made for such employee benefits was $58,469 and $37,440 for the years ended October 31, 2018 and 2017 respectively. The Chinese government is responsible for the medical benefits and the pension liability to be paid to these employees.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; line-height: 107%"> </td> <td style="width: 24px; text-align: justify; line-height: 107%">(B)</td> <td style="text-align: justify; line-height: 107%">Lease commitments</td></tr> </table>   As of October 31, 2018, the Company had outstanding commitments with respect to operating leases, which are due as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 77%; line-height: 107%">2018</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 20%; text-align: right; line-height: 107%">41,298</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">34,415</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">2020</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">14,340</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">90,053</td> <td style="line-height: 107%"> </td></tr> </table>   The Company leased from a third party office space at monthly rent prevailing at October 31, 2018 of $1,867 (2017: $1,963). This operating lease expired on July 20, 2015. The Company continues to lease this premises at same monthly rent pending a formal renewal of the lease.   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; line-height: 107%"> </td> <td style="width: 24px; text-align: justify; line-height: 107%">(C)</td> <td style="text-align: justify; line-height: 107%">Capital commitments</td></tr> </table>   The Company has no outstanding commitments contracted for, net of deposit paid, in respect of acquisitions of plant and machineries as of October 31, 2018 (2017: Nil). 9. GOING CONCERN   As reflected in the accompanying consolidated financial statements, the Company has an accumulated deficit of $8,632,618 as of October 31, 2018 that includes a net loss of $953,320 for the year ended October 31, 2018. The Company’s total current liabilities exceed its total current assets by $5,721,907 and the Company used cash in operations of $832,421. These factors raise substantial doubt about its ability to continue as a going concern. In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to raise additional capital, obtain financing and succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.   To continue as a going concern, the Company is actively pursuing additional funding and strategic partners to enable it to implement its business plan. Management believes that these actions, if successful, will allow the Company to continue its operations through the next fiscal year. As of October 31, 2018, the Company had outstanding commitments with respect to operating leases, which are due as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 77%; line-height: 107%">2018</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 20%; text-align: right; line-height: 107%">41,298</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">2019</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">34,415</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">2020</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">14,340</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Total</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">90,053</td> <td style="line-height: 107%"> </td></tr> </table> No No Yes Non-accelerated Filer true false false false 11983373 -37500 6559 7463 6860 -57 105 -603 904 36 36 286756 242144 223437 215095 185642 228068 409079 443163 393494 106506 500000 10000000 58469 37440 1963 1867 2015-07-20 14340 1915159 2082118 651154 707920 56766 0.06 0.94 0.06 0.94 0.25 P5Y 0.50 6.8013 7.8015 6.6328 1 1 7.7842 1 7.8393 6.9737 1 7.8351 6.5629 1.00 0.70 1 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font: 12pt Times New Roman, Times, Serif"> </td> <td style="width: 24px; font: 12pt Times New Roman, Times, Serif; text-align: justify">(A)</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">Organization</td></tr> </table>   Advanced Biomedical Technologies, Inc. (fka “Geostar Mineral Corporation” or “Geostar”) (“ABMT”) was incorporated in Nevada on September 12, 2006.   Shenzhen Changhua Biomedical Engineering Co., Ltd. (“Shenzhen Changhua”) was incorporated in the People’s Republic of China (“PRC”) on September 25, 2002 as a limited liability company with a registered capital of $724,017. Shenzhen Changhua is owned by two stockholders in the proportion of 70% and 30% respectively. Shenzhen Changhua has been involved in the development of polymer screws, rods and binding wires for fixation on human fractured bones. The Company is currently involved in researching, manufacturing and conducting clinical trials on its products and intends to raise additional capital to produce and market its products commercially. The Company holds one Class III permit and one Class II permit from the China Food and Drug Administration (“CFDA”), formally the State Food and Drug Administration (“SFDA”) of the PRC. The Company holds two patents issued by the State Intellectual Property Office of the P.R.C. (“SIPO”). The Company has no revenue since its inception and, in accordance with Accounting Standards Codification (“ASC”) Topic 915, “Development Stage Entities”, is considered a Development Stage Company.   Masterise Holdings Limited (“Masterise”) was incorporated in the British Virgin Islands on 31 May, 2007 as an investment holding company. Masterise is owned as to 63% by the spouse of Shenzhen Changhua’s 70% majority stockholder and 37% by a third party corporation.   On January 29, 2008, Masterise entered into a Share Purchase Agreement (“the Agreement”) with a stockholder of Shenzhen Changhua whereupon Masterise acquired 70% of Shenzhen Changhua for US$64,100 in cash. The acquisition was completed on February 25, 2008. As both Masterise and Shenzhen Changhua are under common control and management, the acquisition was accounted for as a reorganization of entities under common control. Accordingly, the operations of Shenzhen Changhua were included in the consolidated financial statements as if the transactions had occurred retroactively.   On December 31, 2008, ABMT consummated a Share Exchange Agreement (“the Exchange Agreement”) with the stockholders of Masterise pursuant to which Geostar issued 50,000 shares of Common Stock to the stockholders of Masterise for 100% equity interest in Masterise.   Concurrently, on December 31, 2008, a major stockholder of ABMT also consummated an Affiliate Stock Purchase Agreement (the “Affiliate Agreement”) with thirteen individuals including all the stockholders of Masterise, pursuant to which the major stockholder sold a total of 5,001,000 shares of ABMT’s common stock for a total aggregate consideration of $5,000, including 4,438,250 shares to the stockholders of Masterise.   On consummation of the Exchange Agreement and the Affiliate Agreement, the 70% majority stockholder of Masterise became an 80.7% stockholder of ABMT.   On March 13, 2009, the name of the Company was changed from Geostar Mineral Corporation to Advanced Biomedical Technologies, Inc.   The merger of ABMT and Masterise was treated for accounting purposes as a capital transaction and recapitalization by Masterise (“the accounting acquirer”) and a re-organization by ABMT (“the accounting acquiree”). The financial statements have been prepared as if the re-organization had occurred retroactively.   Accordingly, these financial statements include the following:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 96px; text-align: justify"> </td> <td style="width: 72px; text-align: justify">(1)</td> <td style="text-align: justify">The balance sheet consisting of the net assets of the acquirer at historical cost and the net assets of the acquiree at historical cost.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">(2)</td> <td style="text-align: justify">The statement of operations including the operations of the acquirer for the periods presented and the operations of the acquiree from the date of the transaction.</td></tr> </table>   ABMT, Masterise and Shenzhen Changhua are hereinafter referred to as (“the Company”).   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; text-align: justify">(B)</td> <td style="text-align: justify">Principles of consolidation</td></tr> </table>   The accompanying consolidated financial statements include the financial statements of ABMT and its wholly owned subsidiaries, Masterise and its 70% owned subsidiary, Shenzhen Changhua. The noncontrolling interests represent the noncontrolling stockholders’ 30% proportionate share of the results of Shenzhen Changhua.   All significant inter-company balances and transactions have been eliminated in consolidation.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; text-align: justify">(C)</td> <td style="text-align: justify">Use of estimates</td></tr> </table>   The preparation of the financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; text-align: justify">(D)</td> <td style="text-align: justify">Cash and cash equivalents</td></tr> </table>   For purpose of the statements of cash flows, cash and cash equivalents include cash on hand and demand deposits with a bank with a maturity of less than three months. As of October 31, 2018 and 2017, all the cash and cash equivalents were denominated in United States Dollars (“US$”), Hong Kong Dollars (“HK$”) and Renminbi (“RMB”) and were placed with banks in the United States of America, Hong Kong and PRC. Balances at financial institutions or state-owned banks within the PRC are not freely convertible into foreign currencies and the remittance of these funds out of the PRC is subject to exchange control restrictions imposed by the PRC government.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; text-align: justify">(E)</td> <td style="text-align: justify">Property and equipment</td></tr> </table>   Property and equipment are stated at cost, less accumulated depreciation. Expenditures for additions, major renewals and betterments are capitalized and expenditures for maintenance and repairs are charged to expense as incurred.   Depreciation is provided on a straight-line basis, less estimated residual value over the assets estimated useful lives. The estimated useful lives of the assets are 5 years.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; text-align: justify">(F)</td> <td style="text-align: justify">Long-lived assets</td></tr> </table>   The Company accounts for long-lived assets under the FASB Codification Topic 360 (ASC 360) “Accounting for Impairment or Disposal of Long-Lived Assets”. In accordance with ASC Topic 360, long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets, when undiscounted future cash flows will not be sufficient to recover an asset’s carrying amount, the asset is written down to its fair value. The long-lived assets of the Company, which are subject to evaluation, consist primarily of property and equipment. For the years ended October 31, 2018 and 2017, the Company has not recognized any allowances for impairment.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; text-align: justify">(G)</td> <td style="text-align: justify">Fair value of financial instruments</td></tr> </table>   FASB Codification Topic 825 (ASC Topic 825), “Disclosure About Fair Value of Financial Instruments,” requires certain disclosures regarding the fair value of financial instruments. The carrying amounts of other receivables and prepaid expenses other payables and accrued liabilities and due to directors, a stockholder and related parties approximate their fair values because of the short-term nature of the instruments. The management of the Company is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial statements.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; text-align: justify">(H)</td> <td style="text-align: justify">Income taxes</td></tr> </table>   The Company accounts for income taxes under the FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period included the enactment date.   We assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where there is greater than 50% likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that may potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is a 50% or less likelihood that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; text-align: justify">(I)</td> <td style="text-align: justify">Research and development</td></tr> </table>   Research and development costs related to both present and future products are expensed as incurred. Total expenditure on research and development charged to general and administrative expenses for the years ended October 31, 2018 and 2017 were $56,512 and $48,053 respectively.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; text-align: justify">(J)</td> <td style="text-align: justify">Foreign currency translation</td></tr> </table>   The reporting currency of the Company is the US dollar. ABMT, Masterise and Shenzhen Changhua maintain their accounting records in their functional currencies of US$, HK$ and RMB respectively.   Foreign currency transactions during the year are translated to the functional currency at the approximate rates of exchange on the dates of transactions. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the approximate rates of exchange at that date. Non-monetary assets and liabilities are translated at the rates of exchange prevailing at the time the asset or liability was acquired. Exchange gains or losses are recorded in the statement of operations.   The financial statements of Masterise and Shenzhen Changhua (whose functional currency is HK$ and RMB respectively) are translated into US$ using the closing rate method. The balance sheet items are translated into US$ using the exchange rates at the respective balance sheet dates. The capital and various reserves are translated at historical exchange rates prevailing at the time of the transactions while income and expenses items are translated at the average exchange rate for the year. All exchange differences are recorded within equity.   The exchange rates used to translate amounts in HK$ and RMB into US$ for the purposes of preparing the financial statements were as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 42%; padding-bottom: 1.5pt"> </td> <td style="width: 1%"> </td> <td style="width: 28%; border-bottom: black 1.5pt solid; text-align: center">October 31, 2018</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 28%; border-bottom: black 1.5pt solid; text-align: center">October 31, 2017</td></tr> <tr style="background-color: #CCEEFF"> <td>Balance sheet items, except for share capital, additional paid-in capital and accumulated deficits, as of year end</td> <td> </td> <td>   US$1=HK$7.8393=RMB6.9737</td> <td> </td> <td>   US$1= HK$7.8015=RMB6.6328</td></tr> <tr style="background-color: white"> <td>Amounts included in the statements of operations and cash flows for the year</td> <td> </td> <td>   US$1=HK$7.8351=RMB6.5629</td> <td> </td> <td>   US$1= HK$7.7842=RMB6.8013</td></tr> </table>   The translation gain and loss recorded for the years ended October 31, 2018 and 2017 were $262,770 and $94,255 respectively.   No presentation is made that RMB amounts have been, or would be, converted into US$ at the above rates. Although the Chinese government regulations now allow convertibility of RMB for current account transactions, significant restrictions still remain. Hence, such translations should not be construed as representations that RMB could be converted into US$ at that rate or any other rate.   The value of RMB against US$ and other currencies may fluctuate and is affected by, among other things, changes in China’s political and economic conditions. Any significant revaluation of RMB may materially affect the Company’s financial condition in terms of US$ reporting.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; text-align: justify">(K)</td> <td style="text-align: justify">Other comprehensive loss</td></tr> </table>   The foreign currency translation gain or loss resulting from translation of the financial statements expressed in RMB and HK$ to US$ is reported as other comprehensive gain or loss in the statements of operations and stockholders’ deficit. Other comprehensive gain and loss for the years ended October 31, 2018 and 2017 were $262,770 and $94,255 respectively.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; text-align: justify">(L)</td> <td style="text-align: justify">Loss per share</td></tr> </table>   Basic loss per share are computed by dividing income available to stockholders by the weighted average number of shares outstanding during the year. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the potential shares had been issued and if the additional shares were diluted. There are no potentially dilutive securities as at October 31, 2018 and October 31, 2017.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; text-align: justify">(M)</td> <td style="text-align: justify">Segments</td></tr> </table>   The Company operates in only one segment, thereafter segment disclosure is not presented.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px; text-align: justify">(N)</td> <td style="text-align: justify">Recent Accounting Pronouncements</td></tr> </table>   Business Combination: Clarifying the Definition of a Business   In January 2017, the FASB issued ASU No. 2017-1 “Topic 805, Business Combinations: Clarifying the Definition of a Business”. The amendments in this update provide a screen to determine when a set is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. The amendments in this update affect all reporting entities that must determine whether they have acquired or sold a business. Public business entities should apply the amendments in this update to annual periods beginning after December 15, 2017, including interim periods within those periods. All other entities should apply the amendments to annual periods beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2019. The Company does not expect the adoption of ASU 2017-1 to have a material impact on its consolidated financial statements.   Simplifying the Test for Goodwill Impairment   In January 2017, the FASB issued ASU No. 2017-4 “Topic 350: Intangibles-Goodwill and Other: Simplifying the Test for Goodwill Impairment.” The amendments in this update eliminate step two of the goodwill impairment test and specifies that goodwill impairment should be measured by comparing the fair value of a reporting unit with its carrying amount. Additionally, the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets should be disclosed. The amendments in this update are effective for annual or interim goodwill impairment tests performed in fiscal years beginning after December 15, 2019; early adoption is permitted. The Company does not expect the adoption of ASU 2017-4 to have a material impact on its consolidated financial statements.   Share-based Compensation   In May 2017, the FASB issued guidance on changes to terms and conditions of share-based payment awards. The amendment provides guidance about which changes to terms or conditions of a share-based payment award require an entity to apply modification accounting. The guidance is effective for the fiscal year beginning on January 1, 2018, including interim periods within that year.   In June 2018, the scope of Topic 718 has been expanded to include sharebased payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2018 and after December 15, 2019 for all other entities. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606.   The Company does not anticipate that adoption of these guidances will have a material impact on its consolidated financial statements.   Revenue Recognition   In May 2014, the FASB issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. Under the new standard, a good or service is transferred to the customer when (or as) the customer obtains control of the good or service, which differs from the risk and rewards approach under current guidance. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. In March, April and May 2016, the FASB issued three additional updates regarding identifying performance obligations and licensing, certain principal versus agent considerations and various narrow scope improvements based on practical questions raised by users. In September 2017, the FASB issued additional amendments providing clarification and implementation guidance. The guidance may be adopted through either retrospective application to all periods presented in the financial statements (full retrospective approach) or through a cumulative effect adjustment to retained earnings at the effective date (modified retrospective approach). The guidance is effective for the fiscal periods beginning on January 1, 2018.   Leases   In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. The new standard, as amended by ASU 2018-01 and ASU 2018-11, is effective for annual periods beginning after December 15, 2018 on a modified retrospective basis. The Company will adopt ASU 2016-02 in its first quarter of the year ending October 31 2020. The Company expects its leases designated as operating leases in Note 6, “Commitments and Contingencies,” will be reported on the consolidated balance sheets upon adoption. However, the ultimate impact of adopting ASU 2016-02 will depend on the lease terms as of the adoption date.   The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoptions of any such pronouncements may be expected to cause a material impact on the financial condition or the results of operations. 2. PROPERTY AND EQUIPMENT   The following is a summary of property and equipment at October 31, 2018 and 2017:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">October 31,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%; line-height: 107%">Plant and machinery</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">296,517</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">280,871</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Motor vehicles</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">39,534</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">41,566</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Office equipment</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">34,572</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">34,902</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Computer software</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">5,017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">5,017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Office improvements</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">145,480</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">121,126</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">521,120</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">483,482</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Less: accumulated depreciation</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">418,225</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">422,967</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Property and equipment, net</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">102,895</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">60,515</td> <td style="line-height: 107%"> </td></tr> </table>   Depreciation expense for the year ended October 31, 2018 and 2017 was $16,295 and $13,604 respectively. 3. OTHER PAYABLES AND ACCRUED EXPENSES   Other payables and accrued expenses at October 31, 2018 and 2017 consisted of the followings:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="6" style="text-align: center">October 31,</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Other payables</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">215,095</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">223,437</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Accrued expenses</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">228,068</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">185,642</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">443,163</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">409,079</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> 5. STOCKHOLDERS’ DEFICIENCY   Common stock   On December 8, 2011, the Company issued 100,000 shares of restricted common stock at $0.2 to Dr. John Lynch, the Company’s chief officer of dental technologies, for services for a term of twelve months. The shares were valued at the closing price on the date of grant yielding an aggregate fair value of $20,000, fully recognised in prior years as consultancy fees included in general and administrative expenses.   On 28 October 2013, the Company issued 150,000 shares of restricted common stock as directors’ services compensation for past services to each of Mr. Chi Ming Yu and Kai Gui, directors of the Company. The shares were valued at the closing price of $0.71 per share on the date of grant, yielding an aggregate fair value of $213,000.   On 13 November 2015, $106,506 of the interest payable to a Company’s stockholder and $393,494 of the interest payable to two related parties, totaled $500,000, were converted into 10,000,000 shares of common stock at a conversion price of $0.05 per share and which were issued to the said stockholder.   On 31 March 2016, the Company issued 100,000 and 150,000 shares of restricted common stock as directors’ compensation for past services to Mr. Chi Ming Yu and Mr. Kai Gui, directors of the Company respectively. The shares were valued at the closing price of $0.21 per share on the date of grant, yielding an aggregate fair value of $52,500.   On 28 April 2017, the Company issued 100,000 and 150,000 shares of restricted common stock as directors’ compensation for past services to Mr. Chi Ming Yu and Mr. Kai Gui, directors of the Company respectively. The shares were valued at the closing price of $0.15 per share on the date of grant, yielding an aggregate fair value of $37,500.   On 23 October 2018, the Company issued 100,000 and 150,000 shares of restricted common stock as directors’ compensation for past services to Mr. Chi Ming Yu and Mr. Kai Gui, directors of the Company respectively. The shares were valued at the closing price of $0.211 per share on the date of grant, yielding an aggregate fair value of $52,750. 7. INCOME TAX   ABMT was incorporated in the United States and has incurred net operating loss for income tax purposes for 2018 and 2017. ABMT has net operating loss carry forwards for income taxes amounting to approximately $2,082,118 and $1,915,159 as of October 31, 2018 and 2017 respectively which may be available to reduce future years’ taxable income. These carry forwards, will expire, if not utilized, commencing in 2029. Management believes that the realization of the benefits from these losses appears uncertain due to the Company’s limited operating history and continuing losses. Accordingly, a full, deferred tax asset valuation allowance has been provided and no deferred tax asset valuation allowance has been provided and no deferred tax asset benefit has been recorded. The valuation allowance at October 31, 2018 and 2017 was $707,920 and $651,154 respectively. The net change in the valuation allowance for 2018 was an increase of $56,766.   Masterise was incorporated in the BVI and under current law of the BVI, is not subject to tax on income.   Shenzhen Changhua was incorporated in the PRC and is subject to PRC income tax which is computed according to the relevant laws and regulations in the PRC. The income tax rate has been 25%. No income tax expense has been provided by Shenzhen Changhua as it has incurred losses. The losses cannot be carried forward as Shenzhen Changhua has not yet commenced operation. 8. CONCENTRATIONS AND RISKS   As at October 31, 2018 and 2017, 94% and 6% of the Company’s assets were located in the P.R.C. and the United States respectively. 10. SUBSEQUENT EVENT   The Company has evaluated the existence of significant events subsequent to the balance sheet date through the date the financial statements were issued and has determined that there were no subsequent events or transactions which would require recognition or disclosure in the financial statements. <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"> </td> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">(A)</td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">Organization</td></tr> </table>   Advanced Biomedical Technologies, Inc. (fka “Geostar Mineral Corporation” or “Geostar”) (“ABMT”) was incorporated in Nevada on September 12, 2006.   Shenzhen Changhua Biomedical Engineering Co., Ltd. (“Shenzhen Changhua”) was incorporated in the People’s Republic of China (“PRC”) on September 25, 2002 as a limited liability company with a registered capital of $724,017. Shenzhen Changhua is owned by two stockholders in the proportion of 70% and 30% respectively. Shenzhen Changhua has been involved in the development of polymer screws, rods and binding wires for fixation on human fractured bones. The Company is currently involved in researching, manufacturing and conducting clinical trials on its products and intends to raise additional capital to produce and market its products commercially. The Company holds one Class III permit and one Class II permit from the China Food and Drug Administration (“CFDA”), formally the State Food and Drug Administration (“SFDA”) of the PRC. The Company holds two patents issued by the State Intellectual Property Office of the P.R.C. (“SIPO”). The Company has no revenue since its inception and, in accordance with Accounting Standards Codification (“ASC”) Topic 915, “Development Stage Entities”, is considered a Development Stage Company.   Masterise Holdings Limited (“Masterise”) was incorporated in the British Virgin Islands on 31 May, 2007 as an investment holding company. Masterise is owned as to 63% by the spouse of Shenzhen Changhua’s 70% majority stockholder and 37% by a third party corporation.   On January 29, 2008, Masterise entered into a Share Purchase Agreement (“the Agreement”) with a stockholder of Shenzhen Changhua whereupon Masterise acquired 70% of Shenzhen Changhua for US$64,100 in cash. The acquisition was completed on February 25, 2008. As both Masterise and Shenzhen Changhua are under common control and management, the acquisition was accounted for as a reorganization of entities under common control. Accordingly, the operations of Shenzhen Changhua were included in the consolidated financial statements as if the transactions had occurred retroactively.   On December 31, 2008, ABMT consummated a Share Exchange Agreement (“the Exchange Agreement”) with the stockholders of Masterise pursuant to which Geostar issued 50,000 shares of Common Stock to the stockholders of Masterise for 100% equity interest in Masterise.   Concurrently, on December 31, 2008, a major stockholder of ABMT also consummated an Affiliate Stock Purchase Agreement (the “Affiliate Agreement”) with thirteen individuals including all the stockholders of Masterise, pursuant to which the major stockholder sold a total of 5,001,000 shares of ABMT’s common stock for a total aggregate consideration of $5,000, including 4,438,250 shares to the stockholders of Masterise.   On consummation of the Exchange Agreement and the Affiliate Agreement, the 70% majority stockholder of Masterise became an 80.7% stockholder of ABMT.   On March 13, 2009, the name of the Company was changed from Geostar Mineral Corporation to Advanced Biomedical Technologies, Inc.   The merger of ABMT and Masterise was treated for accounting purposes as a capital transaction and recapitalization by Masterise (“the accounting acquirer”) and a re-organization by ABMT (“the accounting acquiree”). The financial statements have been prepared as if the re-organization had occurred retroactively.   Accordingly, these financial statements include the following:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 96px; text-align: justify; line-height: 107%"> </td> <td style="width: 72px; text-align: justify; line-height: 107%">(1)</td> <td style="text-align: justify; line-height: 107%">The balance sheet consisting of the net assets of the acquirer at historical cost and the net assets of the acquiree at historical cost.</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%"> </td> <td style="text-align: justify; line-height: 107%">(2)</td> <td style="text-align: justify; line-height: 107%">The statement of operations including the operations of the acquirer for the periods presented and the operations of the acquiree from the date of the transaction.</td></tr> </table>   ABMT, Masterise and Shenzhen Changhua are hereinafter referred to as (“the Company”). <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"> </td> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">(B)</td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">Principles of consolidation</td></tr> </table>   The accompanying consolidated financial statements include the financial statements of ABMT and its wholly owned subsidiaries, Masterise and its 70% owned subsidiary, Shenzhen Changhua. The noncontrolling interests represent the noncontrolling stockholders’ 30% proportionate share of the results of Shenzhen Changhua.   All significant inter-company balances and transactions have been eliminated in consolidation. <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"> </td> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">(C)</td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">Use of estimates</td></tr> </table>   The preparation of the financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"> </td> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">(D)</td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">Cash and cash equivalents</td></tr> </table>   For purpose of the statements of cash flows, cash and cash equivalents include cash on hand and demand deposits with a bank with a maturity of less than three months. As of October 31, 2018 and 2017, all the cash and cash equivalents were denominated in United States Dollars (“US$”), Hong Kong Dollars (“HK$”) and Renminbi (“RMB”) and were placed with banks in the United States of America, Hong Kong and PRC. Balances at financial institutions or state-owned banks within the PRC are not freely convertible into foreign currencies and the remittance of these funds out of the PRC is subject to exchange control restrictions imposed by the PRC government. <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"> </td> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">(E)</td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">Property and equipment</td></tr> </table>   Property and equipment are stated at cost, less accumulated depreciation. Expenditures for additions, major renewals and betterments are capitalized and expenditures for maintenance and repairs are charged to expense as incurred.   Depreciation is provided on a straight-line basis, less estimated residual value over the assets estimated useful lives. The estimated useful lives of the assets are 5 years. <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"> </td> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">(F)</td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">Long-lived assets</td></tr> </table>   The Company accounts for long-lived assets under the FASB Codification Topic 360 (ASC 360) “Accounting for Impairment or Disposal of Long-Lived Assets”. In accordance with ASC Topic 360, long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets, when undiscounted future cash flows will not be sufficient to recover an asset’s carrying amount, the asset is written down to its fair value. The long-lived assets of the Company, which are subject to evaluation, consist primarily of property and equipment. For the years ended October 31, 2018 and 2017, the Company has not recognized any allowances for impairment. <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"> </td> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">(G)</td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">Fair value of financial instruments</td></tr> </table>   FASB Codification Topic 825 (ASC Topic 825), “Disclosure About Fair Value of Financial Instruments,” requires certain disclosures regarding the fair value of financial instruments. The carrying amounts of other receivables and prepaid expenses other payables and accrued liabilities and due to directors, a stockholder and related parties approximate their fair values because of the short-term nature of the instruments. The management of the Company is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial statements. <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"> </td> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">(H)</td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">Income taxes</td></tr> </table>   The Company accounts for income taxes under the FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period included the enactment date.   We assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where there is greater than 50% likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that may potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is a 50% or less likelihood that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements. <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"> </td> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">(I)</td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">Research and development</td></tr> </table>   Research and development costs related to both present and future products are expensed as incurred. Total expenditure on research and development charged to general and administrative expenses for the years ended October 31, 2018 and 2017 were $56,512 and $48,053 respectively. <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font: 12pt Times New Roman, Times, Serif"> </td> <td style="width: 24px; font: 12pt Times New Roman, Times, Serif; text-align: justify">(J)</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">Foreign currency translation</td></tr> </table>   The reporting currency of the Company is the US dollar. ABMT, Masterise and Shenzhen Changhua maintain their accounting records in their functional currencies of US$, HK$ and RMB respectively.   Foreign currency transactions during the year are translated to the functional currency at the approximate rates of exchange on the dates of transactions. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the approximate rates of exchange at that date. Non-monetary assets and liabilities are translated at the rates of exchange prevailing at the time the asset or liability was acquired. Exchange gains or losses are recorded in the statement of operations.   The financial statements of Masterise and Shenzhen Changhua (whose functional currency is HK$ and RMB respectively) are translated into US$ using the closing rate method. The balance sheet items are translated into US$ using the exchange rates at the respective balance sheet dates. The capital and various reserves are translated at historical exchange rates prevailing at the time of the transactions while income and expenses items are translated at the average exchange rate for the year. All exchange differences are recorded within equity.   The exchange rates used to translate amounts in HK$ and RMB into US$ for the purposes of preparing the financial statements were as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 42%; padding-bottom: 1.5pt"> </td> <td style="width: 1%"> </td> <td style="width: 28%; border-bottom: black 1.5pt solid; text-align: center">October 31, 2018</td> <td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 28%; border-bottom: black 1.5pt solid; text-align: center">October 31, 2017</td></tr> <tr style="background-color: #CCEEFF"> <td>Balance sheet items, except for share capital, additional paid-in capital and accumulated deficits, as of year end</td> <td> </td> <td>   US$1=HK$7.8393=RMB6.9737</td> <td> </td> <td>   US$1= HK$7.8015=RMB6.6328</td></tr> <tr style="background-color: white"> <td>Amounts included in the statements of operations and cash flows for the year</td> <td> </td> <td>   US$1=HK$7.8351=RMB6.5629</td> <td> </td> <td>   US$1= HK$7.7842=RMB6.8013</td></tr> </table>   The translation gain and loss recorded for the years ended October 31, 2018 and 2017 were $262,770 and $94,255 respectively.   No presentation is made that RMB amounts have been, or would be, converted into US$ at the above rates. Although the Chinese government regulations now allow convertibility of RMB for current account transactions, significant restrictions still remain. Hence, such translations should not be construed as representations that RMB could be converted into US$ at that rate or any other rate.   The value of RMB against US$ and other currencies may fluctuate and is affected by, among other things, changes in China’s political and economic conditions. Any significant revaluation of RMB may materially affect the Company’s financial condition in terms of US$ reporting. <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font: 12pt Times New Roman, Times, Serif"> </td> <td style="width: 24px; font: 12pt Times New Roman, Times, Serif; text-align: justify">(K)</td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">Other comprehensive loss</td></tr> </table>   The foreign currency translation gain or loss resulting from translation of the financial statements expressed in RMB and HK$ to US$ is reported as other comprehensive gain or loss in the statements of operations and stockholders’ deficit. Other comprehensive gain and loss for the years ended October 31, 2018 and 2017 were $262,770 and $94,255 respectively. <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"> </td> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">(L)</td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">Loss per share</td></tr> </table>   Basic loss per share are computed by dividing income available to stockholders by the weighted average number of shares outstanding during the year. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the potential shares had been issued and if the additional shares were diluted. There are no potentially dilutive securities as at October 31, 2018 and October 31, 2017. <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"> </td> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">(M)</td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">Segments</td></tr> </table>   The Company operates in only one segment, thereafter segment disclosure is not presented. <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif"> </td> <td style="width: 24px; font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">(N)</td> <td style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; text-align: justify">Recent Accounting Pronouncements</td></tr> </table>   Business Combination: Clarifying the Definition of a Business   In January 2017, the FASB issued ASU No. 2017-1 “Topic 805, Business Combinations: Clarifying the Definition of a Business”. The amendments in this update provide a screen to determine when a set is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. The amendments in this update affect all reporting entities that must determine whether they have acquired or sold a business. Public business entities should apply the amendments in this update to annual periods beginning after December 15, 2017, including interim periods within those periods. All other entities should apply the amendments to annual periods beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2019. The Company does not expect the adoption of ASU 2017-1 to have a material impact on its consolidated financial statements.   Simplifying the Test for Goodwill Impairment   In January 2017, the FASB issued ASU No. 2017-4 “Topic 350: Intangibles-Goodwill and Other: Simplifying the Test for Goodwill Impairment.” The amendments in this update eliminate step two of the goodwill impairment test and specifies that goodwill impairment should be measured by comparing the fair value of a reporting unit with its carrying amount. Additionally, the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets should be disclosed. The amendments in this update are effective for annual or interim goodwill impairment tests performed in fiscal years beginning after December 15, 2019; early adoption is permitted. The Company does not expect the adoption of ASU 2017-4 to have a material impact on its consolidated financial statements.   Share-based Compensation   In May 2017, the FASB issued guidance on changes to terms and conditions of share-based payment awards. The amendment provides guidance about which changes to terms or conditions of a share-based payment award require an entity to apply modification accounting. The guidance is effective for the fiscal year beginning on January 1, 2018, including interim periods within that year.   In June 2018, the scope of Topic 718 has been expanded to include sharebased payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2018 and after December 15, 2019 for all other entities. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606.   The Company does not anticipate that adoption of these guidances will have a material impact on its consolidated financial statements.   Revenue Recognition   In May 2014, the FASB issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. Under the new standard, a good or service is transferred to the customer when (or as) the customer obtains control of the good or service, which differs from the risk and rewards approach under current guidance. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. In March, April and May 2016, the FASB issued three additional updates regarding identifying performance obligations and licensing, certain principal versus agent considerations and various narrow scope improvements based on practical questions raised by users. In September 2017, the FASB issued additional amendments providing clarification and implementation guidance. The guidance may be adopted through either retrospective application to all periods presented in the financial statements (full retrospective approach) or through a cumulative effect adjustment to retained earnings at the effective date (modified retrospective approach). The guidance is effective for the fiscal periods beginning on January 1, 2018.   Leases   In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. The new standard, as amended by ASU 2018-01 and ASU 2018-11, is effective for annual periods beginning after December 15, 2018 on a modified retrospective basis. The Company will adopt ASU 2016-02 in its first quarter of the year ending October 31 2020. The Company expects its leases designated as operating leases in Note 6, “Commitments and Contingencies,” will be reported on the consolidated balance sheets upon adoption. However, the ultimate impact of adopting ASU 2016-02 will depend on the lease terms as of the adoption date.   The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoptions of any such pronouncements may be expected to cause a material impact on the financial condition or the results of operations. The exchange rates used to translate amounts in HK$ and RMB into US$ for the purposes of preparing the financial statements were as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 42%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 28%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">October 31, 2018</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 28%; border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">October 31, 2017</td></tr> <tr style="background-color: #CCEEFF"> <td style="line-height: 107%">Balance sheet items, except for share capital, additional paid-in capital and accumulated deficits, as of year end</td> <td style="line-height: 107%"> </td> <td>   US$1=HK$7.8393=RMB6.9737</td> <td style="line-height: 107%"> </td> <td>   US$1= HK$7.8015=RMB6.6328</td></tr> <tr style="background-color: white"> <td style="line-height: 107%">Amounts included in the statements of operations and cash flows for the year</td> <td style="line-height: 107%"> </td> <td>   US$1=HK$7.8351=RMB6.5629</td> <td style="line-height: 107%"> </td> <td>   US$1= HK$7.7842=RMB6.8013</td></tr> </table> The following is a summary of property and equipment at October 31, 2018 and 2017:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="6" style="text-align: center; line-height: 107%">October 31,</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2018</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%">2017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td colspan="2" style="line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%; line-height: 107%">Plant and machinery</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">296,517</td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%"> </td> <td style="width: 1%; line-height: 107%">$</td> <td style="width: 14%; text-align: right; line-height: 107%">280,871</td> <td style="width: 1%; line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Motor vehicles</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">39,534</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">41,566</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Office equipment</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">34,572</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">34,902</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Computer software</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">5,017</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">5,017</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">Office improvements</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">145,480</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">121,126</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">521,120</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%">483,482</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Less: accumulated depreciation</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">418,225</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; line-height: 107%"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%">422,967</td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="text-align: right; line-height: 107%"> </td> <td style="line-height: 107%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">Property and equipment, net</td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">102,895</td> <td style="line-height: 107%"> </td> <td style="line-height: 107%"> </td> <td style="border-bottom: black 2.25pt double; line-height: 107%">$</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%">60,515</td> <td style="line-height: 107%"> </td></tr> </table> Other payables and accrued expenses at October 31, 2018 and 2017 consisted of the followings:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="6" style="text-align: center">October 31,</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Other payables</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">215,095</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">223,437</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Accrued expenses</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">228,068</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">185,642</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">443,163</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">409,079</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> As of October 31, 2018 and 2017, advances from related parties were as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="6" style="text-align: center">October 31,</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Yu Chi Fung</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">1,715,840</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">1,710,759</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Que Feng</td> <td> </td> <td> </td> <td style="text-align: right">36,040</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">35,782</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Chen Tie Jun</td> <td> </td> <td> </td> <td style="text-align: right">2,344,849</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,800,541</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Shenzhen Hygeian Medical Device Co., Ltd.</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">228,842</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">220,098</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Amount due to related parties</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">4,325,571</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,767,180</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Advances from a stockholder and related parties are unsecured, repayable on demand and bearing interest at 7% per annum. Interest expenses on advances from a stockholder and the related parties accrued for the years ended October 31, 2018 and 2017 were as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="6" style="text-align: center">October 31,</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Titan Technology Development Limited, a stockholder</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">42,884</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">37,379</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Related parties:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Que Feng</td> <td> </td> <td> </td> <td style="text-align: right">2,133</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,059</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Yu Chi Fang</td> <td> </td> <td> </td> <td style="text-align: right">98,431</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">93,951</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Chen Tie Jun</td> <td> </td> <td> </td> <td style="text-align: right">128,680</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">97,045</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Shenzhen Hygeian Medical Device Co., Ltd.</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">14,628</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">11,710</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Interest expenses to a stockholder and related parties</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">286,756</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">242,144</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   As of October 31, 2018 and 2017, advances from directors were as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="6" style="text-align: center">October 31,</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">2017</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%">Wang Wei</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">252,377</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">298,818</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Gui Kai</td> <td> </td> <td> </td> <td style="text-align: right">567</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Yu Chi Ming</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">20,930</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">22,602</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Amount due to directors</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">273,874</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">321,420</td> <td style="padding-bottom: 1.5pt"> </td></tr> </table>   Advances from directors were unsecured, repayable on demand and interest free. Imputed interests on the amounts owed to Wang Wei, a director, were $13,815 and $15,623 for the years ended October 31, 2018, and 2017 respectively. 41298 64100 0.30 Advanced Biomedical Technologies Inc. (the "Company") is filing this Amendment No. 1 (the "Amendment No. 1") to its Annual Report on Form 10-K for the fiscal year ended October 31, 2018, filed on February 13, 2019 (the "Original 10-K"), as the audit of the Company's annual financial statements contained therein has now been completed. The Company is now filing this Amendment No. 1 to include the Report of Independent Registered Public Accounting Firm, For convenience and ease of reference, the Company is filing the annual report in its entirety with applicable changes. Unless otherwise stated, all information contained in this Form 10K/A is as of February 13, 2019, the filing date of the original Annual Report. Except as stated herein, this Form 10K/A does not reflect events or transactions occurring after such filing date and does not contain any modifications or updates to the disclosure in the Annual Report that may have been affected by events or transactions occurring subsequent to such filing date. No information in the Annual Report other than as set forth above is amended hereby. EX-101.SCH 13 abmt-20181031.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Stockholders' Deficit (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies and Organization link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Other Payables and Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Stockholders' Deficiency link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Income Tax link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Concentrations and Risks link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Summary of Significant Accounting Policies and Organization (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Summary of Significant Accounting Policies and Organization (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Other Payables and Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Summary of Significant Accounting Policies and Organization (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Summary of Significant Accounting Policies and Organization - Schedule of Exchange Rates Used in Translation (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Other Payables and Accrued Expenses - Schedule of Other Payables and Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Related Party Transactions - Schedule of Advances from Related Parties (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Stockholders' Deficiency (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Obligations of Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Income Tax (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Concentrations and Risks (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 14 abmt-20181031_cal.xml XBRL CALCULATION FILE EX-101.DEF 15 abmt-20181031_def.xml XBRL DEFINITION FILE EX-101.LAB 16 abmt-20181031_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Accumulated Other Comprehensive Loss [Member] Consolidated Entities [Axis] ABMT [Member] Related Party [Axis] Titan Technology Development Limited, a Stockholder [Member] Income Statement Location [Axis] Statement of Operations and Cash Flows [Member] Currency [Axis] RMB [Member] Balance Sheet Location [Axis] Balance Sheet Items Except for Share Capital, Additional Paid-In Capital and Accumulated Deficits, as of Year End [Member] HKD [Member] USD [Member] Property, Plant and Equipment, Type [Axis] Plant and Machinery [Member] Motor Vehicles [Member] Office Equipment [Member] Computer Software [Member] Office Improvements [Member] Award Type [Axis] Restricted Stock [Member] Related Party Transaction [Axis] Mr. Chi Ming Yu [Member] Mr. Kai Gui [Member] Two Related Parties [Member] Company's Stockholder [Member] Dr. John Lynch [Member] Yu Chi Fung [Member] Que Feng [Member] Chen Tie Jun [Member] Wang Wei [Member] Yu Chi Ming [Member] Lease Arrangement, Type [Axis] Office Space [Member] Concentration Risk Benchmark [Axis] Assets [Member] Concentration Risk Type [Axis] Geographic Concentration Risk [Member] Geographical [Axis] UNITED STATES [Member] P.R.C [Member] Shenzhen Hygeian Medical Device Co., Ltd. [Member] Mr. Chi Ming Yu and Kai Gui [Member] Ownership [Axis] Shenzhen Changhua [Member] Masterise [Member] Majority Shareholders [Member] Investment, Name [Axis] Masterise [Member] Gui Kai [Member] P.R.C [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Amendment Description Current Fiscal Year End Date Entity a Well-known Seasoned Issuer Entity a Voluntary Filer Entity's Reporting Status Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Ex Transition Period Entity Shell Company Entity Public Float Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash and cash equivalents Other receivables and prepaid expenses Total Current Assets Property and equipment, cost Less: Accumulated depreciation PROPERTY AND EQUIPMENT, NET LONG-TERM PREPAID EXPENSES, NET DEPOSIT FOR PURCHASE OF PROPERTY AND EQUIPMENT TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' DEFICIT CURRENT LIABILITIES Other payables and accrued expenses Due to directors Due to a stockholder Due to related parties Total Current Liabilities COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' DEFICIT Common stock, $0.00001 par value, 100,000,000 shares authorized, 69,624,850 issued and outstanding as of October 31, 2018 and October 31, 2017 Additional paid-in capital Accumulated deficit Accumulated other comprehensive income/(loss) Total Deficit TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] OPERATING EXPENSES General and administrative expenses Depreciation Research and development Total Operating Expenses LOSS FROM OPERATIONS OTHER (EXPENSES) INCOME Interest income Interest paid to a stockholder and related parties Interest paid to a third party Imputed interest Other, net Total Other (Expenses) Income, net LOSS BEFORE TAXES Income tax expense NET LOSS Net loss attributable to non-controlling interests NET LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS OTHER COMPREHENSIVE INCOME Foreign currency translation income Total other comprehensive gain/(loss) COMPREHENSIVE GAIN/(LOSS) ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS Net loss per share-basic and diluted - basic and diluted Weighted average number of shares outstanding during the year - basic and diluted Statement [Table] Statement [Line Items] Balance Balance, shares Stock issued for debt conversion at 0.05 per share Stock issued for debt conversion at 0.05 per share, shares Stock issued for services Stock issued for services, shares Imputed interest on advances from directors Net loss for the period Foreign currency translation loss Balance Balance, shares Statement of Stockholders' Equity [Abstract] Debt conversion price, per share Shares issued for service, per share Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net loss attributable to ABMT common stockholders Adjustments to reconcile net loss to cash used in operating activities: Loss on disposal of property and equipment Stock issued for services Imputed interest Changes in operating assets and liabilities Decrease (increase) in: Other receivables and prepaid expenses Increase in: Other payables and accrued expenses Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment (Increase) decrease in deposit for purchase of property and equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Due to a stockholder Due to directors Due to related parties Net cash provided by financing activities EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS AT THE BEGINNING OF YEAR CASH AND CASH EQUIVALENTS AT THE END OF YEAR Supplemental of cash flow information Interest income Income tax Other non cash items Interest expenses Accounting Policies [Abstract] Summary of Significant Accounting Policies and Organization Property, Plant and Equipment [Abstract] Property and Equipment Payables and Accruals [Abstract] Other Payables and Accrued Expenses Related Party Transactions [Abstract] Related Party Transactions Equity [Abstract] Stockholders' Deficiency Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Income Tax Disclosure [Abstract] Income Tax Risks and Uncertainties [Abstract] Concentrations and Risks Organization, Consolidation and Presentation of Financial Statements [Abstract] Going Concern Subsequent Events [Abstract] Subsequent Event Organization Principles of Consolidation Use of Estimates Cash and Cash Equivalents Property and Equipment Long-lived Assets Fair Value of Financial Instruments Income Taxes Research and Development Foreign Currency Translation Other Comprehensive Loss Loss Per Share Segments Recent Accounting Pronouncements Schedule of Exchange Rates Used in Translation Schedule of Property and Equipment Schedule of Other Payables and Accrued Expenses Schedule of Advances from Related Parties Schedule of Future Minimum Lease Obligations of Operating Leases Registered capital Ownership interest - majority stockholder Ownership interest - minority stockholder Ownership acquired Payment for acquisition Stock issued in acquisition, shares Equity method investment ownership percentage Stock sold per affiliate agreement, shares Stock sold per affiliate agreement Ownership by non-controlling stockholders Estimated useful lives of property and equipment Long-lived assets, allowances for impairment Likelyhood that tax benefit sustained Research and development costs Foreign currency translation gain (loss) Other comprehensive gain (loss) Potentially dilutive securities Number of operating segment Exchange rate Depreciation expense Property and equipment, gross Less: accumulated depreciation Property and equipment, net Other payables Accrued expenses Other payables and accrued expenses Due to stockholder Interest rate Imputed interests Interest expenses to a stockholder and related parties Number of restricted common stock services, shares Number of restricted common stock for services Common stock price per share Debt conversion of common stock Debt conversion of common stock shares Debt conversion price per share Contributions under defined contribution plan Rent expense Lease expiration date Plant and machineries commitments 2018 2019 2020 Total Net operating loss carry forwards Deferred tax asset valuation allowance Net change in the valuation allowance Income tax rate Concentration risk, percentage Net loss Working capital deficit Net cash used in operating activities The financial statement for which currency rates are applied in computing translation adjustments.. Chen Tie Jun [Member] Chi Ming Yu [Member] Information about related party. Person serving on the board of directors (who collectively have responsibility for governing the entity). Person serving on the board of directors (who collectively have responsibility for governing the entity). Lease arrangements by type. Carrying amount as of the balance sheet date of obligations due stockholders. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer). Hui Wang [Member] The financial statements for which currency rates are applied in computing translation adjustments.. Interest paid to a stockholder and related parties. Masterise Holdings Limited [Member] Name of investment. Mr. Chi Ming Yu and Kai Gui [Member] Office Space [Member] P.R.C [Member] Que Feng [Member] Related Parties [Member] Shenzhen Changhua Biomedical Engineering Company Limited [Member] Shenzhen Changhua [Member] Shenzhen Hygeian Medical Device Co., Ltd. [Member] Stockholder and Related Parties [Member] Stockholder [Member] Titan Technology Development Limited, a Stockholder [Member] Titan Technology Development Ltd - Stockholder [Member] Two Directors [Member] Two Related Parties [Member] United States [Member] Wang Hui [Member] Working capital deficit. Yu Chi Fung [Member] Three Related Parties [Member] Repayments to officer or stockholders. Four Related Parties [Member] Interest owed to directors and related company. Other non cash interest expenses. Organization [Policy Text Block] Tabular disclosure of of exchange rates used in translation. Wang Wei [Member] Yu Chi Ming [Member] Gui Kai [Member] Percentage likelyhood that tax benefit will be sustained. Masterise [Member] [Default Label] CHINA Assets, Current Assets Liabilities, Current Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense, Other Other Nonoperating Expense Other Operating Income (Expense), Net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding Gain (Loss) on Disposition of Property Plant Equipment Issuance of Stock and Warrants for Services or Claims Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Payments to Acquire Property, Plant, and Equipment Increase (Decrease) in Restricted Cash Net Cash Provided by (Used in) Investing Activities RepaymentsToOfficerOrStockholders Repayments of Related Party Debt Proceeds from Related Party Debt Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Interest Paid, Excluding Capitalized Interest, Operating Activities Property, Plant and Equipment, Policy [Policy Text Block] Other Liabilities, Current Operating Leases, Future Minimum Payments Due EX-101.PRE 17 abmt-20181031_pre.xml XBRL PRESENTATION FILE XML 18 R1.htm IDEA: XBRL DOCUMENT v3.19.1

Document and Entity Information - USD ($)
12 Months Ended

Oct. 31, 2018

Mar. 29, 2019

Apr. 28, 2018

Document And Entity Information

Entity Registrant Name Advanced Biomedical Technologies Inc.

Entity Central Index Key 0001385799

Document Type 10-K/A

Document Period End Date Oct. 31, 2018

Amendment Flag true

Amendment Description Advanced Biomedical Technologies Inc. (the "Company") is filing this Amendment No. 1 (the "Amendment No. 1") to its Annual Report on Form 10-K for the fiscal year ended October 31, 2018, filed on February 13, 2019 (the "Original 10-K"), as the audit of the Company's annual financial statements contained therein has now been completed. The Company is now filing this Amendment No. 1 to include the Report of Independent Registered Public Accounting Firm, For convenience and ease of reference, the Company is filing the annual report in its entirety with applicable changes. Unless otherwise stated, all information contained in this Form 10K/A is as of February 13, 2019, the filing date of the original Annual Report. Except as stated herein, this Form 10K/A does not reflect events or transactions occurring after such filing date and does not contain any modifications or updates to the disclosure in the Annual Report that may have been affected by events or transactions occurring subsequent to such filing date. No information in the Annual Report other than as set forth above is amended hereby.

Current Fiscal Year End Date --10-31

Entity a Well-known Seasoned Issuer No

Entity a Voluntary Filer No

Entity's Reporting Status Current Yes

Entity Filer Category Non-accelerated Filer

Entity Small Business Flag true

Entity Emerging Growth Company false

Entity Ex Transition Period false

Entity Shell Company false

Entity Public Float $ 11,983,373

Entity Common Stock, Shares Outstanding 69,624,850

Trading Symbol ABMT

Document Fiscal Period Focus FY

Document Fiscal Year Focus 2018

X

- References
No definition available.
+ Details

Name: ABMT_DocumentAndEntityInformationAbstract

Namespace Prefix: ABMT_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of changes contained within amended document.
+ References
No definition available.
+ Details

Name: dei_AmendmentDescription

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details

Name: dei_EntityExTransitionPeriod

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.
+ References
No definition available.
+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 19 R2.htm IDEA: XBRL DOCUMENT v3.19.1

Consolidated Balance Sheets - USD ($)

Oct. 31, 2018

Oct. 31, 2017

CURRENT ASSETS

Cash and cash equivalents $ 6,860 $ 7,463

Other receivables and prepaid expenses 32,649 17,469

Total Current Assets 39,509 24,932

Property and equipment, cost 521,120 483,482

Less: Accumulated depreciation (418,225) (422,967)

PROPERTY AND EQUIPMENT, NET 102,895 60,515

LONG-TERM PREPAID EXPENSES, NET

DEPOSIT FOR PURCHASE OF PROPERTY AND EQUIPMENT

TOTAL ASSETS 142,404 85,447

CURRENT LIABILITIES

Other payables and accrued expenses 443,163 409,079

Due to directors 273,874 321,420

Due to a stockholder 718,808 582,795

Due to related parties 4,325,571 3,767,180

Total Current Liabilities 5,761,416 5,080,474

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' DEFICIT

Common stock, $0.00001 par value, 100,000,000 shares authorized, 69,624,850 issued and outstanding as of October 31, 2018 and October 31, 2017 696 694

Additional paid-in capital 2,740,183 2,673,620

Accumulated deficit (8,632,618) (7,679,298)

Accumulated other comprehensive income/(loss) 272,727 9,957

Total Deficit (5,619,012) (4,995,027)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 142,404 $ 85,447

X

- Definition
Interest owed to directors and related company.
+ References
No definition available.
+ Details

Name: ABMT_DepositForPurchasePropertyEquipment

Namespace Prefix: ABMT_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of obligations due stockholders. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
+ References
No definition available.
+ Details

Name: ABMT_DueToDirectors

Namespace Prefix: ABMT_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580
+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(12))
-URI http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(17))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a)(5))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DueToOfficersOrStockholdersCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.
+ References
No definition available.
+ Details

Name: us-gaap_OtherAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 20 R3.htm IDEA: XBRL DOCUMENT v3.19.1

Consolidated Balance Sheets (Parenthetical) - $ / shares

Oct. 31, 2018

Oct. 31, 2017

Statement of Financial Position [Abstract]

Common stock, par value $ 0.00001 $ 0.00001

Common stock, shares authorized 100,000,000 100,000,000

Common stock, shares issued 69,624,850 69,624,850

Common stock, shares outstanding 69,624,850 69,624,850

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 21 R4.htm IDEA: XBRL DOCUMENT v3.19.1

Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended

Oct. 31, 2018

Oct. 31, 2017

OPERATING EXPENSES

General and administrative expenses $ 561,210 $ 341,956

Depreciation 16,295 13,604

Research and development 56,512 48,053

Total Operating Expenses 634,017 403,613

LOSS FROM OPERATIONS (634,017) (403,613)

OTHER (EXPENSES) INCOME

Interest income 36 36

Interest paid to a stockholder and related parties (286,756) (242,144)

Interest paid to a third party

Imputed interest (13,815) (15,623)

Other, net (18,768) (30,256)

Total Other (Expenses) Income, net (319,303) (287,987)

LOSS BEFORE TAXES (953,320) (691,600)

Income tax expense

NET LOSS (953,320) (691,600)

Net loss attributable to non-controlling interests

NET LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS (953,320) (691,600)

OTHER COMPREHENSIVE INCOME

Foreign currency translation income 262,770 (94,255)

Total other comprehensive gain/(loss) 262,770 (94,255)

COMPREHENSIVE GAIN/(LOSS) ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS $ (690,550) $ (785,855)

Net loss per share-basic and diluted - basic and diluted $ (0.01) $ (0.01)

Weighted average number of shares outstanding during the year - basic and diluted 69,381,015 68,277,590

X

- Definition
Interest paid to a stockholder and related parties.
+ References
No definition available.
+ Details

Name: ABMT_InterestExpenseToStockholderAndRelatedParties

Namespace Prefix: ABMT_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTaxAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense for debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_InterestExpenseDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of interest expense classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_InterestExpenseOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(b))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599
+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of Net Income (Loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686
+ Details

Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=109228884&loc=d3e1436-108581

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherIncomeAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expense related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.
+ References
No definition available.
+ Details

Name: us-gaap_OtherOperatingIncomeExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 22 R5.htm IDEA: XBRL DOCUMENT v3.19.1

Condensed Consolidated Statements of Stockholders' Deficit - USD ($)

Common Stock [Member]

Additional Paid-in Capital [Member]

Accumulated Deficit [Member]

Accumulated Other Comprehensive Loss [Member]

Total

Balance at Oct. 31, 2015 $ 569 $ 1,949,132 $ (6,262,961) $ (148,227) $ (4,461,487)

Balance, shares at Oct. 31, 2015 56,874,850

Stock issued for debt conversion at 0.05 per share $ 100 499,900 500,000

Stock issued for debt conversion at 0.05 per share, shares 10,000,000

Stock issued for services $ 2 52,498 52,500

Stock issued for services, shares 250,000

Imputed interest on advances from directors 18,990 18,990

Net loss for the period (724,737) (724,737)

Foreign currency translation loss 252,439 252,439

Balance at Oct. 31, 2016 $ 671 2,520,520 (6,987,698) 104,212 (4,362,295)

Balance, shares at Oct. 31, 2016 67,124,850

Stock issued for debt conversion at 0.05 per share $ 20 99,980 100,000

Stock issued for debt conversion at 0.05 per share, shares 2,000,000

Stock issued for services $ 3 37,497 37,500

Stock issued for services, shares 250,000

Imputed interest on advances from directors 15,623 15,623

Net loss for the period (691,600) (691,600)

Foreign currency translation loss (94,255) (94,255)

Balance at Oct. 31, 2017 $ 694 2,673,620 (7,679,298) 9,957 (4,995,027)

Balance, shares at Oct. 31, 2017 69,374,850

Stock issued for services $ 2 52,748 52,750

Stock issued for services, shares 250,000

Imputed interest on advances from directors 13,815 13,815

Net loss for the period (953,320) (953,320)

Foreign currency translation loss 262,770 262,770

Balance at Oct. 31, 2018 $ 696 $ 2,740,183 $ (8,632,618) $ 272,727 $ (5,619,012)

Balance, shares at Oct. 31, 2018 69,624,850

X

- Definition
Amount of other increase (decrease) in additional paid in capital (APIC).
+ References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=109240241&loc=d3e32157-110900

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=109240241&loc=d3e32211-110900

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=109240241&loc=d3e32022-110900

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (a-c)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The gross value of stock issued during the period upon the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 23 R6.htm IDEA: XBRL DOCUMENT v3.19.1

Condensed Consolidated Statements of Stockholders' Deficit (Parenthetical) - $ / shares

Oct. 31, 2018

Oct. 31, 2017

Oct. 31, 2016

Nov. 13, 2015

Statement of Stockholders' Equity [Abstract]

Debt conversion price, per share $ 0.05 $ 0.05 $ 0.05

Shares issued for service, per share $ 0.211 $ 0.15 $ 1

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870
+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfStockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R7.htm IDEA: XBRL DOCUMENT v3.19.1

Consolidated Statements of Cash Flows - USD ($)
12 Months Ended

Oct. 31, 2018

Oct. 31, 2017

Oct. 31, 2016

CASH FLOWS FROM OPERATING ACTIVITIES

Net loss attributable to ABMT common stockholders $ (953,320) $ (691,600) $ (724,737)

Adjustments to reconcile net loss to cash used in operating activities:

Depreciation 16,295 13,604

Loss on disposal of property and equipment 37,500

Stock issued for services 52,750

Imputed interest 13,815 15,623

Decrease (increase) in:

Other receivables and prepaid expenses (16,861) 3,291

Increase in:

Other payables and accrued expenses 54,900 63,870

Net cash used in operating activities (832,421) (557,712)

CASH FLOWS FROM INVESTING ACTIVITIES

Purchase of property and equipment (64,405) (453)

(Increase) decrease in deposit for purchase of property and equipment 1,213

Net cash used in investing activities (64,405) 760

CASH FLOWS FROM FINANCING ACTIVITIES

Due to a stockholder 136,441 89,444

Due to directors (34,932) (48,351)

Due to related parties 794,771 516,658

Net cash provided by financing activities 896,280 557,751

EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS (57) 105

NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS (603) 904

CASH AND CASH EQUIVALENTS AT THE BEGINNING OF YEAR 7,463 6,559

CASH AND CASH EQUIVALENTS AT THE END OF YEAR 6,860 7,463 $ 6,559

Supplemental of cash flow information

Interest income 36 36

Income tax

Other non cash items

Interest expenses $ 286,756 $ 242,144

X

- Definition
Other non cash interest expenses.
+ References
No definition available.
+ Details

Name: ABMT_InterestExpenses

Namespace Prefix: ABMT_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Repayments to officer or stockholders.
+ References
No definition available.
+ Details

Name: ABMT_RepaymentsToOfficerOrStockholders

Namespace Prefix: ABMT_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906
+ Details

Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586
+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_IncreaseDecreaseInRestrictedCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense for debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_InterestExpenseDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 17
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R8.htm IDEA: XBRL DOCUMENT v3.19.1

Summary of Significant Accounting Policies and Organization
12 Months Ended

Oct. 31, 2018

Accounting Policies [Abstract]

Summary of Significant Accounting Policies and Organization

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION

(A) Organization

Advanced Biomedical Technologies, Inc. (fka “Geostar Mineral Corporation” or “Geostar”) (“ABMT”) was incorporated in Nevada on September 12, 2006.

Shenzhen Changhua Biomedical Engineering Co., Ltd. (“Shenzhen Changhua”) was incorporated in the People’s Republic of China (“PRC”) on September 25, 2002 as a limited liability company with a registered capital of $724,017. Shenzhen Changhua is owned by two stockholders in the proportion of 70% and 30% respectively. Shenzhen Changhua has been involved in the development of polymer screws, rods and binding wires for fixation on human fractured bones. The Company is currently involved in researching, manufacturing and conducting clinical trials on its products and intends to raise additional capital to produce and market its products commercially. The Company holds one Class III permit and one Class II permit from the China Food and Drug Administration (“CFDA”), formally the State Food and Drug Administration (“SFDA”) of the PRC. The Company holds two patents issued by the State Intellectual Property Office of the P.R.C. (“SIPO”). The Company has no revenue since its inception and, in accordance with Accounting Standards Codification (“ASC”) Topic 915, “Development Stage Entities”, is considered a Development Stage Company.

Masterise Holdings Limited (“Masterise”) was incorporated in the British Virgin Islands on 31 May, 2007 as an investment holding company. Masterise is owned as to 63% by the spouse of Shenzhen Changhua’s 70% majority stockholder and 37% by a third party corporation.

On January 29, 2008, Masterise entered into a Share Purchase Agreement (“the Agreement”) with a stockholder of Shenzhen Changhua whereupon Masterise acquired 70% of Shenzhen Changhua for US$64,100 in cash. The acquisition was completed on February 25, 2008. As both Masterise and Shenzhen Changhua are under common control and management, the acquisition was accounted for as a reorganization of entities under common control. Accordingly, the operations of Shenzhen Changhua were included in the consolidated financial statements as if the transactions had occurred retroactively.

On December 31, 2008, ABMT consummated a Share Exchange Agreement (“the Exchange Agreement”) with the stockholders of Masterise pursuant to which Geostar issued 50,000 shares of Common Stock to the stockholders of Masterise for 100% equity interest in Masterise.

Concurrently, on December 31, 2008, a major stockholder of ABMT also consummated an Affiliate Stock Purchase Agreement (the “Affiliate Agreement”) with thirteen individuals including all the stockholders of Masterise, pursuant to which the major stockholder sold a total of 5,001,000 shares of ABMT’s common stock for a total aggregate consideration of $5,000, including 4,438,250 shares to the stockholders of Masterise.

On consummation of the Exchange Agreement and the Affiliate Agreement, the 70% majority stockholder of Masterise became an 80.7% stockholder of ABMT.

On March 13, 2009, the name of the Company was changed from Geostar Mineral Corporation to Advanced Biomedical Technologies, Inc.

The merger of ABMT and Masterise was treated for accounting purposes as a capital transaction and recapitalization by Masterise (“the accounting acquirer”) and a re-organization by ABMT (“the accounting acquiree”). The financial statements have been prepared as if the re-organization had occurred retroactively.

Accordingly, these financial statements include the following:

(1) The balance sheet consisting of the net assets of the acquirer at historical cost and the net assets of the acquiree at historical cost.

(2) The statement of operations including the operations of the acquirer for the periods presented and the operations of the acquiree from the date of the transaction.

ABMT, Masterise and Shenzhen Changhua are hereinafter referred to as (“the Company”).

(B) Principles of consolidation

The accompanying consolidated financial statements include the financial statements of ABMT and its wholly owned subsidiaries, Masterise and its 70% owned subsidiary, Shenzhen Changhua. The noncontrolling interests represent the noncontrolling stockholders’ 30% proportionate share of the results of Shenzhen Changhua.

All significant inter-company balances and transactions have been eliminated in consolidation.

(C) Use of estimates

The preparation of the financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

(D) Cash and cash equivalents

For purpose of the statements of cash flows, cash and cash equivalents include cash on hand and demand deposits with a bank with a maturity of less than three months. As of October 31, 2018 and 2017, all the cash and cash equivalents were denominated in United States Dollars (“US$”), Hong Kong Dollars (“HK$”) and Renminbi (“RMB”) and were placed with banks in the United States of America, Hong Kong and PRC. Balances at financial institutions or state-owned banks within the PRC are not freely convertible into foreign currencies and the remittance of these funds out of the PRC is subject to exchange control restrictions imposed by the PRC government.

(E) Property and equipment

Property and equipment are stated at cost, less accumulated depreciation. Expenditures for additions, major renewals and betterments are capitalized and expenditures for maintenance and repairs are charged to expense as incurred.

Depreciation is provided on a straight-line basis, less estimated residual value over the assets estimated useful lives. The estimated useful lives of the assets are 5 years.

(F) Long-lived assets

The Company accounts for long-lived assets under the FASB Codification Topic 360 (ASC 360) “Accounting for Impairment or Disposal of Long-Lived Assets”. In accordance with ASC Topic 360, long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets, when undiscounted future cash flows will not be sufficient to recover an asset’s carrying amount, the asset is written down to its fair value. The long-lived assets of the Company, which are subject to evaluation, consist primarily of property and equipment. For the years ended October 31, 2018 and 2017, the Company has not recognized any allowances for impairment.

(G) Fair value of financial instruments

FASB Codification Topic 825 (ASC Topic 825), “Disclosure About Fair Value of Financial Instruments,” requires certain disclosures regarding the fair value of financial instruments. The carrying amounts of other receivables and prepaid expenses other payables and accrued liabilities and due to directors, a stockholder and related parties approximate their fair values because of the short-term nature of the instruments. The management of the Company is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial statements.

(H) Income taxes

The Company accounts for income taxes under the FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period included the enactment date.

We assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where there is greater than 50% likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that may potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is a 50% or less likelihood that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements.

(I) Research and development

Research and development costs related to both present and future products are expensed as incurred. Total expenditure on research and development charged to general and administrative expenses for the years ended October 31, 2018 and 2017 were $56,512 and $48,053 respectively.

(J) Foreign currency translation

The reporting currency of the Company is the US dollar. ABMT, Masterise and Shenzhen Changhua maintain their accounting records in their functional currencies of US$, HK$ and RMB respectively.

Foreign currency transactions during the year are translated to the functional currency at the approximate rates of exchange on the dates of transactions. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the approximate rates of exchange at that date. Non-monetary assets and liabilities are translated at the rates of exchange prevailing at the time the asset or liability was acquired. Exchange gains or losses are recorded in the statement of operations.

The financial statements of Masterise and Shenzhen Changhua (whose functional currency is HK$ and RMB respectively) are translated into US$ using the closing rate method. The balance sheet items are translated into US$ using the exchange rates at the respective balance sheet dates. The capital and various reserves are translated at historical exchange rates prevailing at the time of the transactions while income and expenses items are translated at the average exchange rate for the year. All exchange differences are recorded within equity.

The exchange rates used to translate amounts in HK$ and RMB into US$ for the purposes of preparing the financial statements were as follows:

October 31, 2018 October 31, 2017

Balance sheet items, except for share capital, additional paid-in capital and accumulated deficits, as of year end

US$1=HK$7.8393=RMB6.9737

US$1= HK$7.8015=RMB6.6328

Amounts included in the statements of operations and cash flows for the year

US$1=HK$7.8351=RMB6.5629

US$1= HK$7.7842=RMB6.8013

The translation gain and loss recorded for the years ended October 31, 2018 and 2017 were $262,770 and $94,255 respectively.

No presentation is made that RMB amounts have been, or would be, converted into US$ at the above rates. Although the Chinese government regulations now allow convertibility of RMB for current account transactions, significant restrictions still remain. Hence, such translations should not be construed as representations that RMB could be converted into US$ at that rate or any other rate.

The value of RMB against US$ and other currencies may fluctuate and is affected by, among other things, changes in China’s political and economic conditions. Any significant revaluation of RMB may materially affect the Company’s financial condition in terms of US$ reporting.

(K) Other comprehensive loss

The foreign currency translation gain or loss resulting from translation of the financial statements expressed in RMB and HK$ to US$ is reported as other comprehensive gain or loss in the statements of operations and stockholders’ deficit. Other comprehensive gain and loss for the years ended October 31, 2018 and 2017 were $262,770 and $94,255 respectively.

(L) Loss per share

Basic loss per share are computed by dividing income available to stockholders by the weighted average number of shares outstanding during the year. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the potential shares had been issued and if the additional shares were diluted. There are no potentially dilutive securities as at October 31, 2018 and October 31, 2017.

(M) Segments

The Company operates in only one segment, thereafter segment disclosure is not presented.

(N) Recent Accounting Pronouncements

Business Combination: Clarifying the Definition of a Business

In January 2017, the FASB issued ASU No. 2017-1 “Topic 805, Business Combinations: Clarifying the Definition of a Business”. The amendments in this update provide a screen to determine when a set is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. The amendments in this update affect all reporting entities that must determine whether they have acquired or sold a business. Public business entities should apply the amendments in this update to annual periods beginning after December 15, 2017, including interim periods within those periods. All other entities should apply the amendments to annual periods beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2019. The Company does not expect the adoption of ASU 2017-1 to have a material impact on its consolidated financial statements.

Simplifying the Test for Goodwill Impairment

In January 2017, the FASB issued ASU No. 2017-4 “Topic 350: Intangibles-Goodwill and Other: Simplifying the Test for Goodwill Impairment.” The amendments in this update eliminate step two of the goodwill impairment test and specifies that goodwill impairment should be measured by comparing the fair value of a reporting unit with its carrying amount. Additionally, the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets should be disclosed. The amendments in this update are effective for annual or interim goodwill impairment tests performed in fiscal years beginning after December 15, 2019; early adoption is permitted. The Company does not expect the adoption of ASU 2017-4 to have a material impact on its consolidated financial statements.

Share-based Compensation

In May 2017, the FASB issued guidance on changes to terms and conditions of share-based payment awards. The amendment provides guidance about which changes to terms or conditions of a share-based payment award require an entity to apply modification accounting. The guidance is effective for the fiscal year beginning on January 1, 2018, including interim periods within that year.

In June 2018, the scope of Topic 718 has been expanded to include sharebased payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2018 and after December 15, 2019 for all other entities. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606.

The Company does not anticipate that adoption of these guidances will have a material impact on its consolidated financial statements.

Revenue Recognition

In May 2014, the FASB issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. Under the new standard, a good or service is transferred to the customer when (or as) the customer obtains control of the good or service, which differs from the risk and rewards approach under current guidance. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. In March, April and May 2016, the FASB issued three additional updates regarding identifying performance obligations and licensing, certain principal versus agent considerations and various narrow scope improvements based on practical questions raised by users. In September 2017, the FASB issued additional amendments providing clarification and implementation guidance. The guidance may be adopted through either retrospective application to all periods presented in the financial statements (full retrospective approach) or through a cumulative effect adjustment to retained earnings at the effective date (modified retrospective approach). The guidance is effective for the fiscal periods beginning on January 1, 2018.

Leases

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. The new standard, as amended by ASU 2018-01 and ASU 2018-11, is effective for annual periods beginning after December 15, 2018 on a modified retrospective basis. The Company will adopt ASU 2016-02 in its first quarter of the year ending October 31 2020. The Company expects its leases designated as operating leases in Note 6, “Commitments and Contingencies,” will be reported on the consolidated balance sheets upon adoption. However, the ultimate impact of adopting ASU 2016-02 will depend on the lease terms as of the adoption date.

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoptions of any such pronouncements may be expected to cause a material impact on the financial condition or the results of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R9.htm IDEA: XBRL DOCUMENT v3.19.1

Property and Equipment
12 Months Ended

Oct. 31, 2018

Property, Plant and Equipment [Abstract]

Property and Equipment

2. PROPERTY AND EQUIPMENT

The following is a summary of property and equipment at October 31, 2018 and 2017:

October 31,

2018 2017

Plant and machinery $ 296,517 $ 280,871

Motor vehicles 39,534 41,566

Office equipment 34,572 34,902

Computer software 5,017 5,017

Office improvements 145,480 121,126

521,120 483,482

Less: accumulated depreciation 418,225 422,967

Property and equipment, net $ 102,895 $ 60,515

Depreciation expense for the year ended October 31, 2018 and 2017 was $16,295 and $13,604 respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R10.htm IDEA: XBRL DOCUMENT v3.19.1

Other Payables and Accrued Expenses
12 Months Ended

Oct. 31, 2018

Payables and Accruals [Abstract]

Other Payables and Accrued Expenses

3. OTHER PAYABLES AND ACCRUED EXPENSES

Other payables and accrued expenses at October 31, 2018 and 2017 consisted of the followings:

October 31,

2018 2017

Other payables $ 215,095 $ 223,437

Accrued expenses 228,068 185,642

$ 443,163 $ 409,079

X

- Definition
The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a),20,24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R11.htm IDEA: XBRL DOCUMENT v3.19.1

Related Party Transactions
12 Months Ended

Oct. 31, 2018

Related Party Transactions [Abstract]

Related Party Transactions

4. RELATED PARTY TRANSACTIONS

As of October 31, 2018 and 2017, the Company owed $718,808 and $582,795 respectively to Titan Technology Development Limited, a stockholder.

As of October 31, 2018 and 2017, advances from related parties were as follows:

October 31,

2018 2017

Yu Chi Fung $ 1,715,840 $ 1,710,759

Que Feng 36,040 35,782

Chen Tie Jun 2,344,849 1,800,541

Shenzhen Hygeian Medical Device Co., Ltd. 228,842 220,098

Amount due to related parties $ 4,325,571 $ 3,767,180

Advances from a stockholder and related parties are unsecured, repayable on demand and bearing interest at 7% per annum. Interest expenses on advances from a stockholder and the related parties accrued for the years ended October 31, 2018 and 2017 were as follows:

October 31,

2018 2017

Titan Technology Development Limited, a stockholder $ 42,884 $ 37,379

Related parties:

Que Feng 2,133 2,059

Yu Chi Fang 98,431 93,951

Chen Tie Jun 128,680 97,045

Shenzhen Hygeian Medical Device Co., Ltd. 14,628 11,710

Interest expenses to a stockholder and related parties $ 286,756 $ 242,144

As of October 31, 2018 and 2017, advances from directors were as follows:

October 31,

2018 2017

Wang Wei $ 252,377 $ 298,818

Gui Kai 567 -

Yu Chi Ming 20,930 22,602

Amount due to directors $ 273,874 $ 321,420

Advances from directors were unsecured, repayable on demand and interest free. Imputed interests on the amounts owed to Wang Wei, a director, were $13,815 and $15,623 for the years ended October 31, 2018, and 2017 respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R12.htm IDEA: XBRL DOCUMENT v3.19.1

Stockholders' Deficiency
12 Months Ended

Oct. 31, 2018

Equity [Abstract]

Stockholders' Deficiency

5. STOCKHOLDERS’ DEFICIENCY

Common stock

On December 8, 2011, the Company issued 100,000 shares of restricted common stock at $0.2 to Dr. John Lynch, the Company’s chief officer of dental technologies, for services for a term of twelve months. The shares were valued at the closing price on the date of grant yielding an aggregate fair value of $20,000, fully recognised in prior years as consultancy fees included in general and administrative expenses.

On 28 October 2013, the Company issued 150,000 shares of restricted common stock as directors’ services compensation for past services to each of Mr. Chi Ming Yu and Kai Gui, directors of the Company. The shares were valued at the closing price of $0.71 per share on the date of grant, yielding an aggregate fair value of $213,000.

On 13 November 2015, $106,506 of the interest payable to a Company’s stockholder and $393,494 of the interest payable to two related parties, totaled $500,000, were converted into 10,000,000 shares of common stock at a conversion price of $0.05 per share and which were issued to the said stockholder.

On 31 March 2016, the Company issued 100,000 and 150,000 shares of restricted common stock as directors’ compensation for past services to Mr. Chi Ming Yu and Mr. Kai Gui, directors of the Company respectively. The shares were valued at the closing price of $0.21 per share on the date of grant, yielding an aggregate fair value of $52,500.

On 28 April 2017, the Company issued 100,000 and 150,000 shares of restricted common stock as directors’ compensation for past services to Mr. Chi Ming Yu and Mr. Kai Gui, directors of the Company respectively. The shares were valued at the closing price of $0.15 per share on the date of grant, yielding an aggregate fair value of $37,500.

On 23 October 2018, the Company issued 100,000 and 150,000 shares of restricted common stock as directors’ compensation for past services to Mr. Chi Ming Yu and Mr. Kai Gui, directors of the Company respectively. The shares were valued at the closing price of $0.211 per share on the date of grant, yielding an aggregate fair value of $52,750.

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R13.htm IDEA: XBRL DOCUMENT v3.19.1

Commitments and Contingencies
12 Months Ended

Oct. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

6. COMMITMENTS AND CONTINGENCIES

(A) Employee benefits

The full time employees of the Company are entitled to employee benefits including medical care, welfare subsidies, unemployment insurance and pension benefits through a Chinese government mandated multi-employer defined contribution plan. The Company is required to accrue for these benefits based on certain percentages of the employees’ salaries and make contributions to the plans out of the amounts accrued for medical and pension benefits. The total provisions and contributions made for such employee benefits was $58,469 and $37,440 for the years ended October 31, 2018 and 2017 respectively. The Chinese government is responsible for the medical benefits and the pension liability to be paid to these employees.

(B) Lease commitments

As of October 31, 2018, the Company had outstanding commitments with respect to operating leases, which are due as follows:

2018 $ 41,298

2019 34,415

2020 14,340

Total $ 90,053

The Company leased from a third party office space at monthly rent prevailing at October 31, 2018 of $1,867 (2017: $1,963). This operating lease expired on July 20, 2015. The Company continues to lease this premises at same monthly rent pending a formal renewal of the lease.

(C) Capital commitments

The Company has no outstanding commitments contracted for, net of deposit paid, in respect of acquisitions of plant and machineries as of October 31, 2018 (2017: Nil).

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 31 R14.htm IDEA: XBRL DOCUMENT v3.19.1

Income Tax
12 Months Ended

Oct. 31, 2018

Income Tax Disclosure [Abstract]

Income Tax

7. INCOME TAX

ABMT was incorporated in the United States and has incurred net operating loss for income tax purposes for 2018 and 2017. ABMT has net operating loss carry forwards for income taxes amounting to approximately $2,082,118 and $1,915,159 as of October 31, 2018 and 2017 respectively which may be available to reduce future years’ taxable income. These carry forwards, will expire, if not utilized, commencing in 2029. Management believes that the realization of the benefits from these losses appears uncertain due to the Company’s limited operating history and continuing losses. Accordingly, a full, deferred tax asset valuation allowance has been provided and no deferred tax asset valuation allowance has been provided and no deferred tax asset benefit has been recorded. The valuation allowance at October 31, 2018 and 2017 was $707,920 and $651,154 respectively. The net change in the valuation allowance for 2018 was an increase of $56,766.

Masterise was incorporated in the BVI and under current law of the BVI, is not subject to tax on income.

Shenzhen Changhua was incorporated in the PRC and is subject to PRC income tax which is computed according to the relevant laws and regulations in the PRC. The income tax rate has been 25%. No income tax expense has been provided by Shenzhen Changhua as it has incurred losses. The losses cannot be carried forward as Shenzhen Changhua has not yet commenced operation.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 R15.htm IDEA: XBRL DOCUMENT v3.19.1

Concentrations and Risks
12 Months Ended

Oct. 31, 2018

Risks and Uncertainties [Abstract]

Concentrations and Risks

8. CONCENTRATIONS AND RISKS

As at October 31, 2018 and 2017, 94% and 6% of the Company’s assets were located in the P.R.C. and the United States respectively.

X

- Definition
The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479
+ Details

Name: us-gaap_ConcentrationRiskDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RisksAndUncertaintiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 33 R16.htm IDEA: XBRL DOCUMENT v3.19.1

Going Concern
12 Months Ended

Oct. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Going Concern

9. GOING CONCERN

As reflected in the accompanying consolidated financial statements, the Company has an accumulated deficit of $8,632,618 as of October 31, 2018 that includes a net loss of $953,320 for the year ended October 31, 2018. The Company’s total current liabilities exceed its total current assets by $5,721,907 and the Company used cash in operations of $832,421. These factors raise substantial doubt about its ability to continue as a going concern. In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the accompanying balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to raise additional capital, obtain financing and succeed in its future operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

To continue as a going concern, the Company is actively pursuing additional funding and strategic partners to enable it to implement its business plan. Management believes that these actions, if successful, will allow the Company to continue its operations through the next fiscal year.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 40
-URI http://asc.fasb.org/subtopic&trid=51888271
+ Details

Name: us-gaap_SubstantialDoubtAboutGoingConcernTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R17.htm IDEA: XBRL DOCUMENT v3.19.1

Subsequent Event
12 Months Ended

Oct. 31, 2018

Subsequent Events [Abstract]

Subsequent Event

10. SUBSEQUENT EVENT

The Company has evaluated the existence of significant events subsequent to the balance sheet date through the date the financial statements were issued and has determined that there were no subsequent events or transactions which would require recognition or disclosure in the financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R18.htm IDEA: XBRL DOCUMENT v3.19.1

Summary of Significant Accounting Policies and Organization (Policies)
12 Months Ended

Oct. 31, 2018

Accounting Policies [Abstract]

Organization

(A) Organization

Advanced Biomedical Technologies, Inc. (fka “Geostar Mineral Corporation” or “Geostar”) (“ABMT”) was incorporated in Nevada on September 12, 2006.

Shenzhen Changhua Biomedical Engineering Co., Ltd. (“Shenzhen Changhua”) was incorporated in the People’s Republic of China (“PRC”) on September 25, 2002 as a limited liability company with a registered capital of $724,017. Shenzhen Changhua is owned by two stockholders in the proportion of 70% and 30% respectively. Shenzhen Changhua has been involved in the development of polymer screws, rods and binding wires for fixation on human fractured bones. The Company is currently involved in researching, manufacturing and conducting clinical trials on its products and intends to raise additional capital to produce and market its products commercially. The Company holds one Class III permit and one Class II permit from the China Food and Drug Administration (“CFDA”), formally the State Food and Drug Administration (“SFDA”) of the PRC. The Company holds two patents issued by the State Intellectual Property Office of the P.R.C. (“SIPO”). The Company has no revenue since its inception and, in accordance with Accounting Standards Codification (“ASC”) Topic 915, “Development Stage Entities”, is considered a Development Stage Company.

Masterise Holdings Limited (“Masterise”) was incorporated in the British Virgin Islands on 31 May, 2007 as an investment holding company. Masterise is owned as to 63% by the spouse of Shenzhen Changhua’s 70% majority stockholder and 37% by a third party corporation.

On January 29, 2008, Masterise entered into a Share Purchase Agreement (“the Agreement”) with a stockholder of Shenzhen Changhua whereupon Masterise acquired 70% of Shenzhen Changhua for US$64,100 in cash. The acquisition was completed on February 25, 2008. As both Masterise and Shenzhen Changhua are under common control and management, the acquisition was accounted for as a reorganization of entities under common control. Accordingly, the operations of Shenzhen Changhua were included in the consolidated financial statements as if the transactions had occurred retroactively.

On December 31, 2008, ABMT consummated a Share Exchange Agreement (“the Exchange Agreement”) with the stockholders of Masterise pursuant to which Geostar issued 50,000 shares of Common Stock to the stockholders of Masterise for 100% equity interest in Masterise.

Concurrently, on December 31, 2008, a major stockholder of ABMT also consummated an Affiliate Stock Purchase Agreement (the “Affiliate Agreement”) with thirteen individuals including all the stockholders of Masterise, pursuant to which the major stockholder sold a total of 5,001,000 shares of ABMT’s common stock for a total aggregate consideration of $5,000, including 4,438,250 shares to the stockholders of Masterise.

On consummation of the Exchange Agreement and the Affiliate Agreement, the 70% majority stockholder of Masterise became an 80.7% stockholder of ABMT.

On March 13, 2009, the name of the Company was changed from Geostar Mineral Corporation to Advanced Biomedical Technologies, Inc.

The merger of ABMT and Masterise was treated for accounting purposes as a capital transaction and recapitalization by Masterise (“the accounting acquirer”) and a re-organization by ABMT (“the accounting acquiree”). The financial statements have been prepared as if the re-organization had occurred retroactively.

Accordingly, these financial statements include the following:

(1) The balance sheet consisting of the net assets of the acquirer at historical cost and the net assets of the acquiree at historical cost.

(2) The statement of operations including the operations of the acquirer for the periods presented and the operations of the acquiree from the date of the transaction.

ABMT, Masterise and Shenzhen Changhua are hereinafter referred to as (“the Company”).

Principles of Consolidation

(B) Principles of consolidation

The accompanying consolidated financial statements include the financial statements of ABMT and its wholly owned subsidiaries, Masterise and its 70% owned subsidiary, Shenzhen Changhua. The noncontrolling interests represent the noncontrolling stockholders’ 30% proportionate share of the results of Shenzhen Changhua.

All significant inter-company balances and transactions have been eliminated in consolidation.

Use of Estimates

(C) Use of estimates

The preparation of the financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and Cash Equivalents

(D) Cash and cash equivalents

For purpose of the statements of cash flows, cash and cash equivalents include cash on hand and demand deposits with a bank with a maturity of less than three months. As of October 31, 2018 and 2017, all the cash and cash equivalents were denominated in United States Dollars (“US$”), Hong Kong Dollars (“HK$”) and Renminbi (“RMB”) and were placed with banks in the United States of America, Hong Kong and PRC. Balances at financial institutions or state-owned banks within the PRC are not freely convertible into foreign currencies and the remittance of these funds out of the PRC is subject to exchange control restrictions imposed by the PRC government.

Property and Equipment

(E) Property and equipment

Property and equipment are stated at cost, less accumulated depreciation. Expenditures for additions, major renewals and betterments are capitalized and expenditures for maintenance and repairs are charged to expense as incurred.

Depreciation is provided on a straight-line basis, less estimated residual value over the assets estimated useful lives. The estimated useful lives of the assets are 5 years.

Long-lived Assets

(F) Long-lived assets

The Company accounts for long-lived assets under the FASB Codification Topic 360 (ASC 360) “Accounting for Impairment or Disposal of Long-Lived Assets”. In accordance with ASC Topic 360, long-lived assets held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For purposes of evaluating the recoverability of long-lived assets, when undiscounted future cash flows will not be sufficient to recover an asset’s carrying amount, the asset is written down to its fair value. The long-lived assets of the Company, which are subject to evaluation, consist primarily of property and equipment. For the years ended October 31, 2018 and 2017, the Company has not recognized any allowances for impairment.

Fair Value of Financial Instruments

(G) Fair value of financial instruments

FASB Codification Topic 825 (ASC Topic 825), “Disclosure About Fair Value of Financial Instruments,” requires certain disclosures regarding the fair value of financial instruments. The carrying amounts of other receivables and prepaid expenses other payables and accrued liabilities and due to directors, a stockholder and related parties approximate their fair values because of the short-term nature of the instruments. The management of the Company is of the opinion that the Company is not exposed to significant interest or credit risks arising from these financial statements.

Income Taxes

(H) Income taxes

The Company accounts for income taxes under the FASB Codification Topic 740-10-25 (“ASC 740-10-25”). Under ASC 740-10-25, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period included the enactment date.

We assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where there is greater than 50% likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that may potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is a 50% or less likelihood that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements.

Research and Development

(I) Research and development

Research and development costs related to both present and future products are expensed as incurred. Total expenditure on research and development charged to general and administrative expenses for the years ended October 31, 2018 and 2017 were $56,512 and $48,053 respectively.

Foreign Currency Translation

(J) Foreign currency translation

The reporting currency of the Company is the US dollar. ABMT, Masterise and Shenzhen Changhua maintain their accounting records in their functional currencies of US$, HK$ and RMB respectively.

Foreign currency transactions during the year are translated to the functional currency at the approximate rates of exchange on the dates of transactions. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the approximate rates of exchange at that date. Non-monetary assets and liabilities are translated at the rates of exchange prevailing at the time the asset or liability was acquired. Exchange gains or losses are recorded in the statement of operations.

The financial statements of Masterise and Shenzhen Changhua (whose functional currency is HK$ and RMB respectively) are translated into US$ using the closing rate method. The balance sheet items are translated into US$ using the exchange rates at the respective balance sheet dates. The capital and various reserves are translated at historical exchange rates prevailing at the time of the transactions while income and expenses items are translated at the average exchange rate for the year. All exchange differences are recorded within equity.

The exchange rates used to translate amounts in HK$ and RMB into US$ for the purposes of preparing the financial statements were as follows:

October 31, 2018 October 31, 2017

Balance sheet items, except for share capital, additional paid-in capital and accumulated deficits, as of year end

US$1=HK$7.8393=RMB6.9737

US$1= HK$7.8015=RMB6.6328

Amounts included in the statements of operations and cash flows for the year

US$1=HK$7.8351=RMB6.5629

US$1= HK$7.7842=RMB6.8013

The translation gain and loss recorded for the years ended October 31, 2018 and 2017 were $262,770 and $94,255 respectively.

No presentation is made that RMB amounts have been, or would be, converted into US$ at the above rates. Although the Chinese government regulations now allow convertibility of RMB for current account transactions, significant restrictions still remain. Hence, such translations should not be construed as representations that RMB could be converted into US$ at that rate or any other rate.

The value of RMB against US$ and other currencies may fluctuate and is affected by, among other things, changes in China’s political and economic conditions. Any significant revaluation of RMB may materially affect the Company’s financial condition in terms of US$ reporting.

Other Comprehensive Loss

(K) Other comprehensive loss

The foreign currency translation gain or loss resulting from translation of the financial statements expressed in RMB and HK$ to US$ is reported as other comprehensive gain or loss in the statements of operations and stockholders’ deficit. Other comprehensive gain and loss for the years ended October 31, 2018 and 2017 were $262,770 and $94,255 respectively.

Loss Per Share

(L) Loss per share

Basic loss per share are computed by dividing income available to stockholders by the weighted average number of shares outstanding during the year. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional shares that would have been outstanding if the potential shares had been issued and if the additional shares were diluted. There are no potentially dilutive securities as at October 31, 2018 and October 31, 2017.

Segments

(M) Segments

The Company operates in only one segment, thereafter segment disclosure is not presented.

Recent Accounting Pronouncements

(N) Recent Accounting Pronouncements

Business Combination: Clarifying the Definition of a Business

In January 2017, the FASB issued ASU No. 2017-1 “Topic 805, Business Combinations: Clarifying the Definition of a Business”. The amendments in this update provide a screen to determine when a set is not a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. The amendments in this update affect all reporting entities that must determine whether they have acquired or sold a business. Public business entities should apply the amendments in this update to annual periods beginning after December 15, 2017, including interim periods within those periods. All other entities should apply the amendments to annual periods beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2019. The Company does not expect the adoption of ASU 2017-1 to have a material impact on its consolidated financial statements.

Simplifying the Test for Goodwill Impairment

In January 2017, the FASB issued ASU No. 2017-4 “Topic 350: Intangibles-Goodwill and Other: Simplifying the Test for Goodwill Impairment.” The amendments in this update eliminate step two of the goodwill impairment test and specifies that goodwill impairment should be measured by comparing the fair value of a reporting unit with its carrying amount. Additionally, the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets should be disclosed. The amendments in this update are effective for annual or interim goodwill impairment tests performed in fiscal years beginning after December 15, 2019; early adoption is permitted. The Company does not expect the adoption of ASU 2017-4 to have a material impact on its consolidated financial statements.

Share-based Compensation

In May 2017, the FASB issued guidance on changes to terms and conditions of share-based payment awards. The amendment provides guidance about which changes to terms or conditions of a share-based payment award require an entity to apply modification accounting. The guidance is effective for the fiscal year beginning on January 1, 2018, including interim periods within that year.

In June 2018, the scope of Topic 718 has been expanded to include sharebased payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606, Revenue from Contracts with Customers. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2018 and after December 15, 2019 for all other entities. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606.

The Company does not anticipate that adoption of these guidances will have a material impact on its consolidated financial statements.

Revenue Recognition

In May 2014, the FASB issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. Under the new standard, a good or service is transferred to the customer when (or as) the customer obtains control of the good or service, which differs from the risk and rewards approach under current guidance. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. In March, April and May 2016, the FASB issued three additional updates regarding identifying performance obligations and licensing, certain principal versus agent considerations and various narrow scope improvements based on practical questions raised by users. In September 2017, the FASB issued additional amendments providing clarification and implementation guidance. The guidance may be adopted through either retrospective application to all periods presented in the financial statements (full retrospective approach) or through a cumulative effect adjustment to retained earnings at the effective date (modified retrospective approach). The guidance is effective for the fiscal periods beginning on January 1, 2018.

Leases

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. The new standard, as amended by ASU 2018-01 and ASU 2018-11, is effective for annual periods beginning after December 15, 2018 on a modified retrospective basis. The Company will adopt ASU 2016-02 in its first quarter of the year ending October 31 2020. The Company expects its leases designated as operating leases in Note 6, “Commitments and Contingencies,” will be reported on the consolidated balance sheets upon adoption. However, the ultimate impact of adopting ASU 2016-02 will depend on the lease terms as of the adoption date.

The Company has reviewed all recently issued, but not yet effective, accounting pronouncements and do not believe the future adoptions of any such pronouncements may be expected to cause a material impact on the financial condition or the results of operations.

X

- Definition
Organization [Policy Text Block]
+ References
No definition available.
+ Details

Name: ABMT_OrganizationPolicyTextBlock

Namespace Prefix: ABMT_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 305
-SubTopic 10
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6375392&loc=d3e26790-107797

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for comprehensive income.
+ References
No definition available.
+ Details

Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.3A-02)
-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.3A-03)
-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355100-122828

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684
+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining the fair value of financial instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 60
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13279-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895
+ Details

Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 05
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.CC)
-URI http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742
+ Details

Name: us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 954
-SubTopic 740
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=84176650&loc=d3e32247-109318

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=84176650&loc=d3e32280-109318

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 05
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327
+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpensePolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for segment reporting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790
+ Details

Name: us-gaap_SegmentReportingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R19.htm IDEA: XBRL DOCUMENT v3.19.1

Summary of Significant Accounting Policies and Organization (Tables)
12 Months Ended

Oct. 31, 2018

Accounting Policies [Abstract]

Schedule of Exchange Rates Used in Translation

The exchange rates used to translate amounts in HK$ and RMB into US$ for the purposes of preparing the financial statements were as follows:

October 31, 2018 October 31, 2017

Balance sheet items, except for share capital, additional paid-in capital and accumulated deficits, as of year end

US$1=HK$7.8393=RMB6.9737

US$1= HK$7.8015=RMB6.6328

Amounts included in the statements of operations and cash flows for the year

US$1=HK$7.8351=RMB6.5629

US$1= HK$7.7842=RMB6.8013

X

- Definition
Tabular disclosure of of exchange rates used in translation.
+ References
No definition available.
+ Details

Name: ABMT_ScheduleOfExchangeRatesUsedInTranslationTableTextBlock

Namespace Prefix: ABMT_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 37 R20.htm IDEA: XBRL DOCUMENT v3.19.1

Property and Equipment (Tables)
12 Months Ended

Oct. 31, 2018

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

The following is a summary of property and equipment at October 31, 2018 and 2017:

October 31,

2018 2017

Plant and machinery $ 296,517 $ 280,871

Motor vehicles 39,534 41,566

Office equipment 34,572 34,902

Computer software 5,017 5,017

Office improvements 145,480 121,126

521,120 483,482

Less: accumulated depreciation 418,225 422,967

Property and equipment, net $ 102,895 $ 60,515

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R21.htm IDEA: XBRL DOCUMENT v3.19.1

Other Payables and Accrued Expenses (Tables)
12 Months Ended

Oct. 31, 2018

Payables and Accruals [Abstract]

Schedule of Other Payables and Accrued Expenses

Other payables and accrued expenses at October 31, 2018 and 2017 consisted of the followings:

October 31,

2018 2017

Other payables $ 215,095 $ 223,437

Accrued expenses 228,068 185,642

$ 443,163 $ 409,079

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R22.htm IDEA: XBRL DOCUMENT v3.19.1

Related Party Transactions (Tables)
12 Months Ended

Oct. 31, 2018

Related Party Transactions [Abstract]

Schedule of Advances from Related Parties

As of October 31, 2018 and 2017, advances from related parties were as follows:

October 31,

2018 2017

Yu Chi Fung $ 1,715,840 $ 1,710,759

Que Feng 36,040 35,782

Chen Tie Jun 2,344,849 1,800,541

Shenzhen Hygeian Medical Device Co., Ltd. 228,842 220,098

Amount due to related parties $ 4,325,571 $ 3,767,180

Advances from a stockholder and related parties are unsecured, repayable on demand and bearing interest at 7% per annum. Interest expenses on advances from a stockholder and the related parties accrued for the years ended October 31, 2018 and 2017 were as follows:

October 31,

2018 2017

Titan Technology Development Limited, a stockholder $ 42,884 $ 37,379

Related parties:

Que Feng 2,133 2,059

Yu Chi Fang 98,431 93,951

Chen Tie Jun 128,680 97,045

Shenzhen Hygeian Medical Device Co., Ltd. 14,628 11,710

Interest expenses to a stockholder and related parties $ 286,756 $ 242,144

As of October 31, 2018 and 2017, advances from directors were as follows:

October 31,

2018 2017

Wang Wei $ 252,377 $ 298,818

Gui Kai 567 -

Yu Chi Ming 20,930 22,602

Amount due to directors $ 273,874 $ 321,420

Advances from directors were unsecured, repayable on demand and interest free. Imputed interests on the amounts owed to Wang Wei, a director, were $13,815 and $15,623 for the years ended October 31, 2018, and 2017 respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R23.htm IDEA: XBRL DOCUMENT v3.19.1

Commitments and Contingencies (Tables)
12 Months Ended

Oct. 31, 2018

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Lease Obligations of Operating Leases

As of October 31, 2018, the Company had outstanding commitments with respect to operating leases, which are due as follows:

2018 $ 41,298

2019 34,415

2020 14,340

Total $ 90,053

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R24.htm IDEA: XBRL DOCUMENT v3.19.1

Summary of Significant Accounting Policies and Organization (Details Narrative)
12 Months Ended

Dec. 31, 2008

USD ($)

shares

Jan. 29, 2008

USD ($)

May 31, 2007

Sep. 25, 2002

USD ($)

Oct. 31, 2018

USD ($)

Segment

shares

Oct. 31, 2017

USD ($)

shares

Dec. 31, 2018

Estimated useful lives of property and equipment 5 years

Long-lived assets, allowances for impairment

Likelyhood that tax benefit sustained 50.00%

Research and development costs $ 56,512 48,053

Foreign currency translation gain (loss) 262,770 (94,255)

Other comprehensive gain (loss) $ 262,770 $ (94,255)

Potentially dilutive securities | shares

Number of operating segment | Segment 1

Majority Shareholders [Member] | Masterise [Member]

Ownership acquired 70.00%

Stock sold per affiliate agreement, shares | shares 4,438,250

ABMT [Member]

Stock issued in acquisition, shares | shares 50,000

Equity method investment ownership percentage 100.00%

ABMT [Member] | Majority Shareholders [Member]

Ownership acquired 80.70%

Stock sold per affiliate agreement, shares | shares 5,001,000

Stock sold per affiliate agreement $ 5,000

Shenzhen Changhua [Member]

Registered capital $ 724,017

Ownership interest - majority stockholder 70.00%

Ownership interest - minority stockholder 30.00%

Shenzhen Changhua [Member] | ABMT [Member]

Ownership by non-controlling stockholders 30.00%

Masterise [Member]

Ownership interest - majority stockholder 63.00%

Ownership interest - minority stockholder 37.00%

Ownership acquired 70.00%

Payment for acquisition $ 64,100

Masterise [Member] | ABMT [Member]

Equity method investment ownership percentage 70.00%

X

- Definition
Percentage likelyhood that tax benefit will be sustained.
+ References
No definition available.
+ Details

Name: ABMT_LikelyhoodThatTaxBenefitSustained

Namespace Prefix: ABMT_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of voting equity interests acquired at the acquisition date in the business combination.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463
+ Details

Name: us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The amount of total capital as defined in the regulations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 948
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 505
-Section 50
-Paragraph 1H
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=84167132&loc=d3e65071-112826

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 948
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=6490092&loc=d3e47080-110998

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 505
-Section 50
-Paragraph 1H
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=84167132&loc=d3e65071-112826
+ Details

Name: us-gaap_Capital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571
+ Details

Name: us-gaap_EquityMethodInvestmentOwnershipPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 958
-SubTopic 220
-Section 45
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114873921&loc=SL114875236-224282

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228
+ Details

Name: us-gaap_ImpairmentOfLongLivedAssetsHeldForUse

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Percentage investment held by the managing member or general partner of the limited liability company (LLC) or limited partnership (LP).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055
+ Details

Name: us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPManagingMemberOrGeneralPartnerOwnershipInterest

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage investment held by members or limited partners of limited liability company (LLC) or limited partnership (LP).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055
+ Details

Name: us-gaap_LimitedLiabilityCompanyLLCOrLimitedPartnershipLPMembersOrLimitedPartnersOwnershipInterest

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.
+ References
No definition available.
+ Details

Name: us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=109228884&loc=d3e1436-108581

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireBusinessesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Cash received on stock transaction after deduction of issuance costs.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.
+ References
No definition available.
+ Details

Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of stock issued during the period pursuant to acquisitions.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=us-gaap_MajorityShareholderMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ABMT_MasteriseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_OwnershipAxis=ABMT_ShenzhenChanghuaBiomedicalEngineeringCompanyLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_OwnershipAxis=ABMT_MasteriseHoldingsLimitedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 42 R25.htm IDEA: XBRL DOCUMENT v3.19.1

Summary of Significant Accounting Policies and Organization - Schedule of Exchange Rates Used in Translation (Details)

Oct. 31, 2018

Oct. 31, 2017

USD [Member] | Statement of Operations and Cash Flows [Member]

Exchange rate 1 1

HKD [Member] | Statement of Operations and Cash Flows [Member]

Exchange rate 7.8351 7.7842

RMB [Member] | Statement of Operations and Cash Flows [Member]

Exchange rate 6.5629 6.8013

Balance Sheet Items Except for Share Capital, Additional Paid-In Capital and Accumulated Deficits, as of Year End [Member] | USD [Member]

Exchange rate 1 1

Balance Sheet Items Except for Share Capital, Additional Paid-In Capital and Accumulated Deficits, as of Year End [Member] | HKD [Member]

Exchange rate 7.8393 7.8015

Balance Sheet Items Except for Share Capital, Additional Paid-In Capital and Accumulated Deficits, as of Year End [Member] | RMB [Member]

Exchange rate 6.9737 6.6328

X

- Definition
Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521
+ Details

Name: us-gaap_ForeignCurrencyExchangeRateTranslation1

Namespace Prefix: us-gaap_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: instant

X

- Details

Name: srt_CurrencyAxis=currency_USD

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementLocationAxis=ABMT_IncomeStatementAndCashFLowsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CurrencyAxis=currency_HKD

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_CurrencyAxis=currency_CNY

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=ABMT_BalanceSheetMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R26.htm IDEA: XBRL DOCUMENT v3.19.1

Property and Equipment (Details Narrative) - USD ($)
12 Months Ended

Oct. 31, 2018

Oct. 31, 2017

Property, Plant and Equipment [Abstract]

Depreciation expense $ 16,295 $ 13,604

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 44 R27.htm IDEA: XBRL DOCUMENT v3.19.1

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)

Oct. 31, 2018

Oct. 31, 2017

Property and equipment, gross $ 521,120 $ 483,482

Less: accumulated depreciation 418,225 422,967

Property and equipment, net 102,895 60,515

Plant and Machinery [Member]

Property and equipment, gross 296,517 280,871

Motor Vehicles [Member]

Property and equipment, gross 39,534 41,566

Office Equipment [Member]

Property and equipment, gross 34,572 34,902

Computer Software [Member]

Property and equipment, gross 5,017 5,017

Office Improvements [Member]

Property and equipment, gross $ 145,480 $ 121,126

X

- Definition
Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.14)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R28.htm IDEA: XBRL DOCUMENT v3.19.1

Other Payables and Accrued Expenses - Schedule of Other Payables and Accrued Expenses (Details) - USD ($)

Oct. 31, 2018

Oct. 31, 2017

Payables and Accruals [Abstract]

Other payables $ 215,095 $ 223,437

Accrued expenses 228,068 185,642

Other payables and accrued expenses $ 443,163 $ 409,079

X

- Definition
Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableOtherCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 46 R29.htm IDEA: XBRL DOCUMENT v3.19.1

Related Party Transactions (Details Narrative) - USD ($)
12 Months Ended

Oct. 31, 2018

Oct. 31, 2017

Due to stockholder $ 718,808 $ 582,795

Interest rate 7.00% 7.00%

Imputed interests $ 13,815 $ 15,623

Titan Technology Development Limited, a Stockholder [Member]

Due to stockholder $ 718,808 $ 582,795

X

- Definition
Amounts due to recorded owners or owners with a beneficial interest of more than 10 percent of the voting interests or officers of the company. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(12))
-URI http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(17))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(a)(5))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DueToOfficersOrStockholdersCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense for debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_InterestExpenseDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.
+ References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ABMT_TitanTechnologyDevelopmentLimitedStockholderMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 47 R30.htm IDEA: XBRL DOCUMENT v3.19.1

Related Party Transactions - Schedule of Advances from Related Parties (Details) - USD ($)
12 Months Ended

Oct. 31, 2018

Oct. 31, 2017

Due to related parties $ 4,325,571 $ 3,767,180

Interest expenses to a stockholder and related parties 286,756 242,144

Due to directors 273,874 321,420

Yu Chi Fung [Member]

Due to related parties 1,715,840 1,710,759

Interest expenses to a stockholder and related parties 98,431 93,951

Que Feng [Member]

Due to related parties 36,040 35,782

Interest expenses to a stockholder and related parties 2,133 2,059

Chen Tie Jun [Member]

Due to related parties 2,344,849 1,800,541

Interest expenses to a stockholder and related parties 128,680 97,045

Shenzhen Hygeian Medical Device Co., Ltd. [Member]

Due to related parties 228,842 220,098

Interest expenses to a stockholder and related parties 14,628 11,710

Wang Wei [Member]

Due to directors 252,377 298,818

Gui Kai [Member]

Due to directors 567

Yu Chi Ming [Member]

Due to directors 20,930 22,602

Titan Technology Development Limited, a Stockholder [Member]

Interest expenses to a stockholder and related parties $ 42,884 $ 37,379

X

- Definition
Carrying amount as of the balance sheet date of obligations due stockholders. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
+ References
No definition available.
+ Details

Name: ABMT_DueToDirectors

Namespace Prefix: ABMT_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Interest paid to a stockholder and related parties.
+ References
No definition available.
+ Details

Name: ABMT_InterestExpenseToStockholderAndRelatedParties

Namespace Prefix: ABMT_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ABMT_YuChiFungMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ABMT_QueFengMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ABMT_ChenTieJunMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ABMT_ShenzhenHygeianMedicalDeviceCoLtdMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ABMT_WangWeiMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ABMT_GuiKaiMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ABMT_YuChiMingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ABMT_TitanTechnologyDevelopmentLimitedStockholderMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 48 R31.htm IDEA: XBRL DOCUMENT v3.19.1

Stockholders' Deficiency (Details Narrative) - USD ($)
12 Months Ended

Oct. 23, 2018

Apr. 28, 2017

Mar. 31, 2016

Nov. 13, 2015

Oct. 28, 2013

Dec. 08, 2011

Oct. 31, 2018

Oct. 31, 2017

Oct. 31, 2016

Number of restricted common stock for services $ 52,750 $ 37,500 $ 52,500

Common stock price per share $ 0.211 $ 0.15 $ 1

Debt conversion of common stock $ 500,000

Debt conversion of common stock shares 10,000,000

Debt conversion price per share $ 0.05 $ 0.05 $ 0.05

Company's Stockholder [Member]

Debt conversion of common stock $ 106,506

Two Related Parties [Member]

Debt conversion of common stock $ 393,494

Restricted Stock [Member] | Dr. John Lynch [Member]

Number of restricted common stock services, shares 100,000

Number of restricted common stock for services $ 20,000

Common stock price per share $ 0.20

Restricted Stock [Member] | Mr. Chi Ming Yu [Member]

Number of restricted common stock services, shares 100,000 100,000 100,000 150,000

Common stock price per share $ 0.211 $ 0.15 $ 0.21 $ 0.71

Restricted Stock [Member] | Mr. Kai Gui [Member]

Number of restricted common stock services, shares 150,000 150,000 150,000 150,000

Common stock price per share $ 0.211 $ 0.15 $ 0.21 $ 0.71

Restricted Stock [Member] | Mr. Chi Ming Yu and Kai Gui [Member]

Number of restricted common stock for services $ 52,750 $ 37,500 $ 52,500 $ 213,000

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870
+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Per share or per unit amount of equity securities issued.
+ References
No definition available.
+ Details

Name: us-gaap_SharesIssuedPricePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueIssuedForServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=ABMT_CompanyStockholderMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=ABMT_TwoRelatedPartiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=us-gaap_OfficerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=ABMT_Director4Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=ABMT_Director3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=ABMT_MrChiMingYuAndKaiGuiMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 49 R32.htm IDEA: XBRL DOCUMENT v3.19.1

Commitments and Contingencies (Details Narrative) - USD ($)
12 Months Ended

Oct. 31, 2018

Oct. 31, 2017

Contributions under defined contribution plan $ 58,469 $ 37,440

Lease expiration date Jul. 20, 2015

Plant and machineries commitments

Office Space [Member]

Rent expense $ 1,867 $ 1,963

X

- Definition
Date which lease or group of leases is set to expire, in CCYY-MM-DD format.
+ References
No definition available.
+ Details

Name: us-gaap_LeaseExpirationDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of contributions made to multiemployer plan by employer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 80
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 80
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 80
-Section 50
-Paragraph 5
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947
+ Details

Name: us-gaap_MultiemployerPlanContributionsByEmployer

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 25
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=77910348&loc=d3e34039-112682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesRentExpenseMinimumRentals

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.
+ References
No definition available.
+ Details

Name: us-gaap_OtherCommitment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LeaseArrangementTypeAxis=ABMT_OfficeSpaceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 50 R33.htm IDEA: XBRL DOCUMENT v3.19.1

Commitments and Contingencies - Schedule of Future Minimum Lease Obligations of Operating Leases (Details)

Oct. 31, 2018

USD ($)

Commitments and Contingencies Disclosure [Abstract]

2018 $ 41,298

2019 34,415

2020 14,340

Total $ 90,053

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 51 R34.htm IDEA: XBRL DOCUMENT v3.19.1

Income Tax (Details Narrative) - USD ($)
12 Months Ended

Oct. 31, 2018

Oct. 31, 2017

Net operating loss carry forwards $ 2,082,118 $ 1,915,159

Deferred tax asset valuation allowance 707,920 $ 651,154

Net change in the valuation allowance $ 56,766

P.R.C [Member]

Income tax rate 25.00%

X

- Definition
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319
+ Details

Name: us-gaap_OperatingLossCarryforwards

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84176650&loc=d3e32123-109318
+ Details

Name: us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_StatementGeographicalAxis=country_CN

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 52 R35.htm IDEA: XBRL DOCUMENT v3.19.1

Concentrations and Risks (Details Narrative) - Assets [Member] - Geographic Concentration Risk [Member]
12 Months Ended

Oct. 31, 2018

Oct. 31, 2017

P.R.C [Member]

Concentration risk, percentage 94.00% 94.00%

UNITED STATES [Member]

Concentration risk, percentage 6.00% 6.00%

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592
+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AssetsTotalMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=ABMT_PeoplesRepublicOfChinaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=country_US

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R36.htm IDEA: XBRL DOCUMENT v3.19.1

Going Concern (Details Narrative) - USD ($)
12 Months Ended

Oct. 31, 2018

Oct. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Accumulated deficit $ (8,632,618) $ (7,679,298)

Net loss (953,320) (691,600)

Working capital deficit 5,721,907

Net cash used in operating activities $ (832,421) $ (557,712)

X

- Definition
Working capital deficit.
+ References
No definition available.
+ Details

Name: ABMT_WorkingCapitalDeficit

Namespace Prefix: ABMT_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

EXCEL 54 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 55 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 56 report.css IDEA: XBRL DOCUMENT / Updated 2009-11-04 / / v2.2.0.24 / / DefRef Styles / ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } / Report Styles / ..pl a, .pl a:visited { color: black; text-decoration: none; } / table / ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } / Top labels / ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; / word-wrap: break-word; / } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } / Header rows... / ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } / Calendars... / ..report .rc { background-color: #f0f0f0; } / Even rows... / ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } / Odd rows... / ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } / styles for footnote marker / ..report .fn { white-space: nowrap; } / styles for numeric types / ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } / styles for text types / ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.1 html 131 158 1 false 40 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://advbiomed.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://advbiomed.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://advbiomed.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://advbiomed.com/role/StatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Deficit Sheet http://advbiomed.com/role/StatementsOfStockholdersDeficit Condensed Consolidated Statements of Stockholders' Deficit Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Stockholders' Deficit (Parenthetical) Sheet http://advbiomed.com/role/StatementsOfStockholdersDeficitParenthetical Condensed Consolidated Statements of Stockholders' Deficit (Parenthetical) Statements 6 false false R7.htm 00000007 - Statement - Consolidated Statements of Cash Flows Sheet http://advbiomed.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies and Organization Sheet http://advbiomed.com/role/SummaryOfSignificantAccountingPoliciesAndOrganization Summary of Significant Accounting Policies and Organization Notes 8 false false R9.htm 00000009 - Disclosure - Property and Equipment Sheet http://advbiomed.com/role/PropertyAndEquipment Property and Equipment Notes 9 false false R10.htm 00000010 - Disclosure - Other Payables and Accrued Expenses Sheet http://advbiomed.com/role/OtherPayablesAndAccruedExpenses Other Payables and Accrued Expenses Notes 10 false false R11.htm 00000011 - Disclosure - Related Party Transactions Sheet http://advbiomed.com/role/RelatedPartyTransactions Related Party Transactions Notes 11 false false R12.htm 00000012 - Disclosure - Stockholders' Deficiency Sheet http://advbiomed.com/role/StockholdersDeficiency Stockholders' Deficiency Notes 12 false false R13.htm 00000013 - Disclosure - Commitments and Contingencies Sheet http://advbiomed.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 00000014 - Disclosure - Income Tax Sheet http://advbiomed.com/role/IncomeTax Income Tax Notes 14 false false R15.htm 00000015 - Disclosure - Concentrations and Risks Sheet http://advbiomed.com/role/ConcentrationsAndRisks Concentrations and Risks Notes 15 false false R16.htm 00000016 - Disclosure - Going Concern Sheet http://advbiomed.com/role/GoingConcern Going Concern Notes 16 false false R17.htm 00000017 - Disclosure - Subsequent Event Sheet http://advbiomed.com/role/SubsequentEvent Subsequent Event Notes 17 false false R18.htm 00000018 - Disclosure - Summary of Significant Accounting Policies and Organization (Policies) Sheet http://advbiomed.com/role/SummaryOfSignificantAccountingPoliciesAndOrganizationPolicies Summary of Significant Accounting Policies and Organization (Policies) Policies http://advbiomed.com/role/SummaryOfSignificantAccountingPoliciesAndOrganization 18 false false R19.htm 00000019 - Disclosure - Summary of Significant Accounting Policies and Organization (Tables) Sheet http://advbiomed.com/role/SummaryOfSignificantAccountingPoliciesAndOrganizationTables Summary of Significant Accounting Policies and Organization (Tables) Tables http://advbiomed.com/role/SummaryOfSignificantAccountingPoliciesAndOrganization 19 false false R20.htm 00000020 - Disclosure - Property and Equipment (Tables) Sheet http://advbiomed.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://advbiomed.com/role/PropertyAndEquipment 20 false false R21.htm 00000021 - Disclosure - Other Payables and Accrued Expenses (Tables) Sheet http://advbiomed.com/role/OtherPayablesAndAccruedExpensesTables Other Payables and Accrued Expenses (Tables) Tables http://advbiomed.com/role/OtherPayablesAndAccruedExpenses 21 false false R22.htm 00000022 - Disclosure - Related Party Transactions (Tables) Sheet http://advbiomed.com/role/RelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://advbiomed.com/role/RelatedPartyTransactions 22 false false R23.htm 00000023 - Disclosure - Commitments and Contingencies (Tables) Sheet http://advbiomed.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://advbiomed.com/role/CommitmentsAndContingencies 23 false false R24.htm 00000024 - Disclosure - Summary of Significant Accounting Policies and Organization (Details Narrative) Sheet http://advbiomed.com/role/SummaryOfSignificantAccountingPoliciesAndOrganizationDetailsNarrative Summary of Significant Accounting Policies and Organization (Details Narrative) Details http://advbiomed.com/role/SummaryOfSignificantAccountingPoliciesAndOrganizationTables 24 false false R25.htm 00000025 - Disclosure - Summary of Significant Accounting Policies and Organization - Schedule of Exchange Rates Used in Translation (Details) Sheet http://advbiomed.com/role/SummaryOfSignificantAccountingPoliciesAndOrganization-ScheduleOfExchangeRatesUsedInTranslationDetails Summary of Significant Accounting Policies and Organization - Schedule of Exchange Rates Used in Translation (Details) Details 25 false false R26.htm 00000026 - Disclosure - Property and Equipment (Details Narrative) Sheet http://advbiomed.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://advbiomed.com/role/PropertyAndEquipmentTables 26 false false R27.htm 00000027 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) Sheet http://advbiomed.com/role/PropertyAndEquipment-ScheduleOfPropertyAndEquipmentDetails Property and Equipment - Schedule of Property and Equipment (Details) Details 27 false false R28.htm 00000028 - Disclosure - Other Payables and Accrued Expenses - Schedule of Other Payables and Accrued Expenses (Details) Sheet http://advbiomed.com/role/OtherPayablesAndAccruedExpenses-ScheduleOfOtherPayablesAndAccruedExpensesDetails Other Payables and Accrued Expenses - Schedule of Other Payables and Accrued Expenses (Details) Details 28 false false R29.htm 00000029 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://advbiomed.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://advbiomed.com/role/RelatedPartyTransactionsTables 29 false false R30.htm 00000030 - Disclosure - Related Party Transactions - Schedule of Advances from Related Parties (Details) Sheet http://advbiomed.com/role/RelatedPartyTransactions-ScheduleOfAdvancesFromRelatedPartiesDetails Related Party Transactions - Schedule of Advances from Related Parties (Details) Details 30 false false R31.htm 00000031 - Disclosure - Stockholders' Deficiency (Details Narrative) Sheet http://advbiomed.com/role/StockholdersDeficiencyDetailsNarrative Stockholders' Deficiency (Details Narrative) Details http://advbiomed.com/role/StockholdersDeficiency 31 false false R32.htm 00000032 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://advbiomed.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://advbiomed.com/role/CommitmentsAndContingenciesTables 32 false false R33.htm 00000033 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Obligations of Operating Leases (Details) Sheet http://advbiomed.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumLeaseObligationsOfOperatingLeasesDetails Commitments and Contingencies - Schedule of Future Minimum Lease Obligations of Operating Leases (Details) Details 33 false false R34.htm 00000034 - Disclosure - Income Tax (Details Narrative) Sheet http://advbiomed.com/role/IncomeTaxDetailsNarrative Income Tax (Details Narrative) Details http://advbiomed.com/role/IncomeTax 34 false false R35.htm 00000035 - Disclosure - Concentrations and Risks (Details Narrative) Sheet http://advbiomed.com/role/ConcentrationsAndRisksDetailsNarrative Concentrations and Risks (Details Narrative) Details http://advbiomed.com/role/ConcentrationsAndRisks 35 false false R36.htm 00000036 - Disclosure - Going Concern (Details Narrative) Sheet http://advbiomed.com/role/GoingConcernDetailsNarrative Going Concern (Details Narrative) Details http://advbiomed.com/role/GoingConcern 36 false false All Reports Book All Reports abmt-20181031.xml abmt-20181031.xsd abmt-20181031_cal.xml abmt-20181031_def.xml abmt-20181031_lab.xml abmt-20181031_pre.xml http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/country/2017-01-31 http://xbrl.sec.gov/currency/2017-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 59 0001493152-19-004187-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-19-004187-xbrl.zip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�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end

Lender:	TITAN TECHNOLOGY DEVELOPMENT LIMITED
Address:	1903 HING YIP COMMERCIAL CENTRE, 272 DES VOEUX ROAD CENTRAL, HONG KONG.
	(Hong Kong Company Registration No.: 718332)

Borrower:	ADVANCED BIOMEDICAL TECHNOLOGIES, INC.
Address:	350 FIFTH AVE., 59TH FLOOR, NEW YORK, NY 10118
	USA (Incorporated in the State of Nevada, USA)

2)	Use of Proceed: For Changhua’s R&D, Clinical Trial, GMP Facilities Upgrading and Operation Expenses.

3)	Interest Rate: Annual interest rate is seven percent (7%).

4)	Loan Repayment period: 12 months

5)	Repayment:

Lender:	TITAN TECHNOLOGY DEVELOPMENT LIMITED

Signature:	/s/ Chi Fung YU
Name and Title:	Chi Fung YU, Chairman

Borrower:	ADVANCED BIOMEDICAL TECHNOLOGIES, INC.

Signature:	/s/ Hui Wang
Name and Title:	Hui Wang, Director and Chief Executive Officer

1.	Statement of Policy
2.	Implementation and Enforcement
3.	Relations with Competitors and Other Third Parties
4.	Insider Trading, Securities Compliance and Public Statements
5.	Financial Reporting
6.	Human Resources
7.	Environmental, Health and Safety
8.	Conflicts of Interest
9.	International Trade
10.	Government Relations
11.	Contractors, Consultants, and Temporary Workers
12.	Conclusion

1.	I have reviewed this annual report on Form 10-K of Advanced Biomedical Technologies Inc.; (the “registrant”);

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13(a)-15(e) and 15(d)-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

	d)	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

	a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

	By:	/s/ Kai Gui
	Name:	Kai Gui,
	Title:	Director, Secretary and Chief Financial Officer

(1)	The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and

(2)	The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated this 29th day of March, 2019.

/s/ Hui Wang
Hui Wang
Director and Chief Executive Officer

/s/ Kai Gui
Kai Gui
Director, Secretary, and Chief Financial Officer

(1)	Communications - The chairperson and others on the committee shall, to the extent appropriate, have contact throughout the year with senior management, other committee chairpersons, and other key committee advisors, external and internal auditors, etc., as applicable, to strengthen the committee’s knowledge of relevant current and prospective business issues.

(2)	Committee Education/Orientation - The committee, with management, shall develop and participate in a process for review of important financial and operating topics that present potential significant risk to the company. Additionally, individual committee members are encouraged to participate in relevant and appropriate self-study education to assure understanding of the business and environment in which the company operates.

(3)	Annual Plan - The committee, with input from management and other key committee advisors shall develop an annual plan responsive to the “primary committee responsibilities” detailed herein. The annual plan shall be reviewed and approved by the full board.

(4)	Meeting Agenda - Committee meeting agendas shall be the responsibility of the committee chairperson, with input from committee members. It is expected that the chairperson would also ask for management and key committee advisors, and perhaps others, to participate in this process.

(5)	Committee Expectations and Information Needs - The committee shall communicate committee expectations and the nature, timing, and extent of committee information needs to management, internal audit, and external parties, including external auditors. Written materials. Including key performance indicators and measures related to key business and financial risks shall be received from management, auditors, and others at least one week in advance of meeting dates. Meeting conduct will assume board members have reviewed written materials in sufficient depth to participate in committee/board dialogue.

(6)	External Resources -The committee shall be authorized to access internal and external resources, as the committee requires, carrying out its responsibilities.

(7)	Committee Meeting Attendees - The committee shall request members of management, counsel, internal audit, and external auditors, as applicable, to participate in committee meetings, as necessary, to carry out the committee responsibilities. Periodically and at least annually, the committee shall meet in private session with only the committee members. It shall be understood that either internal or external auditors, or counsel, may, at any time, request a meeting with the audit committee or committee chairperson with or without management attendance. In any case, the committee shall meet in executive session separately with internal and external auditors, at least annually.

(8)	Reporting to the Board of Directors - The committee, through the committee chairperson, shall report periodically, as deemed necessary, but at least semi-annually, to the full board. In addition, summarized minutes from committee meetings, separately identifying monitoring activities from approvals, shall be available to each board member at least one week prior to the subsequent board of directors meeting.

(9)	Committee Self Assessment - The committee shall review, discuss, and assess its own performance as well as the committee role and responsibilities, seeking input from senior management, the full board, and others. Changes in role and/or responsibilities, if any, shall be recommended to the full board for approval.

(1)	The external auditors, in their capacity as independent public accountants, shall be responsible to the board of directors and the audit committee as representatives of the shareholders.

(2)	As the external auditors review financial reports, they will be reporting to the audit committee. They shall report all relevant issues to the committee responsive to agreed-on committee expectations. In executing its oversight role, the board or committee should review the work of external auditors.

(3)	The internal audit function shall be responsible to the board of directors through the committee.

(4)	If either the internal or the external auditors identify significant issues relative to the overall board responsibility that have been communicated to management but, in their judgment, have not been adequately addressed, they should communicate these issues to the committee chairperson.

(5)	Changes in the directors of internal audit or corporate compliance shall be subject to committee approval.

(1)	Risk Management - The company’s business risk management process, including the adequacy of the company’s overall control environment and controls in selected areas representing significant financial and business risk.

(2)	Annual Reports and Other Major Regulatory Filings - All major financial reports in advance of filings or distribution.

(3)	Internal Controls and Regulatory Compliance - The company’s system of internal controls for detecting accounting and reporting financial errors, fraud and defalcations, legal violations, and noncompliance with the corporate code of conduct.

(4)	Internal Audit Responsibilities - The annual audit plan and the process used to develop the plan. Status of activities, significant findings, recommendations, and management’s response.

(5)	Regulatory Examinations - SEC inquiries and the results of examinations by other regulatory authorities in terms of important findings, recommendations, and management’s response.

(6)	External Audit Responsibilities - Auditor independence and the overall scope and focus of the annual/interim audit, including the scope and level of involvement with unaudited quarterly or other interim-period information.

(7)	Financial Reporting and Controls - Key financial statement issues and risks, their impact or potential effect on reported financial information, the processes used by management to address such matters, related auditor views, and the basis for audit conclusions. Important conclusions on interim and/or year-end audit work in advance of the public release of financials.

(8)	Auditor Recommendations - Important internal and external auditor recommendations on financial reporting, controls, other matters, and management’s response. The views of management and auditors on the overall quality of annual and interim financial reporting.

(1)	The code of ethical conduct.

(2)	Changes in important accounting principles and the application thereof in both interim in and annual financial reports.

(3)	Significant conflicts of interest and related-party transactions.

(4)	External auditor performance and changes in external audit firm (subject to ratification by the full board).

(5)	Internal auditor performance and changes in internal audit leadership and/or key financial management.

(6)	Procedures for whistle blowers.

(7)	Pre-approve allowable services to be provided by the auditor.

(8)	Retention of complaints.

	●	Review and, as necessary, help revise the Corporation’s controls and other procedures (“Disclosure Controls and Procedures”) to ensure that (i) information required by the Corporation to be disclosed to the Securities and Exchange Commission (the “SEC”), and other written information that the Corporation will disclose to the public is recorded, processed, summarized and reported accurately and on a timely basis, and (ii) such information is accumulated and communicated to management, including the Senior Officers, as appropriate to allow timely decisions regarding required disclosure.

	●	Assist in documenting, and monitoring the integrity and evaluating the effectiveness of, the Disclosure Controls and Procedures.

	●	Review the Corporation’s (i) Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, proxy statement, material registration statements, and any other information filed with the SEC (collectively, the “Reports”), (ii) press releases containing financial information, earnings guidance, forward-looking statements, information about material transactions, or other information material to the Corporation’s security holders, (iii) correspondence broadly disseminated to shareholders, and (iv) other relevant communications or presentations (collectively, the “Disclosure Statements”).

	●	Discuss information relative to the Committee’s responsibilities and proceedings, including (i) the preparation of the Disclosure Statements and (ii) the evaluation of the effectiveness of the Disclosure Controls and Procedures.

	●	Control Environment: The directives of the Board and Audit Committee; the integrity and ethical values of the Corporation’s officers and employees, including the “tone at the top”; the Corporation’s Code of Conduct; and the philosophy and operating style of management, including how employees are organized and how authority is delegated.

	●	Risk Assessment: The identification and analysis of relevant risks to achieving the goal of accurate and timely disclosure, forming a basis for determining how the risks should be managed.

	●	Control Activities: The procedures to ensure that necessary actions are taken to address and handle risks to achievement of objectives.

	●	Information and Communication: The accumulation, delivery and communication of financial information throughout (i.e., up, down and across) the organization.

	●	Monitoring: The assessment of the quality of the financial reporting systems over time through ongoing monitoring and separate evaluations, including through regular management supervision and reporting of deficiencies upstream.

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Oct. 31, 2018	Mar. 29, 2019	Apr. 28, 2018
Document And Entity Information
Entity Registrant Name	Advanced Biomedical Technologies Inc.
Entity Central Index Key	0001385799
Document Type	10-K/A
Document Period End Date	Oct. 31, 2018
Amendment Flag	true
Amendment Description	Advanced Biomedical Technologies Inc. (the "Company") is filing this Amendment No. 1 (the "Amendment No. 1") to its Annual Report on Form 10-K for the fiscal year ended October 31, 2018, filed on February 13, 2019 (the "Original 10-K"), as the audit of the Company's annual financial statements contained therein has now been completed. The Company is now filing this Amendment No. 1 to include the Report of Independent Registered Public Accounting Firm, For convenience and ease of reference, the Company is filing the annual report in its entirety with applicable changes. Unless otherwise stated, all information contained in this Form 10K/A is as of February 13, 2019, the filing date of the original Annual Report. Except as stated herein, this Form 10K/A does not reflect events or transactions occurring after such filing date and does not contain any modifications or updates to the disclosure in the Annual Report that may have been affected by events or transactions occurring subsequent to such filing date. No information in the Annual Report other than as set forth above is amended hereby.
Current Fiscal Year End Date	--10-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 11,983,373
Entity Common Stock, Shares Outstanding		69,624,850
Trading Symbol	ABMT
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2018

Consolidated Balance Sheets - USD ($)	Oct. 31, 2018	Oct. 31, 2017
CURRENT ASSETS
Cash and cash equivalents	$ 6,860	$ 7,463
Other receivables and prepaid expenses	32,649	17,469
Total Current Assets	39,509	24,932
Property and equipment, cost	521,120	483,482
Less: Accumulated depreciation	(418,225)	(422,967)
PROPERTY AND EQUIPMENT, NET	102,895	60,515
LONG-TERM PREPAID EXPENSES, NET
DEPOSIT FOR PURCHASE OF PROPERTY AND EQUIPMENT
TOTAL ASSETS	142,404	85,447
CURRENT LIABILITIES
Other payables and accrued expenses	443,163	409,079
Due to directors	273,874	321,420
Due to a stockholder	718,808	582,795
Due to related parties	4,325,571	3,767,180
Total Current Liabilities	5,761,416	5,080,474
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
Common stock, $0.00001 par value, 100,000,000 shares authorized, 69,624,850 issued and outstanding as of October 31, 2018 and October 31, 2017	696	694
Additional paid-in capital	2,740,183	2,673,620
Accumulated deficit	(8,632,618)	(7,679,298)
Accumulated other comprehensive income/(loss)	272,727	9,957
Total Deficit	(5,619,012)	(4,995,027)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 142,404	$ 85,447

Consolidated Balance Sheets (Parenthetical) - $ / shares	Oct. 31, 2018	Oct. 31, 2017
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	69,624,850	69,624,850
Common stock, shares outstanding	69,624,850	69,624,850

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Oct. 31, 2018	Oct. 31, 2017
OPERATING EXPENSES
General and administrative expenses	$ 561,210	$ 341,956
Depreciation	16,295	13,604
Research and development	56,512	48,053
Total Operating Expenses	634,017	403,613
LOSS FROM OPERATIONS	(634,017)	(403,613)
OTHER (EXPENSES) INCOME
Interest income	36	36
Interest paid to a stockholder and related parties	(286,756)	(242,144)
Interest paid to a third party
Imputed interest	(13,815)	(15,623)
Other, net	(18,768)	(30,256)
Total Other (Expenses) Income, net	(319,303)	(287,987)
LOSS BEFORE TAXES	(953,320)	(691,600)
Income tax expense
NET LOSS	(953,320)	(691,600)
Net loss attributable to non-controlling interests
NET LOSS ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS	(953,320)	(691,600)
OTHER COMPREHENSIVE INCOME
Foreign currency translation income	262,770	(94,255)
Total other comprehensive gain/(loss)	262,770	(94,255)
COMPREHENSIVE GAIN/(LOSS) ATTRIBUTABLE TO ABMT COMMON STOCKHOLDERS	$ (690,550)	$ (785,855)
Net loss per share-basic and diluted - basic and diluted	$ (0.01)	$ (0.01)
Weighted average number of shares outstanding during the year - basic and diluted	69,381,015	68,277,590

Condensed Consolidated Statements of Stockholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]	Total
Balance at Oct. 31, 2015	$ 569	$ 1,949,132	$ (6,262,961)	$ (148,227)	$ (4,461,487)
Balance, shares at Oct. 31, 2015	56,874,850
Stock issued for debt conversion at 0.05 per share	$ 100	499,900			500,000
Stock issued for debt conversion at 0.05 per share, shares	10,000,000
Stock issued for services	$ 2	52,498			52,500
Stock issued for services, shares	250,000
Imputed interest on advances from directors		18,990			18,990
Net loss for the period			(724,737)		(724,737)
Foreign currency translation loss				252,439	252,439
Balance at Oct. 31, 2016	$ 671	2,520,520	(6,987,698)	104,212	(4,362,295)
Balance, shares at Oct. 31, 2016	67,124,850
Stock issued for debt conversion at 0.05 per share	$ 20	99,980			100,000
Stock issued for debt conversion at 0.05 per share, shares	2,000,000
Stock issued for services	$ 3	37,497			37,500
Stock issued for services, shares	250,000
Imputed interest on advances from directors		15,623			15,623
Net loss for the period			(691,600)		(691,600)
Foreign currency translation loss				(94,255)	(94,255)
Balance at Oct. 31, 2017	$ 694	2,673,620	(7,679,298)	9,957	(4,995,027)
Balance, shares at Oct. 31, 2017	69,374,850
Stock issued for services	$ 2	52,748			52,750
Stock issued for services, shares	250,000
Imputed interest on advances from directors		13,815			13,815
Net loss for the period			(953,320)		(953,320)
Foreign currency translation loss				262,770	262,770
Balance at Oct. 31, 2018	$ 696	$ 2,740,183	$ (8,632,618)	$ 272,727	$ (5,619,012)
Balance, shares at Oct. 31, 2018	69,624,850

Condensed Consolidated Statements of Stockholders' Deficit (Parenthetical) - $ / shares	Oct. 31, 2018	Oct. 31, 2017	Oct. 31, 2016	Nov. 13, 2015
Statement of Stockholders' Equity [Abstract]
Debt conversion price, per share		$ 0.05	$ 0.05	$ 0.05
Shares issued for service, per share	$ 0.211	$ 0.15	$ 1

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Oct. 31, 2018	Oct. 31, 2017	Oct. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss attributable to ABMT common stockholders	$ (953,320)	$ (691,600)	$ (724,737)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	16,295	13,604
Loss on disposal of property and equipment		37,500
Stock issued for services	52,750
Imputed interest	13,815	15,623
Decrease (increase) in:
Other receivables and prepaid expenses	(16,861)	3,291
Increase in:
Other payables and accrued expenses	54,900	63,870
Net cash used in operating activities	(832,421)	(557,712)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment	(64,405)	(453)
(Increase) decrease in deposit for purchase of property and equipment		1,213
Net cash used in investing activities	(64,405)	760
CASH FLOWS FROM FINANCING ACTIVITIES
Due to a stockholder	136,441	89,444
Due to directors	(34,932)	(48,351)
Due to related parties	794,771	516,658
Net cash provided by financing activities	896,280	557,751
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	(57)	105
NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS	(603)	904
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF YEAR	7,463	6,559
CASH AND CASH EQUIVALENTS AT THE END OF YEAR	6,860	7,463	$ 6,559
Supplemental of cash flow information
Interest income	36	36
Income tax
Other non cash items
Interest expenses	$ 286,756	$ 242,144

Summary of Significant Accounting Policies and Organization (Details Narrative)					12 Months Ended
	Dec. 31, 2008 USD ($) shares	Jan. 29, 2008 USD ($)	May 31, 2007	Sep. 25, 2002 USD ($)	Oct. 31, 2018 USD ($) Segment shares	Oct. 31, 2017 USD ($) shares	Dec. 31, 2018
Estimated useful lives of property and equipment					5 years
Long-lived assets, allowances for impairment
Likelyhood that tax benefit sustained					50.00%
Research and development costs					$ 56,512	48,053
Foreign currency translation gain (loss)					262,770	(94,255)
Other comprehensive gain (loss)					$ 262,770	$ (94,255)
Potentially dilutive securities \| shares
Number of operating segment \| Segment					1
Majority Shareholders [Member] \| Masterise [Member]
Ownership acquired	70.00%
Stock sold per affiliate agreement, shares \| shares	4,438,250
ABMT [Member]
Stock issued in acquisition, shares \| shares	50,000
Equity method investment ownership percentage	100.00%
ABMT [Member] \| Majority Shareholders [Member]
Ownership acquired	80.70%
Stock sold per affiliate agreement, shares \| shares	5,001,000
Stock sold per affiliate agreement	$ 5,000
Shenzhen Changhua [Member]
Registered capital				$ 724,017
Ownership interest - majority stockholder				70.00%
Ownership interest - minority stockholder				30.00%
Shenzhen Changhua [Member] \| ABMT [Member]
Ownership by non-controlling stockholders							30.00%
Masterise [Member]
Ownership interest - majority stockholder			63.00%
Ownership interest - minority stockholder			37.00%
Ownership acquired		70.00%
Payment for acquisition		$ 64,100
Masterise [Member] \| ABMT [Member]
Equity method investment ownership percentage							70.00%

Summary of Significant Accounting Policies and Organization - Schedule of Exchange Rates Used in Translation (Details)	Oct. 31, 2018	Oct. 31, 2017
USD [Member] \| Statement of Operations and Cash Flows [Member]
Exchange rate	1	1
HKD [Member] \| Statement of Operations and Cash Flows [Member]
Exchange rate	7.8351	7.7842
RMB [Member] \| Statement of Operations and Cash Flows [Member]
Exchange rate	6.5629	6.8013
Balance Sheet Items Except for Share Capital, Additional Paid-In Capital and Accumulated Deficits, as of Year End [Member] \| USD [Member]
Exchange rate	1	1
Balance Sheet Items Except for Share Capital, Additional Paid-In Capital and Accumulated Deficits, as of Year End [Member] \| HKD [Member]
Exchange rate	7.8393	7.8015
Balance Sheet Items Except for Share Capital, Additional Paid-In Capital and Accumulated Deficits, as of Year End [Member] \| RMB [Member]
Exchange rate	6.9737	6.6328

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
Property and Equipment (Details Narrative) - USD ($)	Oct. 31, 2018	Oct. 31, 2017
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 16,295	$ 13,604

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Oct. 31, 2018	Oct. 31, 2017
Property and equipment, gross	$ 521,120	$ 483,482
Less: accumulated depreciation	418,225	422,967
Property and equipment, net	102,895	60,515
Plant and Machinery [Member]
Property and equipment, gross	296,517	280,871
Motor Vehicles [Member]
Property and equipment, gross	39,534	41,566
Office Equipment [Member]
Property and equipment, gross	34,572	34,902
Computer Software [Member]
Property and equipment, gross	5,017	5,017
Office Improvements [Member]
Property and equipment, gross	$ 145,480	$ 121,126